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Malignant pleural mesothelioma (MPM) is an incurable cancer that commonly presents 
at an advanced stage. Although surgery, chemotherapy and radiotherapy treatment may 
be used, median survival from diagnosis is less than 12 months. Consequently, new 
therapeutic approaches are essential. Chimeric antigen receptors (CARs) are fusion 
molecules that couple the HLA-independent binding of a cell surface target to the 
delivery of a tailored T-cell activating signal. The receptor tyrosine kinase c-Met is 
overexpressed in >80% of MPM making it an attractive candidate for CAR T-cell 
immunotherapy. To target c-Met, three candidate CARs were developed named N28z, 
M28z and cM28z. All contained a CD28/CD3ζ endodomain fused to one of three 
stabilised peptides based on the N and K1 domains of hepatocyte growth factor, which is 
the only natural ligand for c-Met. Specificity and functionality of c-Met re-targeted CAR+ 
T-cells was confirmed by co-cultivation with c-Met-expressing NIH 3T3 and MPM cell 
lines. This was indicated by target-dependent cytotoxicity and enhanced cytokine release 
(IL-2 and IFN-γ), when compared to appropriate controls. Anti-tumour activity of all 
three candidate CARs could be further enhanced by pre-treatment of tumour cells with 
poorly cytotoxic doses of chemotherapy (cisplatin and pemetrexed) or by co-incubation 
with the PD-1 blocker, pembrolizumab. No differences between function of the three 
candidate CARs were evident in these studies. To evaluate in vivo anti-tumour activity, 
an intraperitoneal MPM xenograft model was established that was amenable to 
monitoring using bioluminescence imaging. Candidate c-Met re-targeted CARs were co-
expressed with the chimeric cytokine receptor, 4αβ, enabling IL-4 mediated, selective 
enrichment of CAR+ T-cells. In mice with an established tumour burden, I found that 
cM28z/4αβ+ T-cells were superior to other c-Met re-targeted or control T-cells in 
eliciting sustained disease control. Together, these findings demonstrate proof of concept 
for the utility of c-Met re-targeted CAR+ T-cells to recognise and destroy mesothelioma 
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CHAPTER 1  Introduction 
 
 
1.1 Malignant mesothelioma 
 
1.1.1 Epidemiology and Aetiology 
Malignant mesothelioma is a devastating cancer that arises from the mesothelial cells 
lining the body cavities and is associated with high morbidity and mortality. In 
approximately 90% of cases, the disorder occurs in the pleural space (Figure 1-1). 




Figure 1-1. Comparison between healthy lung and malignant pleural 
mesothelioma lung.  
Illustration comparing a healthy lung (left) with a diseased MPM lung (right). Inhalation 
of asbestos fibres results in chronic inflammation leading to development of MPM and 
plaque formation in pleura. Parietal pleura – outer layer, Pleural space – between the 







The primary causative agent associated with the development of malignant 
mesothelioma is inhalation of asbestos fibres (80% attributable fraction [2]). Industrial 
use of asbestos was widespread in many countries during the twentieth century, until 
asbestos mining was banned during the 1980’s and 1990’s in most developed nations. 
However, it is still mined today in Russia, China, Brazil and Canada and is widely used 
both in these countries and other developing countries such as India. Additionally, 
concomitant smoking enhances the risk of malignancy in an asbestos worker, with a 60-
fold increased risk of developing non-small cell lung cancer [3, 4]. Although asbestos 
workers are at highest risk of development of mesothelioma, family members are also at 
increased risk due to fibre exposure from primary clothing bought home.  
 
There is a long latent period between asbestos exposure and the development of 
mesothelioma (average 30-40 years) [5]. Consequently, the incidence of mesothelioma 
continues to rise despite tighter regulation and decreased use of asbestos [6]. The UK 
mortality rate has increased from below 160 deaths in 1968 to more than 2000 deaths in 
2005 [7] (Figure 1-2). It is predicted that the incidence of mesothelioma will peak in 
Europe between 2015 and 2020 [8, 9]. Within the United States of America, over 
100,000 new cases of mesothelioma are predicted over the next four decades. For those 
countries still mining and using asbestos in large quantities, rates of mesothelioma are 
expected to continue increasing decades after its use is banned, however this is still yet to 






Figure 1-2. Mesothelioma in Great Britain: annual deaths and projected 
future deaths. 
There were 2,538 mesothelioma deaths (2,123 males and 415 females) in Great Britain 
during 2013 with 2,548 deaths in 2012. Projected annual deaths are 2,500 annually for 
remainder of this decade. IIDB, Industrial Injuries Disablement Benefit.    
From http://www.hse.gov.uk/Statistics/causdis/mesothelioma/index.htm (accessed 
May 21st, 2016) 
 
 
Cancer risk is greatest following exposure to the needle-like asbestos fibres that 
constitute the amphiboles (sharp, rod-like), best exemplified by crocidolite (blue) and 
amosite (brown) asbestos. Although these forms of asbestos are rarely used today, 
serpentine or chrysotile asbestos (white) is still mined and used widely throughout many 
parts of the world and is also linked to induction of both mesothelioma and other cancers 
[10]. These fibres are typically found within brake linings, ships building and ceiling or 
pool tiles [4]. Thus, as exposure is work-related, mesothelioma is largely considered to be 
an occupational disease and because past exposure was more common in occupations 
with a predominantly male workforce, the current incidence of mesothelioma is higher in 
men. 
 
Other risk factors for mesothelioma are less well understood but include underlying 
genetic background [11], radiation exposure (e.g. radiotherapy for other malignancies 
such as lung and breast cancer [12]) and exposure to non-asbestos mineral fibres, 
notably erionite [13]. Prior infection with the simian virus 40 (SV40), a DNA tumour 
virus, has also been implicated in disease development [5, 14, 15]. It is also established 
that patients who smoke and have been exposed to asbestos have a higher risk of 
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developing lung cancer [16]. More recently, concern has been raised about the potential 
genotoxicity of carbon nanotubes. These possess asbestos-like morphological features 
and are increasingly used in modern technologies and manufacturing processes [17, 18].  
 
1.1.2 Molecular pathogenesis 
Several molecular defects have been described in malignant mesothelioma cells 
(reviewed in [19, 20]). Mutation induced defects in the function of tumour suppressor 
genes are prevalent, notably affecting the CDKN2A gene (encoding p16INK4a/ cyclin-
dependent kinase inhibitor 2A and p14ARF/ alternative reading frame), NF2 (encoding 
neurofibromatosis type 2/ merlin) and the BAP1 gene, which encodes for the BRCA1-
associated protein-1 [20, 21]. In addition, aberrant activation of the Wnt pathway occurs 
in the majority of mesotheliomas, indicated by cytoplasmic accumulation of β-catenin 
[21]. Furthermore, multiple receptor tyrosine kinases (RTKs) are commonly over-active 
in mesothelioma cells, leading to enhanced signalling via the Ras-MAP (mitogen-
activated protein) kinase and phosphatidylinositol 3-kinase pathways. Among a panel of 
42 such receptors analysed, the c-Met and epidermal growth factor receptors (EGFR) are 
activated most frequently in this disease [22]. In addition, several other receptors are 
commonly upregulated in mesothelioma, including AXL, insulin-like growth factor-1 
receptor, vascular endothelial growth factor receptor (VEGFR)-2, RON and other 
members of the ErbB family [23, 24].  
 
In the majority of cases, mesothelioma is believed to originate as a result of chronic 
asbestos-induced serosal inflammation. The physico-chemical properties of amphibole 
asbestos in particular facilitate its deposition and long-term persistence in both the lungs 
and pleura. Several contributory immunopathological mechanisms have been described 
that may link asbestos exposure to mesothelioma development. Asbestos fibres are 
mutagenic and elicit DNA damage primarily from the release of reactive oxygen and 
nitrogen species, both by phagocytic and mesothelial cells [25]. Furthermore, asbestos 
triggers an inflammatory response, owing in large part to its ability to promote the 
release of the high-mobility group box 1 (HMGB1) protein [21].  
 
HMGB1 is an example of a “damage-associated molecular pattern” (DAMP) molecule 
that acts as a potent inflammatory cue through at least two distinct mechanisms. First, 
HMGB1 activates a multi-protein complex termed the NLRP3 inflammasome, found 
within phagocytes, mesothelium and other cell types [26]. Inflammasome activation 
promotes the caspase 1-dependent maturation of interleukin (IL)-1β and IL-18. In turn, 
this triggers the subsequent release of a cascade of chemotactic, mitogenic and 
angiogenic factors, some of which have transforming properties when cultured with 
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mesothelial cells [27]. However, although NLRP3-deficient mice manifest a reduction in 
asbestos-induced lung pathology [21], they are not protected from asbestos-induced 
peritoneal mesothelioma [28]. A second action of HMGB1 is to instigate the release of 
tumour necrosis factor (TNF)-α. This provides NFκB-dependent survival signals to 
mesothelial cells, some of which may harbour an asbestos-induced mutational load [29, 
30]. 
 
1.1.3 Clinical presentation 
Although mesothelioma may present in various tissue types, over 90% of cases occur 
within the pleura, termed malignant pleural mesothelioma (MPM). Patients frequently 
present with symptoms of breathlessness and chest pain that is often insidious with the 
result that disease is often advanced at the time of diagnosis. Imaging modalities such as 
chest x-ray and computed tomography (CT) usually show evidence of pleural effusion 
and/ or irregular pleural thickening within the chest cavity. However, these features are 
not unique to MPM and a definitive tissue diagnosis is required.  
 
Three major histological subtypes of mesothelioma have been described: epithelioid, 
sarcomatoid and biphasic. The epithelioid variant is most common (>50% in most series) 
and has a slightly better prognosis compared between tumours with sarcomatoid 
features. The sarcomatoid subtype is associated with the poorest prognosis and accounts 
for 10% of patients. As determined by histopathology, biphasic tumours comprise at least 
10% of elements from both epithelioid and sarcomatoid tumours [31].  
 
1.1.4 Diagnosis 
Definitive diagnosis of malignant mesothelioma can be challenging and requires 
obtaining an adequate amount of tissue. Generally, this requires a pleural biopsy 
obtained by thoracoscopy or needle biopsy of pleural tissue under CT guidance, or more 
radically, at the time of open thoracotomy. However, tissue obtained during these 
procedures may be compromised by sampling error and small sample size. Initially 
haematoxylin and eosin (H&E) staining is required to detect characteristic morphological 
abnormalities consistent with a malignant process of the pleural lining. Due to the 
limited tissue collected, almost 25% of patients experience an under-classification in the 
correct histology [4]. 
 
Immunohistochemical staining is important to distinguish between mesothelioma and 
adenocarcinomas of lung origin or metastasis [32]. Biomarkers typically found within 
mesothelioma, such as calretinin – which is positive in mesothelioma with a reported 
sensitivity of 95% and specificity of 87% and thrombomodulin, with a 92% specificity 
(but less sensitive at 68%) help to discriminate this tumour from other differential 
30 
 
diagnoses [33]. The International Mesothelioma Interest Group (IMIG) established 
guidelines for diagnosing mesothelioma using a panel of histochemical markers (<80% 
sensitive) [32].  
 
1.1.5 Staging 
A number of staging systems have been used for mesothelioma over the years, almost 
exclusively pertaining to primary pleural mesothelioma [4]. Peritoneal mesothelioma 
does not have its own staging system. The oldest staging system is the Butchart system – 
which is still regularly used in certain countries. It is based upon a simple description of 
the extent of disease irrespective of histological subtype: pleural contained (Stage I), 
chest wall or mediastinal invasion (Stage II), peritoneal or diaphragmatic penetration 
(Stage III), or distant metastases (Stage IV).  
 
The most practical and ubiquitously used system is the tumour-node-metastasis (TNM) 
protocol developed by IMIG (Figure 1-3) [34]. The American Joint Committee on Cancer 
also currently adopts this system as the accepted standard [35]. Most patients present 
with advanced disease that is usually considered unresectable. 
 
Figure 1-3. Tumour-node-metastasis staging system for mesothelioma. 
Modified from [4]. 





1.1.6 Prognostic factors 
Prognostic factors affecting patient outcome have been determined from large 
multicentre trials [36]. Factors associated with poorer prognosis in patients with MPM 
include poor performance status, advanced stage of disease (e.g. stage III/IV), non-
epithelioid histology, weight loss, anaemia, elevated lactate dehydrogenase, elevated 
white blood cell count and elevated platelet count. Subsequently, the European 
Organisation for Research and Treatment of Cancer (EORTC) and the Cancer and 
Leukaemia Group B (CALGB) developed three prognostic scoring methods [37, 38]. 
 
The effect of immune system status is increasingly studied to predict patient survival in 
many malignancies. A low lymphocyte count has recurrently been seen a number of 
advanced stage cancer patients, and is often associated with poor overall survival [39-41]. 
Monocytes are also prevalent immune cells in cancer and are recruited into tumours 
where they alter the tumour microenvironment, promoting tumour progression via local 
immune suppression and angiogenesis [42]. A high monocyte count has previously been 
reported as a poor prognosis factor in patients with solid malignancies [43-45]. 
Furthermore, a low lymphocyte-to-monocyte ratio (LMR), defined as the absolute 
lymphocyte count divided by the absolute monocyte count, is reportedly correlated to 
unfavourable prognosis within a multitude of cancers [46]. Two recent studies have 
reported the prognostic significance of LMR in patients with MPM. Yamagishi et al. 
studied 150 patients and observed that an elevated LMR was independently associated 
with increased overall survival (OS) [47]. Similarly, Tanrikulu et al., analysed 292 MPM 
patients and showed that a decreased LMR was associated with worse survival [48].  
 
Several immune biomarkers have been investigated for their prognostic value in patients 
with MPM. Illustrating this, plasma Activin A has recently been linked to diagnosis and 
tumour volume in MPM and to poorer outcome in patients with epithelioid tumours 
[49]. Similarly, the immune checkpoint receptor CTLA-4 is relatively well characterised 
as a negative regulator of T-cell mediated immune response, and has recently been 
studied for its prognostic value in MPM. Roncellaet al., investigated CTLA-4 expression 
in MPM by immunohistochemistry (IHC), and soluble (s)CTLA-4 levels within sera and 
matched pleural effusions using ELISA from 45 patents [50]. A positive correlation was 
observed between pleural effusion (PE) sCTLA-4 levels and OS in MPM patients. This 
study was considerably smaller in cohort size than the previous studies detailed above 
however further experimental assessment will be required before both prognostic 





1.1.7 Treatment of mesothelioma: current standard of care to novel agents 
The management of malignant mesothelioma remains controversial and at present, there 
is no known curative treatment for MPM. The role of radical surgery as part of multi-
modality therapy has been promoted [51]. However, the incidence of post-operative 
morbidity is relatively high and survival benefit remains unproven [52]. Palliative 
combination chemotherapy using an anti-folate agent (pemetrexed or raltitrexed) in 
combination with cisplatin has been shown to prolong survival by a few months in 
suitable patients [53, 54]. However, only a minority of patients respond well to such 
therapy. Forms of immunotherapy have also been used to treat pleural mesothelioma 
with varying limited effects. Perhaps unsurprisingly, this form of treatment seems to be 
most active in patients with very early stage disease [55-57]. Molecular targeted therapy 
has also emerged as an interesting modality with further searches ongoing for 
therapeutic targets of interest [58-62]. Irrespective of management regimen, long-term 
control of malignant mesothelioma remains elusive and prognosis is generally poor with 
a median survival from presentation of 9 - 12 months [63].  
 
1.1.7.1 Surgery 
Eligible MPM patients may be offered two main surgical procedures, namely extrapleural 
pneumonectomy (EPP) or partial pleurectomy/decortication.  
 
Extrapleural pneumonectomy is a major surgical procedure that entails radical excision 
of the entire lung, including visceral and parietal pleura, pericardium and diaphragm, 
followed by synthetic reconstruction. Usefulness of this surgical procedure is 
controversial, although it may benefit a small sub-group of fit patients with epithelioid 
histology, no evidence of extra-pleural nodal involvement and in whom negative surgical 
resection margins can be achieved [64]. Nonetheless, this extensive surgical procedure is 
associated with a high morbidity and mortality rate of 50% and 4% respectively [65] and 
current guidelines are that EPP should only be performed in the context of a clinical trial, 
in specialised centres as a part of a multimodality treatment regimen [66, 67]. No 
randomised trial has yet shown a survival benefit with EPP. The MARS (Mesothelioma 
and Radical Surgery) trial was established to define the role of EPP in the context of a 
trimodal therapy (either preoperative chemotherapy followed by postoperative 
hemithorax radiotherapy or to no EPP) [68]. Patients were assigned to EPP followed by 
post-operative hemithorax irradiation or no EPP surgery. The study ended with 50 
patients accrued over a 3-year period (primary endpoint); however it was not 
significantly powered to analyse the effectiveness of surgery [69]. The results determined 
that due to the high morbidity associated with EPP, a trimodal therapy including EPP 




Partial pleurectomy or decortication can be defined as significant but incomplete 
resection of the pleural tumour and is often used to relieve an entrapped lung and/ or 
palliate control of chest wall pain. Though this form of surgery is not performed with 
curative intent, it plays a significant role in a sub-group of patients for symptom control.  
 
1.1.7.2 Chemotherapy 
Results published by Kao et al. in 2013 demonstrated that the majority of eligible 
mesothelioma patients pursue palliative therapy rather than aggressive surgery for 
disease management [70]. Despite extensive clinical research, only limited options 
involving combination chemotherapy have achieved a significant survival benefit for 
patients with MPM. Towards the end of the 20th century, it was accepted that a number 
of chemotherapy drugs achieved response rates of the order of 20% when administered 
as single agents, with no existing evidence at the time that combination chemotherapy 
offered any additional benefit [71]. In 2003, data from the EMPHACIS trial (“Evaluation 
of mesothelioma in a Phase III trial of pemetrexed with cisplatin”) were published which 
caused a significant impact in medical management of this disease. EMPHACIS was a 
single blind international and multi-centre randomised controlled trial comprising 448 
patients that compared the combination of pemetrexed (500mg/m2) with cisplatin 
(75mg/m2) to cisplatin alone (75mg/m2), administered intravenously every 21 days [53]. 
The combination regimen was shown to significantly improve response rate (41% 
compared to 17% with single agent cisplatin), leading to an improvement in median 
survival from 9.3 to 12.1 months (hazard ratio (HR) 0.74, p = 0.0003). In addition, 
patients treated with the combination regimen demonstrated a statistically significant 
improvement in symptom control over 18 weeks, when compared with those who 
received cisplatin alone. Subsequently, van Meerbeeck et al. demonstrated that the 
combination of cisplatin plus ralitrexed improved median survival to 11.4 months, 
compared to 8.8 months for cisplatin alone [54]. As a result, the combination of cisplatin 
and pemetrexed is considered standard first-line systemic therapy for unresectable 
MPM, as recommended by the National Institute for Health and Care Excellence. This 
also constitutes standard recommended treatment in the adjuvant setting as part of 
combined modality treatment of resectable MPM disease [72].  
 
Subsequent studies evaluating combination regimens including gemcitabine/platinum 
and vinorelbine/cisplatin have demonstrated response rates of 12-40% though, once 
more neither have shown significant benefit over active symptom control (ASC) [72]. The 
MSO1 trial, run by the Medical Research Council and British Thoracic Society, 
randomised 409 patients to either ASC, ASC and vinorelbine or ASC plus MVP 
(mitomycin, vinorelbine and cisplatin) with the combination of ASC plus vinorelbine 
resulting in a non-significant increase in median survival compared to either ASC alone 
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or ASC plus MVP (9.4 months compared to 7.6 or 7.8 months respectively; HR 0.81, p = 
0.11) [73].  
 
More recently, combinatorial strategies including targeted therapeutic agents have been 
evaluated in order to improve the response rate and outcome of first-line chemotherapy. 
The MAPS (Mesothelioma Avastin Cisplatin Pemetrexed Study) trial evaluated the 
combination of bevacizumab (15mg/kg for 6 cycles) plus cisplatin/pemetrexed for 6 
cycles, followed by maintenance bevacizumab until the endpoint of disease progression 
was observed. Comparison was made with cisplatin/pemetrexed alone, which 
represented standard of care. A total of 448 patients were treated in this multicentre 
randomised phase II/ III French trial [74]. The median overall survival of patients 
enrolled in the triple treatment arm was 18.8 months, representing a 2.7 months increase 
in survival compared to the standard of care treatment arm (HR 0.76, p = 0.012). 
Patients who received triple therapy demonstrated a response rate of 14% and a 6-month 
disease control rate of 73.5%, compared with 43.2% in the control arm [75]. 
Furthermore, the benefit of triple therapy was not confined to patients in the best 
prognostic subgroups. 
 
Despite these advances in medical management of MPM, the majority of patients fail to 
respond to these therapeutic approaches. Presently, there is no standard for second-line 
therapy available to those patients that are deemed suitable for further treatment. A 
number of studies with patients that did not receive pemetrexed as first line treatment 
have been conducted evaluating the use of pemetrexed, both as a single agent and in 
combination, however the benefits are limited [76, 77]. Furthermore, since the 
combination of pemetrexed and cisplatin is commonly given to those eligible as a 
standard first-line regimen, those eligible for pemetrexed as second-line treatment are 
few and far between.  
 
1.1.7.3 Radiotherapy  
The role of radiotherapy for the treatment of MPM is limited. This form of treatment has 
shown little benefit in reducing chest wall masses or alleviating pain. Furthermore, due 
to the extensive nature of the disease there is high risk of toxicity to the underlying lung 
[78] and responses are often of a transient nature. Data from a phase II study in which 
high dose hemithorax radiation was administered following EPP demonstrated low loco-
regional recurrence [79] and a study looking at the role of intensity-modulated 
radiotherapy (IMRT) after EPP has achieved good local control, but with severe 




1.1.7.4 Novel approaches: Targeted therapy and Immunotherapy 
Despite the lack of driver mutations identified for targeted therapy within MPM, the 
resistance of this disease to conventional treatments has meant that a multitude of 
targeted agents have been trialled in patients with this disease (Table 1-1). Novel 
approaches targeting mesothelioma have been characterised according to Hanahan and 
Weinberg’s “Hallmarks of Cancer” by Kondola et al. [81, 82]. The two most significant 
classes pertaining to this PhD will be described in more detail: 
 
1.1.7.4.1 Receptor tyrosine kinase inhibitors 
The capacity of tumour cells to release growth factors that facilitate and accelerate 
tumour cell growth has resulted in the development of drugs to antagonise the action of 
these growth factors. To date however, the majority of these trials have yielded 
disappointing results, with no meaningful increase in progression-free survival (PFS) for 
patients.  
 
The epidermal growth factor receptor (EGFR) is expressed by a variety of epithelial 
malignancies. The dysregulation of EGFR activation results in reduced apoptosis, 
uncontrolled cell proliferation and increased angiogenesis [83]. Over-expression of 
EGFR is found in the majority of mesothelioma tumours [84-86]. A number of clinical 
trials have been conducted using EGFR inhibitors (Table 1-1), although disappointing 
results have been observed thus far. The results from recent studies assessing the 
tyrosine kinase inhibitor (TKI) gefitinib, in malignant mesothelioma are yet to be 
published (NCT00787410; NCT00025207). A further study is evaluating the use of 
cetuximab (a monoclonal antibody targeted against EGFR) combined with either 
cisplatin or carboplatin and pemetrexed (MesoMab - NCT00996567). Targeting of the 
insulin-like growth factor (IGF)-1 receptor is also under evaluation in MPM, using the 
inhibitor cixutumumab (IMC-A12 - NCT01160458). Tivantinib, a TKI targeting the c-Met 
receptor is further detailed in section 1.4.6, however a study was recently terminated in 
malignant mesothelioma (NCT01861301). A second study evaluating the combination of 
tivantinib plus the chemotherapy agents’ pemetrexed and carboplatin is currently 






Table 1-1. Summary of published clinical trials evaluating EGFR inhibitors in 
malignant mesothelioma. Adapted from [87] 
Agent  Study 
design 

























24 5.8 24% No response 
12 SD 




Vascular endothelial growth factor (VEGF) stimulates neovascularisation in a plethora of 
tumours, including MPM. Higher expression levels are associated with more-advanced 
disease and poorer prognosis [91]. Numerous clinical trials evaluating the effect of VEGF 
inhibitors either alone or in combination with chemotherapy in MPM have been 
conducted. Results to date have been largely disappointing and our summarised in a 
review by Kotova et al. [87]. 
 
 
1.1.7.4.2 Immunotherapy of mesothelioma using immune checkpoint blockade 
Clinical evidence to date suggests that the immune system plays a critical role in 
protection against MPM [92-94]. Tumour infiltrating lymphocytes (TILs) play a 
significant role in anti-tumour responses, with the recognition of tumour-specific 
antigens. T-cell infiltration is strongly correlated with improved prognosis in several 
cancer types. In MPM, a high number of CD8+ TILs has been reported to indicate 
improved prognosis [95-97]. The findings are subject to variance between studies 
however as investigators have also intimated there is no clear association [98]. 
Nonetheless, it is clear T lymphocytes are vital for anti-tumour activity however there are 
several mechanisms at play to evade immune destruction. Importantly, the host immune 
system retains potent mechanisms known as checkpoint molecules to stem potentially 




The first checkpoint molecule to be successfully blocked for anti-cancer therapy was 
cytotoxic T lymphocyte antigen-4 (CTLA-4). Following normal T-cell activation, CTLA-4 
is normally upregulated as a negative regulator, competing with the costimulatory 
molecule CD28 to bind to B7 ligands. This switches the positive costimulatory signal into 
a negative signal for activated T-cells. Although necessary under normal conditions to 
protect against autoimmunity, this mechanism is also manipulated by tumour cells to 
restrain antitumor immunity. By blocking checkpoint molecules, a strategy known as 
‘checkpoint blockade’, the anti-tumour immune response can be restored. These agents 
have been established as a new drug class with meaningful therapeutic efficacy in many 
cancers, particularly melanoma [99].  
 
Examples of monoclonal antibodies against CTLA-4 receptor include ipilumumab and 
tremelimumab. Currently the latter CTLA-4 inhibitor, Tremelimumab, is undergoing 
clinical evaluation in malignant mesothelioma. Building on preclinical evidence of 
synergy between chemotherapy and CTLA-4 therapy [100, 101], CTLA-4 blocking 
therapy has shown promise in MPM patients [102]. Calabro et al., reported encouraging 
results with tremelimumab in patients with chemotherapy-resistant MPM (MESOT-
TREM-2008; NCT01649024). With no serious adverse toxicity, disease control was 
reported in 31% patients with a median overall survival of 10.7 months, in comparison to 
8.7 months for patients receiving second line chemotherapy (retrospective review) [103]. 
A second trial with 29 patients investigating a higher frequency of doses at a lower 
concentration of tremelimumab (10mg/kg) reported immune-related partial responses in 
14% of patients and a disease control rate of 52%, with median OS of 11.3 months and 
median immune-related PFS of 6.2 months (NCT01655888) [104, 105]. A large, 
randomised phase II double blind trial comparing tremelimumab to placebo in pleural or 
peritoneal mesothelioma is ongoing (although no longer recruiting) and the field is 
awaiting the results (NCT01843374 – last verified May, 2016).  
 
A second related mechanism by which tumour cells evade immune destruction involves 
the expression of programmed death 1 ligand and programmed death 2 ligand (PD-L1 
and PD-L2). Expression of PD-L1 by MPM tumours has been evaluated predominantly 
by immunohistochemistry on formalin-fixed paraffin embedded material. The expression 
data reported has ranged between 20% and 70% depending on the respective threshold 
distinguishing positive PD-L1 expression in MPM. This has varied from >1% to ≥50% of 
expression between studies [106-109]. Most studies reporting the expression data have 
also specific expression based upon histological subtype (Table 1-2). Notably, expression 
of PD-L1 was associated with significantly poorer outcome. The median survival for 
patients whose tumours expressed PD-L1 was 5 months compared to 14.5 months for 




Table 1-2. Summary of PD-L1 expression published in mesothelioma using 







% PD-L1+ Refs.  
IHC 5H1-A3 106 ≥ 5 40% (E 21%, S 94%, B 
57%) 
[107] 
IHC E1L3N 119 > 1 20% (E 13%, NE 38%) [108] 
IHC 5H1-A3 45 ≥ 50 27% (E 17%, B 7%) [110] 
IHC 5H1-A3 33 ≥ 5 70% [111] 
IHC 22C3 80 > 1 45.2% [112] 
IHC, immunohistochemistry; E, epithelioid subtype; S, sarcomatoid subtype; B, biphasic 
subtype; NE, non-epithelioid subtype. Cut off (%) represents the % threshold 
determining positive expression; % PD-L1 represents the % of tumours that were deemed 
positive by the criteria established in ‘cut off % column’. 
 
The first results of clinical evaluation of inhibition of the PD-1/PD-L1 axis in 
mesothelioma were presented last year. The KEYNOTE-028 (NCT02054806) trial is a 
nonrandomised Phase 1b study that is investigating activity and safety of the PD-1 
inhibitory antibody pembrolizumab in patients with locally advanced or metastatic 
MPM. An overall disease control rate of 76% was observed (n=25 patients), with partial 
response in 28% and stable disease in 48% of patients [112]. The prolonged responses to 
date are striking although the relatively short follow-up time must be taken into 
consideration [112]. Other monoclonal antibodies against PD-L1 and PD-1 are currently 
being tested in phase II trials for patients with MPM (ClinicalTrials.gov identifiers: 
NCT02399371, NCT02497508) (Table 1-3). 
 
However, it remains controversial as to whether PD-L1/2 expression constitutes a 
reliable biomarker of activity of checkpoint blockers that target this axis - conflicting 
observations have been reported by different groups [113, 114]. Presently, a phase II 
study is underway assessing pembrolizumab in malignant mesothelioma 
(NCT02399371). The study will also explore whether PD-L1 expression could be a good 
predictive biomarker for response to PD-1 inhibitors. A further study evaluating 
chemotherapy and/or pembrolizumab is due to commence shortly (NCT02784171). MPM 
patients will either receive cisplatin and pemetrexed alone or in conjunction with 









Table 1-3. Selection of novel agents undergoing or about to undergo clinical 
evaluation in patients with malignant pleural mesothelioma. Adapted from 
[81]. 
 





Antibody against CTLA-4 Tremelimumab IIb NCT01843374 
Antibody against PD-1 Pembrolizumab II NCT02399371 
Antibody against PD-1 Nivolumab II NCT02497508 
Met Tyrosine kinase inhibitor Tivantinib I NCT02049060 
Met Tyrosine kinase inhibitor Tivantinib II NCT01861301 
Monoclonal antibody against mesothelin Amatuximab II NCT02357147 
Anti-mesothelin antibody-drug conjugate BAY94-9343 I NCT01439152 
 
Pan-VEGF receptor tyrosine kinase 
inhibitor 
Cediranib I/II NCT01064648 
 
CTLA-4, cytotoxic T lymphocyte antigen-4; PD-1, programmed death 1; PD-L1, programmed 
death 1 ligand; VEGF, vascular endothelial growth factor; Met, mesenchymal epidermal 
transition factor.  





1.2 The c-Met receptor tyrosine kinase 
 
1.2.1 c-Met receptor Structure and function 
The MET proto-oncogene was first identified following the characterisation of a 
translocation in which a portion of this gene was joined to the translocated promoter 
region (TPR) locus [115]. The name MET was originally derived from the chemical that 
induced the TPR-MET translocation (N-methyl-N’-nitroso-guanidine) but has also been 
used to in reference to its role in metastasis or mesenchymal-epithelial transition [116]. 
The c-Met receptor is synthesised as a single polypeptide precursor of 1436 amino acids, 
and like its unique ligand, hepatocyte growth factor (HGF), it undergoes post-
translational processing in order to become functional. Furin-mediated cleavage occurs 
between amino acids 307 and 308, leading to the formation of the mature αβ c-Met 
heterodimer. The resultant product functions as a single mature 190kDa unit that 
undergoes ligand-induced homodimerisation via the formation of a 2:2 complex with 









Figure 1-4. Structural domains present in the c-Met receptor tyrosine kinase. 
c-Met is produced as an inactive precursor that undergoes proteolytic cleavage and re-
assembles as a disulphide-linked αβ heterodimer. The SEMA (semaphorin) domain 
comprises the α and part of the β chain and constitutes the main ligand-binding moiety. 
Next follows a cysteine rich PSI domain (found in plexins, semaphorins and integrin) and 
a sequence of four immunoglobulin-like IPT (immunoglobulin-plexin-transcription) 
domains, here numbered as IPT1-4. Following the transmembrane (Tm) region, the 
endodomain of the c-Met receptor contains a regulatory juxtamembrane (JM) region, 
catalytic tyrosine kinase (TK) domain and C-terminal motif (C). Key sites of tyrosine and 






The extracellular region of c-Met comprises three distinct elements. The first of these is 
the N-terminal SEMA (semaphorin) domain, which shows homology to semaphorin and 
plexin family members and forms a seven bladed β-propeller fold [118]. The SEMA 
domain provides the HGF β-chain binding unit [119] and consists of the Met α subunit 
and proximal portion of the β chain. Following next is the cysteine-rich or PSI domain 
(found in plexins, semaphorins and integrin) and finally a sequence of four IPT 
(immunoglobulin-plexin-transcription) domains. The endodomain of the c-Met receptor 
is also divided into three modular components. The juxtamembrane region plays a key 
regulatory role and contains two elements that inhibit receptor function when 
phosphorylated. The first of these, S985, serves to inhibit receptor kinase activity [120]. 
Located closely downstream, Y1003 provides a c-Cbl ubiquitin protein ligase-binding 
motif that promotes the physiological down-regulation of receptor expression [121]. 
Immediately beyond the juxtamembrane region is the kinase/ catalytic element of the c-
Met receptor. Upon binding of HGF, three closely located tyrosine residues (Y1230, 
Y1234, Y1235) are phosphorylated within the activation loop of the kinase domain, 
leading to initiation of tyrosine kinase catalytic activity [116, 122, 123]. As a result, two 
additional tyrosines (Y1349 and Y1356) in the terminal endodomain region (the 
unstructured C-terminal motif) are phosphorylated. This serves to create a “bi-dentate” 
docking site for several adaptor and signalling proteins, focussed around the Gab1 (Grb2 
associated binder 1) adaptor and including Grb2-SOS (growth factor receptor bound 
protein 2 complexed with Son of Sevenless), SHC, Crk and Crk-like, pp60c-src, PI3K and 
phospholipase Cγ [124, 125]. Phosphorylation of both Y1349 and Y1356 is sufficient to 
render the c-Met receptor transforming [126]. Several downstream signalling systems are 
activated as a result, including the canonical Ras-MAP kinase/Bcl-xl, Rac/CDC42, 
PI3K/Akt, PI3K/Erk5/Fra1, Rap1/FAK, protein kinase C, Pak4 and STAT3 pathways 
[116, 127-129]. Collectively, these account at least in part for the diversity of mitogenic, 



































Figure 1-5. The HGF-c-Met Signalling Pathway 
The main signalling pathways activated by the HGF-c-Met axis. HGF binding to c-Met 
stimulates receptor dimerisation, leading to the activation of different signalling 
pathways. Upon activation, c-Met kinase domain mediates signalling via adaptor 
proteins and other signalling proteins leading to (i) proliferation through MAPK 
activation, via Gab1-Grb2 resulting in Ras activation; (ii) cell survival via the PI3K and 
Gab1 mediated activation of AKT, resulting in an anti-apoptotic response; (iii) adhesion 
and cell motility mediated via Ras activation and direct interaction with the PI3K-FAK 

































The c-Met receptor tyrosine kinase is activated upon binding by a single ligand species, 
named hepatocyte growth factor (HGF). Hepatocyte growth factor is principally secreted 
by a variety of mesenchymal cell types, including fibroblasts, vascular smooth muscle 
cells and other stromal cells, whereas c-Met is primarily expressed on the surface of 
epithelial cells. By this arrangement, the HGF/ c-Met axis establishes a mesenchymal–
epithelial communication pathway that regulates a number of physiological processes, 
including embryogenesis, organ development, wound healing, angiogenesis and tissue 
homeostasis and regeneration [130]. In keeping with these fundamental activities, mice 
that are null for either MET or HGF are embryonically lethal [131-133]. Several 
functional consequences ensue after the binding of HGF to c-Met, including enhanced 
cell survival, proliferation, cell movement and branching morphogenesis.  
 
 
1.3 Hepatocyte Growth Factor 
  
Hepatocyte growth factor (HGF) is a 90 kiloDalton (kDa) cytokine that was 
independently identified as a stimulus to epithelial cell movement (“scatter factor” [134]) 
and as a potent stimulator of hepatocyte proliferation [135]. Cell scattering refers to the 
ability of HGF to disrupt E-cadherin-based cell-cell adhesion, followed by acquisition of a 
migratory and invasive fibroblast-like phenotype. Hepatocyte growth factor is a member 
of the plasminogen-related growth factor family and is elaborated as an inactive 
precursor polypeptide (pro-HGF) that binds c-Met, but does not activate receptor 
signalling. Pro-HGF protein contains a linear arrangement of six modular elements, 
namely an N-terminal hairpin (N), four Kringle domains (K1-K4) and a serine proteinase 
homology (SPH) region that lacks enzymatic activity (Figure 1-6). In response to tissue 
injury, this precursor undergoes proteolytic cleavage at the junction between R494 and 
V495 and re-assembles as a disulphide-linked active αβ heterodimeric unit [136]. While 
the α subunit alone can bind to c-Met with comparable affinity to HGF, it is biologically 
inactive [137]. A number of smaller splice variants of HGF have been described, 
including NK1, NK2 and NK4 (Figure 1-6). Several soluble and membrane anchored 
serine proteases have the capacity to activate pro-HGF, including HGF activator, 
urokinase-type plasminogen activator, matriptase, hepsin, plasma kallikrein and the 
coagulation Factors XIa and XIIa [116, 138]. Counterbalancing this, two inhibitors of 
























Figure 1-6. Structural domains present in hepatocyte growth factor 
Hepatocyte growth factor is secreted as a single polypeptide precursor that undergoes 
proteolytic cleavage between R494 and V495. The resultant α and β chains form an 
interchain disulphide bond to yield the mature HGF heterodimer. The cartoon shows the 
structural domains present, namely the N-terminal hairpin (H), Kringle (K) domains 1-4 
and the serine protease homology domain (SPH). A number of antagonistic or partial 
agonistic splice variants are also produced in which the N-terminal hairpin and 1 (NK1), 
2 (NK2) and/ or 4 (NK4) Kringle domains are also present.  
 
 
Following its secretion, much of HGF is tethered through binding to cell surface and 
matrix heparin sulphate proteoglycans [139]. Heparin sulphate proteoglycans play an 
important role in the presentation of HGF to the c-Met receptor [140]. Although heparin 
sulphate is not required for binding between HGF and c-Met, it potentiates ligand-
induced c-Met dimerisation and subsequent functional outcome. The NK1 variant of 
HGF contains the high-affinity binding site for c-Met but it does not bind in the absence 
of heparin [141]. When basic amino acids responsible for heparin binding are substituted 
with glutamic acid, NK1 acquires the ability to bind c-Met in a heparin-independent 
manner. However, this mutein is functionally inactive and thus acts as a competitive c-
Met antagonist [142]. 
 
1.4 The HGF/ c-Met axis and mesothelioma 
 
Although activity of the HGF/ c-Met system is required for development, expression of 
these binding partners is generally found at low levels in healthy adult tissues. By 
contrast, dysregulation of the HGF/ c-Met system is prevalent in many lung and other 
cancers, including malignant mesothelioma, and may result from mutation, gene 




1.4.1 HGF expression in mesothelioma 
Harvey and colleagues were first to investigate the expression of c-Met and HGF in 
malignant pleural mesothelioma (MPM) [144]. Using immunohistochemistry, they 
demonstrated that nine of nine MPM tumours (representing all three histological 
subtypes) were reactive for HGF. Eight of the tumours were graded as intensely positive, 
with uniform and diffuse cytoplasmic staining evident in tumour cells together with 
frequent stromal reactivity. In agreement with this finding, HGF was also detected in 
four of four tested MPM-associated pleural effusions [145].  
 
Tolnay et al. subsequently assessed a larger number of MPMs and found that 33 of 39 
stained positively with anti-HGF antibody. Once again, reactivity was evident in both in 
tumour cells and accompanying stroma [146]. While virtually all epithelioid and biphasic 
MPM were positive, the authors noted that biphasic tumours exhibited stronger staining 
in the epithelioid compared to the sarcomatoid portion. Furthermore, only 1 in 8 of the 
sarcomatoid tumours tested positive for HGF. Normal mesothelial cells were negative, a 
finding that contrasts with an earlier report of weak HGF expression in 4 of 8 cases [144]. 
Expression of HGF (but not c-Met) was correlated with tumour micro-vessel density, in 
keeping with the known role of HGF in promoting angiogenesis [146]. 
 
In keeping with these findings, serum levels of HGF (and epidermal growth factor (EGF)) 
are elevated in patients with mesothelioma, compared to healthy individuals of a similar 
age [147]. However, autocrine release of HGF is uncommon in immortalized MPM cell 
lines [148, 149], having primarily been described in cell types with a sarcomatoid or 
mixed phenotype [150].  By analogy with other tumour types [129], this raises the 
possibility that stroma is also an important source of HGF production in mesothelioma. 
In keeping with this, Li et al. have presented evidence that mesothelioma cells release 
platelet-derived growth factor and fibroblast growth factor, which in turn promote an 
influx of activated HGF-secreting fibroblasts into the tumour microenvironment [151]. 
This suggests that a paracrine relationship between stroma and tumour cells may also 
serve to reinforce disease progression in mesothelioma. 
 
1.4.2 c-Met expression in mesothelioma 
Using immunohistochemistry, Harvey et al. also demonstrated strong expression of the 
c-Met receptor in MPM tumour cells and associated stroma [144]. Once again, staining 
was diffuse and mainly cytoplasmic, with some membranous reactivity also apparent. 
Furthermore, in all six MPM-associated pleural effusions where tumour cells were 
identified, c-Met expression was detected [152]. These findings were subsequently 
extended in four larger series, which respectively demonstrated that 74% (n= 39) [146] 
80% (n=35) [153], 82% (n=66) [147] and 76% (n=157) [154] of MPM tumours tested 
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positive for c-Met expression. Similar to HGF staining, expression was most common in 
epithelioid tumours, least frequent in sarcomatoid variants, whereas in biphasic MPMs, 
reactivity was most apparent in the epithelioid component [146]. Fluorescence in situ 
hybridisation confirmed a direct correlation between c-Met expression in tumours at the 
mRNA and protein levels [146]. In the majority of tumours tested, c-Met 
phosphorylation was detected [153, 154]. In mesotheliomas with high-level expression, c-
Met was predominantly located on the plasma membrane, whereas cytoplasmic staining 
was predominantly seen in tumours where expression was lower [154]. Intriguingly 
however, high plasma membrane expression of c-Met was associated with improved 
outcome, although the authors note that this finding requires independent validation 
[154]. By contrast, normal mesothelial cells have generally been found to lack c-Met 
expression at the protein [146] or RNA level [152]. Nonetheless, polarised expression 
along the apical surface was demonstrated in normal mesothelium in one study [144].   
 
In keeping with these findings, studies of both human and murine mesothelioma cell 
lines have confirmed that the majority of those tested express the c-Met receptor [152, 
153]. Comparison with an immortalised cell line derived from healthy mesothelium 
indicates that MET is transcriptionally upregulated in 75% of cases [153]. 
 
1.4.3 MET mutation in mesothelioma 
A number of MET mutations have been identified in primary MPM and derived cell lines 
[147]. Overall however, it has been estimated that somatic mutation of MET is only 
detectable in approximately 3% of such tumours [149]. Similarly, no activating MET 
mutations were identified in an assessment of 30 mesothelioma cell lines [148, 153]. A 
polymorphism (T1010I) that affects the juxtamembrane regulatory domain of MET has 
been identified in a small number of cases of MPM [149] and in derived cell lines [147]. 
While this polymorphism has the capacity to transform an IL-3-dependent cell line, it 
remains uncertain whether this finding has clinical relevance in mesothelioma [149]. 
 
1.4.4 Factors that dysregulate the HGF/ c-Met axis in mesothelioma 
Several factors have been identified that have the capacity to dysregulate expression of 
HGF and/ or c-Met in mesothelial or other cell types and thus may have relevance to 
mesothelioma pathogenesis.  
 
Exposure of murine mesothelial cells to crocidolite (the most pathogenic form of 
asbestos) promotes upregulation of the Fra-1 (fos-related antigen-1) proto-oncogene. 
This in turn leads to AP-1-dependent c-Met upregulation [155]. Furthermore, increasing 
evidence from a number of tumour systems suggests that hypoxia can drive the 




Related to this, Adamson et al. [156] performed an in vivo study in which rats were 
exposed to crocidolite asbestos, delivered by intratracheal instillation. As a result, a 
proliferative burst of bronchoalveolar epithelium and pleural mesothelial cells ensued. 
To dissect mechanisms, they demonstrated that HGF and keratinocyte growth factor 
levels increased in bronchoalveolar and pleural lavage fluid over the following days. 
Evidence that both cytokines contributed to mesothelial cell proliferation was supported 
by antibody blocking studies.  
 
Genetic factors may conspire to upregulate the HGF/ c-Met axis. Studies using a murine 
model of asbestos-induced mesothelioma have indicated that haplo-insufficiency for 
both CDKN2A and NF2 enhances tumour aggressiveness, associated with upregulated 
expression and activation of c-Met and expression of stem cell-associated attributes 
[157]. In addition, loss of function p53 mutation favours c-Met upregulation, perhaps via 
dysregulated microRNA expression [158]. 
 
Finally, the SV40 tumour virus has been linked in a number of studies to mesothelioma 
development, although this remains controversial [159]. Notably however, in 
mesothelioma cell lines that express the large T antigen (an SV40-derived oncoprotein), 
c-Met is constitutively phosphorylated as a result of the establishment of an HGF 
autocrine loop [14].  
 
1.4.5 Consequences of aberrant activation of the HGF/ c-Met axis in 
mesothelioma 
Addition of HGF (either recombinant or derived from tumour samples) to mesothelioma-
derived cell lines results in increased phosphorylation of Akt [160], Erk1/2 and c-Met 
itself [147]. As a result, these cells exhibit an increase in non-directional motility, 
chemotactic migration, altered morphology, cell division and invasiveness in vitro [152, 
161].   
 
In vivo studies using cell lines have also shed light on possible effects of activation of the 
c-Met /HGF axis in malignant mesothelioma. When an autocrine c-Met / HGF loop is 
established in NIH3T3 fibroblasts, these cells acquire tumourigenic capacity when 
inoculated in nude mice [162]. Tumours aberrantly express a number of epithelial 
markers, suggesting that c-Met signalling can promote epithelial trans-differentiation of 
these mesenchymal cell types [163]. This finding is noteworthy since mesotheliomas 
commonly display both epithelial and mesenchymal/ sarcomatoid features and 




1.4.6 Targeting the HGF/c-Met axis in cancer – clinical studies 
Several clinical trials are currently evaluating therapeutic agents directed against the 
HGF/ c-Met axis, in solid and some haematological malignancies [165]. They can be 
grouped into three major categories, based upon their specific targets (HGF and c-Met) 
and mechanisms of actions (monoclonal antibodies and TKIs) – anti-HGF antibodies, 
anti-c-Met antibodies and c-Met TKIs. [166, 167].  
 
1.4.6.1 Anti-HGF  / c-Met Antibodies 
Clinically, the best characterised anti-HGF antibody is Rilotumumab (AMG 102) - a fully 
humanised monoclonal antibody against HGF. In a phase II trial of advanced gastric or 
oesophago-gastric cancer, efficacy was demonstrated in patients with c-Methigh tumours 
(>50% of cells with intermediate or strong c-Met staining) [168]. A phase I/II trial of 
rilotumumab plus erlotinib in NSCLC patients (NCT01233687) is actively recruiting 
(however last verified in 2014; clinicaltrials.gov). The anti-c-Met antibody ornatuzumab 
(MetMab) has been studied predominantly in lung cancer [169]. MetMab is a humanised, 
monoclonal antibody that binds to the Sema domain of c-Met, inhibiting HGF binding; a 
phase II clinical study testing ornatuzumab in combination with erlotinib for advanced 
NSCLC showed significant PFS and OS in c-Met+ NSCLC [170, 171]. However, results 
from this phase II study were not replicated in a larger, phase III study of c-Met IHC-
positive NSCLC patients (NCT02031744 –not verified >1 year) that has been halted due 
to lack of clinically meaningful efficacy [172].  
 
1.4.6.2 c-Met Tyrosine Kinase Inhibitors 
Several small molecule c-Met kinase inhibitors are currently undergoing evaluation in 
patients with advanced c-Met-expressing malignancy [165]. Multi-kinase inhibitors 
include amuvatinib (phase II), cabozantinib (phase II), crizotinib (phase I/II) and 
foretinib (phase I/II) whilst capmatinib (phase I/II) and Tivantinib (phase II) are 
selective c-Met inhibitors.   
 
Cabozantinib strongly inhibits c-Met, VEGFR2 and RET. Approved by the US FDA for 
treatment of aggressive metastatic thyroid cancer [173], phase II studies evaluating this 
agent within a cohort of different solid tumours – melanoma, NSCLC, hepatocellular 
cancer (HCC) and breast cancer all respectively reached objective tumour regression 
[174]. Subsequent studies investigating cabozantinib in CRC and prostate cancer are also 
underway [167].  
 
Clinical studies with tivantinib have been generally well tolerated, showing selected signs 
of clinical activity in patients with cancer [175-182] however interstitial lung disease was 
a serious adverse event resulting in the discontinuation of the ATTENTION trial [167]. In 
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a phase II study for the treatment of HCC, significant improvement was observed in 
patients with c-Methigh tumour expression [179]. However, a multicentre phase II clinical 
trial evaluating tivantinib in patients with mesothelioma who had failed prior therapies 
(NCT01861301) was terminated after recruitment of 18 patients owing to disappointing 
results.  
 
It is evident more potent small molecule TKIs are under clinical evaluation than c-
Met/HGF antibodies, with diverse responses documented. Importantly, results will need 
to be interpreted in the light of increasing evidence that kinase inhibitors engage 
multiple off-targets, typically amidst kinases of structural similarity, which is a 
significant limitation in their widespread use [183].  
 
 
1.5 Caught in the crossfire: interactions between c-Met and 
other signalling networks 
 
Increasing evidence indicates that aberrantly activated receptor/ ligand systems do not 
operate in isolation, but instead engage in cross-talk with other pathways in healthy and 
transformed cells. Many examples of such “cross-talk” have been described in relation to 
the HGF/ c-Met axis and may afford opportunities for the emergence of tumour cell 
resistance to the targeted inhibition of this pathway in isolation [158, 184].  
 
Recent studies have shown complex interactions between HGF/c-Met with other 
membrane receptor tyrosine kinases (RTKs) such as Semaphorin-4D/Plexin B1 [185] and 
SDF1/CXCR4 [186], suggesting the importance of crosstalk between membrane 
receptors of various types [187, 188] 
 
1.5.1 Cross-talk between c-Met and other receptor tyrosine kinases  
The c-Met receptor engages in cross-talk with several other receptor tyrosine kinases, 
many of which are co-expressed in malignant mesothelioma. The best characterised of 
these interactions occurs between c-Met and EGFR. Amplification of MET is a well-
recognised mechanism of mediating resistance of EGFR-mutant lung cancer cells to 
EGFR kinase inhibitors [189]. Stimulation of MPM cells with HGF causes the 
phosphorylation of EGFR while knock down of MET or inhibition of c-Met kinase activity 
can lead to reduced EGFR phosphorylation [149]. The converse relationship also applies 
in that EGF stimulation of MPM cells promotes the enhanced phosphorylation of c-Met. 
In mesothelioma, the EGFR is upregulated in the majority of tumours and is 
phosphorylated in virtually all cases [89]. Nonetheless, EGFR inhibitors have proven 
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ineffective to date when used in isolation to treat patients with mesothelioma [190]. Pre-
clinical studies using a panel of mesothelioma cell lines have demonstrated that 
combined inhibition of both c-Met and EGF receptor achieved greater suppression of cell 
growth, migration and invasion, compared to selective targeting of either receptor alone 
[153]. Furthermore, the AKT inhibitor perifosine also reduced the ligand-induced 
phosphorylation of EGFR and c-Met receptors in mesothelioma cell lines, accompanied 
by inhibition of proliferation and enhanced sensitivity to platinum agents [191]. These 
data raise the possibility that c-Met signalling can buffer against the inhibitory effects of 
EGFR blockade in mesothelioma and raise the prospect that combined inhibition of both 
pathways may warrant clinical evaluation. 
 
Studies of other model systems provide evidence of cross-talk between c-Met and other 
receptor tyrosine kinases. The HGF/ MET axis is closely related to a second ligand 
receptor pair, comprising macrophage stimulating protein (MSP) and the Ron receptor 
tyrosine kinase [130]. In gastric carcinoma models, heterodimerisation and cross-
phosphorylation of the c-Met and RON receptors has been demonstrated upon binding of 
either HGF or MSP [192]. Such a mechanism may also operate in mesothelioma since 
recent preliminary data suggest that both MSP and RON are commonly expressed in this 
tumour [193]. Furthermore, the AXL receptor is also commonly expressed in 
mesothelioma [23] and signals co-operatively and in a bidirectional manner with HGF/ 
c-Met in some models [194]. There is also evidence that other RTKs such as IGF-1R, RET 
[195] and VEGF receptor [62] can elicit the ligand independent transactivation of the c-
Met receptor. Co-operative signalling between c-Met and ErbB2/ ErbB3 has also been 
described [158]. Together, these findings place c-Met as an effector of signalling by 
several other receptor systems and warrants further investigation of the intermediates 
that relay such signals and which may provide important targets for therapeutic 
exploitation. 
 
1.5.2 Cross-talk between c-Met and other receptor types 
Emerging evidence also suggests that cross-talk between c-Met and other (non-tyrosine 
kinase) receptor types also occurs. In several cellular systems, CD44 receptor isoforms 
containing the variant 6 exon (CD44v6) are required in order that HGF can elicit c-Met 
activation, through ternary complex formation [196]. The CD44 variant exon 3 contains a 
heparin sulphate binding site, enabling isoforms that contain this exon to bind HGF, 
perhaps facilitating the more efficient capture and presentation of this ligand to c-Met 
[158]. HGF has also been reported to promote the association of c-Met with CD44 
containing variant exon 10, leading to efficient phosphorylation of c-Met and recruitment 
into caveolin-enriched microdomains [197]. Although CD44 is commonly upregulated on 
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mesotheliomas [198], there has been relatively little study of which CD44 variants are 
expressed in this disease.  
 
Transactivation of MET (and several other RTK) has also been reported upon stimulation 
of several G protein coupled receptors [158, 199]. Additionally, ligand-independent c-Met 
activation has been described following integrin engagement [200]. In keeping with this, 
c-Met can physically associate with a number of integrins [158]. Furthermore, full c-Met 
functioning in some models requires complex formation with the α3β1 [201] or α6β4 
integrin [202].   
 
Another example of this type of cross-talk is the ability of c-Met to associate with 
Semaphorin receptors, namely Plexins and Neuropilins [203]. For example, Sema4D (a 
Plexin B1 ligand) increases the phosphorylation of both its receptor and c-Met leading to 
enhanced tumour invasiveness [204], although the importance of this interaction in 
mesothelioma is unclear. 
 
1.5.3 The role of co-factors in binding of HGF to c-Met  
NK1 binds both to c-Met and heparin sulphate proteoglycans (HSPGs), which are widely 
co-expressed on the mammalian cell surface. Furthermore, a number of co-factors have 
been described that strengthen this interaction. In several cellular systems, CD44 
receptor isoforms containing the variant 6 exon (CD44v6) are required in order that HGF 
can elicit c-Met activation, through ternary complex formation [196]. In keeping with 
this, antagonistic peptides derived from the variant exon 6-encoded 42 amino acid 
sequence can block the binding of HGF to c-Met and thereby abrogate its function [205].  
 
The CD44 variant exon 3 contains a heparin sulphate binding site, enabling isoforms that 
contain this exon to bind HGF, perhaps facilitating the more efficient capture and 
presentation of this ligand to c-Met [158]. HGF has also been reported to promote the 
association of c-Met with CD44 containing variant exon 10, leading to efficient 
phosphorylation of c-Met and recruitment into caveolin-enriched microdomains [197].  
 
Although CD44 is commonly upregulated on mesotheliomas [198], there has been 
relatively little study of which CD44 variants are expressed in this disease. One study has 
suggested that CD44v6 may be under-represented in mesothelioma compared to other 
lung tumours [206]. To add complexity, one recent study in CD44-deficient mice 
suggests that ICAM-1 may alternatively be recruited to provide this co-receptor function 
[207] and small studies within mesothelioma suggest that ICAM-1 is very commonly and 




The other characterised molecules promiscuous to the HGF/c-Met axis are heparin 
sulphate proteoglycans (HSPGs). Heparan sulfate proteoglycans are proteins that are 
covalently linked to sulphated GAG chains [209, 210]. Ubiquitously expressed within 
mammalian tissue, these molecules have been implicated in several important biological 
processes including cell adhesion and migration, tissue morphogenesis, angiogenesis, 
and regulation of blood coagulation [211].  
 
Within the HSPG family, the most well characterised and abundant member is syndecan-
1 [210]. It is highly expressed on many epithelial cells where it plays an active role in cell 
adhesion and epithelial morphogenesis [210, 212]. The interaction of HGF with 
syndecan-1 has been described by Derksen and colleagues, who have shown that 
syndecan-1 on multiple myeloma cells binds HGF. Importantly, syndecan-1 strongly 
promotes HGF-induced signalling through c-Met, resulting in enhanced activation of 
signalling pathways involved in the control of tumour cell proliferation and survival 
[211]. The relationship of expression suggests that HGF might not only interact with c-
Met but also with syndecan-1, resulting in a ternary interaction between c-Met, HGF, and 
syndecan-1 promoting tumourigenesis [213, 214]. Their findings suggest cell surface 
syndecan-1 increases the effective concentration of HGF on the plasma membrane, where 
the binding of several HGF molecules to syndecan-1 may promote dimerisation and 
oligomerisation of the c-Met receptor, leading to enhanced receptor activation [211]. An 
alternative hypothesis put forward was the induction of a conformational change, 
whereby syndecan-1 may influence the affinity of HGF for c-Met. Sakata and colleagues 
have also previously demonstrated this with respect to HSPG binding of the NK1 splice 
variant of HGF [215].  
 
 
1.6 Cancer immunotherapy using chimeric antigen 
receptor-engineered T-cells 
 
Immunotherapy uses the immune system’s cytotoxic mechanisms for targeted tumour 
cell destruction. The existence of sophisticated immune surveillance mechanisms for 
cancer has been well characterised [216]. These immunological mechanisms are 
overcome however once cancer is clinically detectable – a disease that will affect one in 
two individuals born after the year 1960 [217].   
 
A key challenge in overcoming the poorly immunogenic nature of transformed, 
malignant cells is the fact that most tumour-associated antigens are derived from self, or 
subtly modified variations. Numerous mechanisms by which tumour cells evade the 
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immune system have been detailed below – in addition to the impairment of antigen–
presenting machinery, down-regulated expression of both HLA molecules and reduced 
expression of tumour antigens themselves. As tumours progress, they acquire stromal 
support, creating a local and systemic environment that significantly impairs the 
development and maintenance of immune responses [218].  
 
1.6.1 Immune surveillance of cancer and immune evasion by tumour cells 
Immunotherapy was designated breakthrough of the year in 2013, with the dawn of 
immune checkpoint blockers, described in section 1.1.7.4.2. This novel class of 
therapeutic agents represents a paradigm shift in the clinical management of cancer - 
with emphasis on pharmacological manipulation of the host, rather than of the disease.   
 
Immune suppression within the tumour microenvironment is predominantly mediated 
by CD4+ CD25+ FoxP3+ regulatory T-cells (Tregs) [219], in addition to other types of 
suppressor cells. It has previously been reported that tumour-derived Tregs possess 
higher suppressive activity over naturally occurring Tregs [220, 221]. Tumour cell-
mediated chemokine production [222, 223] recruiting Tregs to the tumour 
microenvironment, with evidence suggesting transforming growth factor (TGF)-β (also 
produced by tumour cells), aids the conversion of CD4+ T-cells into suppressive Tregs in 
situ [224]. Myeloid-derived suppressor cells (MDSCs), modulated dendritic cells (DCs) 
and M2 macrophages facilitate in creating an inflammatory microenvironment, 
mediating tumour initiation, angiogenesis and metastasis [225, 226]. Moreover, myeloid 
suppressor cells further inhibit antitumour T-cell function via the production of nitric 
oxide (NO) via the enzyme arginase [219].   
 
Another mediator of T-cell suppression is the immunosuppressive enzyme indoleamine 
2,3-dioxygenase (IDO) [227]. Predominantly produced by plasmacytoid dendritic cells 
(PDC) within tumours and draining lymph nodes (LN), induction is mediated via the B7-
1/2 / CTLA-4 axis [228, 229]. Indoleamine dioxygenase inhibits T-cell responses via 
tryptophan catabolism. Since activated T-cells are highly sensitive to tryptophan 




1.6.2 Introduction to Chimeric Antigen Receptors 
Under the far-reaching umbrella of cancer immunotherapy, the genetic engineering of 
peripheral blood T-cells using chimeric antigen receptor technology represents an 
exciting platform-technology. Chimeric antigen receptors (CARs) are HLA-independent 
fusion molecules that couple the target-specific binding of a cell surface antigen to the 
delivery of a potent cytotoxic T-cell activating signal (Figure 1-7). These molecules are 
delivered to peripheral blood T-cells or natural killer cells by gene transfer, generally 
using retroviral or lentiviral vector systems.  
 
 
Figure 1-7. The structural features of chimeric antigen receptors. 
An antigen-binding targeting moiety is typically comprised of antibody variable heavy 
and light chains from a monoclonal antibody that are able to self-assemble through the 
inclusion of a linker sequence to form a single chain variable fragment (scFv). In a 1st 
generation CAR, the targeting moiety is coupled via a hinge and transmembrane domain 
to an intracellular T-cell signalling domain, typically the CD3ζ chain of the TCR complex. 
The 2nd and 3rd generation CARs contain an additional one or two co-stimulatory 
endodomains, respectively. Co-stimulatory molecules CD28 and 4-1BB are most 
commonly used, although alternative designs may include motifs from ICOS, OX40, 






The ability to generate large numbers of target specific CAR T-cells that can be directed 
against native cell surface antigens circumvents a number of the immune evasion 
mechanisms discussed above.  
 
Immunotherapy using CAR T-cells has been under development for almost three 
decades, but has witnessed a substantial increase in interest over the past 5 years. This 
development has been largely driven by the unprecedented success of the CAR T-cells in 
Phase I clinical trials targeted against a variety of B-cell malignancies, most notably acute 
lymphoblastic leukaemia (ALL) [230]. In that setting, several centres in the United States 
have reported that autologous CAR T-cell immunotherapy targeted against the 
ubiquitous B-cell antigen, CD19, yields complete remission (CR) rates of 80% or greater 
in patients with otherwise untreatable disease. While these clinical data are 
unprecedented for a new cancer medicine, efficacy of this approach has not been 
demonstrated in patients with solid tumours such as MPM. 
 
1.6.3 Evolutionary design of Chimeric Antigen Receptors 
The overall structure of a CAR consists of four domains joined in series, namely: (i) an 
antigen recognition ectodomain (targeting moiety) (ii) a hinge/space (iii) a 
transmembrane domain and (iv) a signalling endodomain (Figure 1-7). These features 
are described in further detail in the following sections.  
 
1.6.3.1 Targeting domain  
The specificity of the CAR is determined by the targeting moiety, which enables the CAR 
to recognise native cell-surface antigens, independent of HLA presentation (Figure 1-7). 
Chimeric antigen receptors have been developed against a multitude of targets [231]. As 
indicated earlier, greatest success has been achieved in patients with B-cell malignancy, 
using CARs targeted against CD19, which is a ubiquitous B-cell antigen. In the context of 
solid tumours, examples of commonly used targets include HER2 [232, 233], the variant 
III mutation of epidermal growth factor receptor (EGFRvIII) [234] and mesothelin 
[235].  
 
Development of targeting moieties used in CAR constructs has proceeded over thirty 
years. In the late 1980’s Kuwana et al. studied T-cell and B-cell antigen recognition 
differences by replacing the structural variable (V)-regions of T-cell receptors (TCRs) 
with those of Immunoglobulin (Ig)-derived V-regions. This initial CAR design required 
that T-cells expressed antibody variable heavy (VH) and light chains (VL) in two separate 
polypeptide chains [236, 237]. To transfer this specificity upon a single chimeric receptor 
molecule, Eshhar et al. pioneered the use of the single chain antibody fragment (scFv). In 
an scFv, the VH and VL chains from a single antibody are joined together using a short 
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linker sequence [238]. In modern CAR designs, antibody-derived single-chain variable 
fragments (scFvs) are most commonly used for target antigen recognition and binding. 
Alternatively, targeting may be achieved using peptides [239], single domain antibodies 
[240] or ligands such as the T1E peptide, which binds several ErbB hetero- and 
homodimers [241-243]. 
 
The ability of CARs to mediate HLA-independent antigen recognition confers two 
advantages over other adoptive cell therapies such as TCR-engineered T-cell protocols. 
First, antigen recognition is not compromised by the frequent occurrence of HLA down 
regulation on tumour cells [244]. Second, this also makes CAR therapy available to all 
patients, regardless of their HLA-haplotype.  
 
The choice of binding moiety is influenced by several factors. The binding of the CAR to 
target antigen usually involves a relatively high-affinity interaction, although this is 
somewhat a “double-edged sword” - if the affinity is too high, healthy tissue that may also 
be expressing the target antigen at low levels may also be targeting, resulting in on-target 
off-tumour toxicity [245]. The use of murine hybridoma-derived scFvs is disadvantaged 
by their ability to induce host immunogenicity. The production of human anti-mouse 
antibodies (HAMAs) within the host can also block CAR T-cell function and may 
contribute to the accelerated clearance of these cells in vivo [246]. Furthermore, these 
blocking antibodies may occasionally lead to life-threatening complications such as 
anaphylaxis, as reported recently in a patient treated with repeated doses of mesothelin-
specific CAR T-cells in whom IgE HAMA developed [247]. Using a humanised or fully 
human scFv sequence for targeting can reduce the risk of such an occurrence.  
 
1.6.3.2 Hinge/ spacer domain  
The hinge and spacer domains play a predominantly structural role in the CAR, however 
they are thought to elicit a functional role in certain cases. The spacer physically 
separates the targeting moiety from the T-cell membrane (Figure 1-7). However, the 
optimum distance required is likely to be different for various antigens. Guest et al., 
evaluated the effects of a spacer/hinge in four different CARs, targeting the pan-B-cell 
antigen CD19, the onco-foetal antigen 5T4, carcinoembryonic antigen (CEA) or neutral 
cell adhesion molecule (NCAM). Enhanced cytokine release and cytotoxicity was 
observed when a spacer was included in 5T4- and NCAM-targeted CARs. However the 
opposing effect was observed with CD19- and CEA-targeted CARs [248].  
 
In a more recent study, both long and short versions of the same spacer region were 
tested in a CD19-targeted CAR. It was shown that only CAR T-cells incorporating the 
short spacer were able to eradicate xenograft tumours. By contrast, CAR T-cells 
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containing the longer spacer regions displayed poor efficacy, nor could they be 
potentiated through increased dosing or combining dual co-stimulatory domains CD28 
and 4-1BB. This same study also noted an increased rate of activation induced cell death 
with cells expressing the longer spacer [249].  
 
The conclusion from these studies is that there is likely to be an optimal length of the 
CAR ectodomain. Membrane distal epitopes do not require a hinge, whereas when 
targeting membrane-proximal epitopes, a spacer region is required for optimal activation 
[250]. However, use of an unnecessarily long spacer increases the distance between the 
surface of the CAR T-cell and tumour cell surface, reducing target cell lysis. This is 
because phosphatases with large ectodomains (e.g. CD45, CD148) may gain access to the 
formed immune synapse between the CAR T-cell and its target, dephosphorylating 
activated molecules of the signalling cascade [250].  
 
Human IgG-derived spacers are commonly used due to their stabilising effect on CAR 
expression. However, interactions between the Fc domain of the spacer and Fc gamma 
receptors (FcγRs) on myeloid cells can lead to activation-induced cell death of T-cells and 
limited persistence in vivo [251, 252]. This can be overcome by deleting or modifying 
regions of the constant heavy (CH)2 domain that are essential for FcγR binding, thereby 
improving the CAR T-cell persistence and anti-tumour activity in vivo in pre-clinical 
models [252, 253].  
 
1.6.3.3 Transmembrane domain 
Similarly, the transmembrane domain may have a combined functional and structural 
role (Figure 1-7). For example, the CD3ζ transmembrane domain has been used in some 
CAR configurations, in which it has been shown to play a vital role in the recruitment of 
endogenous elements of the TCR/CD3 complex to the CAR structure [254]. Other 
transmembrane domains commonly used include those derived from T-cell molecules 
such as CD28 or CD8.  
 
1.6.3.4 Intracellular signalling domain  
Chimeric antigen receptor T-cell activation in response to target antigen is dictated by 
the intracellular signalling domain. This element of CAR engineering has been the 
subject of considerable innovative modifications, in an effort to optimise function and 
therapeutic efficacy. Generically, the evolution of CARs can be characterised within three 
generations depending on the structure of the endodomain (Figure 1-7).   
 
When physiological T-cell activation occurs, the TCR/CD3 complex delivers an activating 
signal known as ‘signal 1’. The CD3 complex is an arrangement of homo- and 
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heterodimers consisting of four subunits – ζ, δ, ε and γ [255-257]. First generation CAR 
T-cells contain a single T-cell activating domain, most commonly derived from the ζ 
chain of the TCR/CD3 complex. Crucially, studies revealed CD3ζ alone provides a 
sufficiently potent ‘signal 1’ from its three immunoreceptor tyrosine-based activation 
motifs (ITAMs) which is capable of substituting for the comprehensive signal provided by 
the entire CD3 complex [258, 259]. 
 
Aside from the downregulation of HLA molecules, the poor immunogenicity of tumours 
results from a lack of expression of costimulatory molecules, which are required to 
provide T-cells with activation ‘signal 2’. This second signal is essential for activated T-
cells to undergo optimal proliferation, accompanied by the release of cytokines, such as 
IL-2. To provide this signal using a CAR-based system, second and third generation 
fusion receptors have been developed, incorporating one or two co-stimulatory domains 
respectively that are placed upstream of CD3ζ (Figure 1−7).  
 
The costimulatory molecule CD28 has typically been used to provide an early second 
signal, leading to high-level IL-2 secretion [260, 261]. A multitude of alternative second 
generation CAR T-cells have also been described, incorporating co-stimulatory elements 
as diverse as 4-1BB [262-265], CD27 [266, 267], OX40 [262, 263], ICOS [263] and 
DAP10 [262, 267].  
 
Second generation CAR T-cells have consistently been shown to improve T-cell function 
compared to first generation counterparts [262, 266, 268]. Highest levels of IL-2 
production have been observed with the incorporation of CD28 [262], although 
depending on the certain disease states, this may be counter productive with enhanced 
intra-tumoural infiltration by regulatory T-cells [269]. Chimeric antigen receptors 
containing 4-1BB have been shown to promote the highest multi-functionality of cytokine 
production [270] and constitutive signalling resulting in sustained T-cell survival [268]. 
Comparatively, co-stimulation by ICOS induced the greatest cytotoxicity [263], 
promoting the persistence of Th17-type CAR+ T-cells [271].   
 
Second generation CARs used in clinical trials most often incorporate CD28 or 4-1BB 
signalling domains, both of which demonstrated prolonged persistence when expressed 
in CD19-targeted CARs [272, 273]. Emerging clinical experience with these two second 
generation configurations suggests that CD28-containing constructs undergo more rapid 
in vivo expansion and decline whereby 4-1BB-contianing fusions may persist for longer 




Third generation CARs incorporate two co-stimulatory modules placed in series within 
the CAR endodomain [275, 276]. Since CD28 and TNF receptor family members each 
initiate different signalling pathways (PI3K for CD28 compared to tumour necrosis 
family receptor-associated factor (TRAF) adaptor proteins for 4-1BB), this approach may 
enhance overall T-cell activity [233, 277]. Third generation CAR T-cells have recently 
commenced clinical evaluations [278], although it remains too soon to comment as to 
whether these represent a significant therapeutic advance over second generation 
configurations.  
 
Co-stimulatory signals to CAR T-cells may also be provided in trans. Functionality of 
trans co-stimulatory fusion molecules were first demonstrated in human T-cells a 
number of years ago [279]. Building upon this foundation, groups from a number of 
institutions have co-expressed a first generation CD3ζ-based CAR with a co-stimulatory 
fusion receptor that engages a second target molecule. This “dual targeting” CAR 
approach has been tested pre-clinically targeting MUC-1 and HER-2 [280], prostate-
specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA) [281], and the 
combination of folate receptor α and mesothelin [282]. The main advantage of 
separating the co-stimulatory molecule from the CD3ζ endodomain is to provide a 
greater level of tumour specificity, diminishing the risk of “on target – off tumour” 
toxicity.  
 
1.6.4 Clinical studies of CAR T-cell immunotherapy   
The past decade has seen an unprecedented rise in the number of clinical studies 
undertaken to evaluate CAR T-cell based immunotherapy. Presently, there are over 120 
clinical trials investigating CAR T-cell therapies listed on clinicaltrials.gov.uk (search 
date 19/05/16), involving a multitude of malignant diseases. CD19-targeted CAR T-cell 
immunotherapy of B-cell malignancy account for the majority of studies, although 
several trials are evaluating CAR T-cell therapy of various solid tumour types.  
 
1.6.4.1 CAR T-cell immunotherapy for haematological malignancy  
Unquestionably, the greatest success with CAR T-cell therapy to date involves CD19-
targeted treatment of B-cell malignancies. CD19 is arguably one of the most ideal 
antigens targeted to date – it is expressed by the majority of B-cell malignancies and at 
all stages of B-cell lineage differentiation. Importantly however, it is not found on 
haematopoietic stem cells or other tissues [283]. Effective targeting of CD19-expressing 
cells by engineered CAR T-cells is generally accompanied by B-cell depletion and 
impaired antibody-generating capabilities, which can be effectively mitigated by 




Striking complete response (CR) rates have been achieved with second-generation CD19-
targeted CAR T-cells in both adult and paediatric patients with B-cell ALL. Relatively 
large-scale studies conducted by groups at Memorial Sloan Kettering Cancer Centre 
(MSKCC), University of Pennsylvania (UPenn) and the National Cancer Institute (NCI) 
have all attained results with remarkable efficacy (average CR rate approaching 90%) 
[285-287]. The significance of near symmetrical results are particularly noteworthy when 
one considers the differences between centres in the selection of CAR scFv targeting 
moieties, co-stimulatory molecules (MSKCC, Seattle and NCI - CD28; UPenn – 4-1BB) 
and conditioning regimens [230].  
 
First reported in 2011, Sadelain and colleagues from MSKCC have now treated 45 ALL 
patients with CD19-targeted CAR T-cells [272, 288] [285]. An 82% CR rate was observed 
without any difference in survival of patients who subsequently did or did not receive an 
allogeneic haematopoietic stem cell transplant (HSCT; John Maher, personal 
communication May 2015). 
 
Maude et al., have reported a 90% CR rate (27/30) in ALL patients treated at UPenn, 
some of whom had failed previous HSCT [287]. Sustained remission (24 months) was 
achieved in 19 patients. A notable difference emerging between these results and those 
from MSKCC was the sustained, long-term persistence of 4-1BB containing CD19-
targeted CAR T-cells, which regularly persisted in high numbers for up to four years post 
infusion. Contrastingly, CD19 re-targeted T-cells containing CD28 co-stimulatory 
domains appear to persist at significant levels for a considerably shorter duration (1-3 
months) [285]. At the NCI, a 70% CR rate was reported from an intent-to-treat analysis 
of 20 children and young adults with ALL [286].  
 
The method to induce sufficient co-stimulation has evolved to a more refined system 
with the use of second generation CARs. In patients with relapsed or refractory non-
Hodgkin’s lymphoma Savoldo et al., directly compared the expansion and persistence in 
vivo of T-cells transduced with a first generation (CD3z) or second (CD28/ CD3z) 
generation CD19-targeted CAR [289]. Only second generation, CD19-28z T-cells were 
able to expand in vivo, resulting in trafficking and infiltration within tumour lesions 
[289]. 
 
1.6.4.2 CAR T-cell immunotherapy of solid tumours  
Refractory or metastatic solid tumours continue to represent the greatest unmet need 
within cancer medicine. Thus, initial clinical studies of CAR T-cell immunotherapy were 
conducted in patients with solid malignancies [246, 290]. However, results were 
disappointing with no detectable efficacy observed. Building upon this foundation, the 
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field of CAR T-cell immunotherapy has evolved to combat this extremely challenging 
setting.  
 
Kershaw et al. undertook the first Phase I CAR T-cell study in patients with metastatic 
epithelial ovarian cancer in 2006 [246]. Patients were treated with a first-generation 
scFv-based CAR targeted against folate receptor-α. Administered intravenously (IV), no 
toxicity was observed; however there was also no evidence of efficacy. The lack of an anti-
tumour response was linked to poor T-cell homing to the tumour and failure of 
transduced T-cell persistence [246]. Park and colleagues observed a similar result in 
neuroblastoma patients treated with CAR-engineered T-cells redirected against the L1-
cell adhesion module CD171 [291]. Although a single partial response (PR) was recorded, 
limited T-cell persistence in vivo was also cited as an explanation for poor anti-tumour 
activity.  
 
The absence of sufficient co-stimulatory signals within first-generation CAR T-cells has 
been cited as the probable reason for the limited persistence and poor efficacy. One 
strategy to improve the persistence of T-cells in vivo has resulted in the greatest success 
to date in patients with solid tumours. Epstein-Barr virus (EBV) specific cytotoxic T-cells 
were transduced with a GD2-specific CAR to treat patients with neuroblastoma. The 
underlying rationale was that native T-cell receptors would be engaged on CAR+ T-cells 
by EBV infected B-cells or latent viral antigens, thereby providing co-stimulation in vivo 
[292]. Long-term persistence (up to 192 weeks) was associated with clinical benefit 
observed in eleven patients with active disease resulting in three complete remissions 
[293].  
 
An interesting observation was the positive correlation between T-cell persistence and 
CD4+ and central memory CD8+ T-cells in the adoptive cell product [293]. A number of 
studies have subsequently studied the expression of CARs within defined populations of 
T-cell subsets [294], or potentially long-lived subsets such a memory stem cells (Tscm) 
[295, 296].  
 
1.6.5 Toxicity associated with CAR T-cell immunotherapy 
Toxicity induced by CAR T-cell immunotherapy in clinical studies has broadly been 
characterised within three major categories – tumour lysis syndrome, cytokine release 
syndrome and on-target off-tumour toxicity.  
 
1.6.5.1 Tumour lysis syndrome 
Tumour lysis syndrome encompasses a combination of metabolic disturbances - 
including elevated serum levels of potassium, uric acid and phosphate. Furthermore, 
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hypocalcaemia may develop, possibly progressing to renal failure. It has been reported 
following the rapid elimination of large numbers of tumour cells, most notably within the 
context of haematological malignancy. It has also presented surprisingly late in some 
patients following delivery of CAR T-cells [273, 297], presumably due to expansion of 
CAR+ T-cells following adoptive transfer resulting in delayed tumour destruction. 
 
1.6.5.2 Cytokine release syndrome 
Cytokine release syndrome (CRS) is the most frequent life-threatening event induced by 
CAR T-cell immunotherapy [287]. This process involves the release of a cascade of 
cytokines from CAR T-cells themselves and cells of the mononuclear phagocyte lineage. 
High concentrations of pro-inflammatory cytokines, including tumour necrosis factor 
(TNF-α), interferon-y (IFN-γ) and IL-6 [298] have been registered. In certain cases, the 
macrophage activation syndrome accompanies CRS – a notable observation following 
pre-clinical models in which CAR T-cell induced CRS implicate macrophage activation as 
a key component of disease pathogenesis [299].  
 
Recent clinical evidence suggests the severity of CRS depends upon the disease burden 
[272, 287]. Due to the often rapid (but unpredictable) onset of CRS, close monitoring of 
patients is required - particularly within 24-48 hours following the infusion of CAR T-
cells. However, there have also been reports of delayed onset of CRS, particularly when a 
small dose of CAR T-cells are administered and undergo substantial expansion in vivo. A 
fine balance exists between the management of CRS relative to T-cell activation and 
effector function. Since a degree of cytokine release is expected, the potential dilemma in 
therapeutically blocking this process may entail the use of immunosuppressive agents 
diminishing any potential anti-tumour efficacy. However, severe CRS may be be rapidly 
lethal, as exemplified in one patient treated with HER2 directed CAR T-cells [300]. 
Recently, further understanding has led to both diagnostic and grading systems being 
developed for this syndrome [285, 301]. A potential biomarker for CRS is the serum C-
reactive protein (CRP). Furthermore, the IL-6 receptor α-blocker, tocilizumab, has also 
been widely incorporated in clinical study protocols as an immunosuppressive agent that 
diminishes the manifestations of CRS. 
 
1.6.5.3 On-target off-tumour toxicity 
On-target off tumour toxicity results from CAR T-cells recognising antigens that are not 
only overexpressed in tumours but also present in healthy tissues at lower levels. 
Although an ‘acceptable’ adverse event in the context of CD19-targeted CAR T-cell 
therapy for otherwise untreatable B-cell malignancy, the challenges with on-target off 
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tumour toxicity within the context of solid tumours has been highlighted by two major 
serious adverse events reported in CAR T-cell Phase I trials.  
 
The first reported case in solid malignancy was a patient with metastatic colon cancer 
treated with an IV infusion of HER-2 re-targeted T-cells [300]. The third generation CAR 
incorporated an scFv derived from the trastuzumab antibody coupled to CD28 + 4-1BB + 
CD3ζ signalling domains. Following lymphodepletion chemotherapy, a total of 1 x 1010 T-
cells (79% CAR+) were infused systemically resulting in recognition of low levels of HER-
2 within lung endothelium, leading to rapid onset of respiratory distress, multi-organ 
failure, cytokine release syndrome (CRS) and unfortunately, death [300, 302]. As a 
consequence, subsequent protocols were amended and HER-2 has been safely targeted 
in sarcoma patients following systemic infusion of second generation (CD28/ CD3ζ) CAR 
T-cells at lower doses and without prior lymphodepletion [303].  
 
The second reported example of on-target off-tumour toxicity occurred in patients with 
metastatic renal cell carcinoma. Carbonic anhydrase-IX (CAIX) is frequently 
overexpressed in the clear cell subtype of this tumour, justifying a clinical trial using 
first-generation CAR T-cells that were targeted against this molecule [290, 304, 305]. 
Significantly however, hepatotoxicity was observed in a number of patients owing to 
recognition of CAIX on biliary epithelial cells. Toxicity was circumvented in subsequent 
studies using a low dose of CAIX blocking antibody, administered prior to CAR T-cells 
[304].  
 
Whilst solid tumours have largely proven refractory to CAR T-cell therapy to date, the 
encouraging data presented in patients with B-cell malignancy fuels further clinical 
development (recent published CAR T-cell trials in solid tumours [306]. Nonetheless, 
there remain a large number of obstacles to the effective treatment of solid malignancies 
with CAR-engineered T-cells. These include the need to refining T-cell trafficking to 
tumour sites and to enhance their persistence, intra-tumoural penetration and effector 
function within hostile tumour microenvironments. Overcoming these challenges will 
require greater innovation in CAR engineering in addition to potential combinatorial 




1.7 Aims of this Thesis 
 
This thesis details the work that I have undertaken to investigate the feasibility of using 
c-Met re-targeted CAR T-cells for the treatment of MPM.  
 
The specific aims of this PhD study are: 
1. Engineering a panel of c-Met-specific CARs. 
2. To determine the target specificity and co-factor dependency of these CARs using 
an NIH 3T3-derived aAPC system. 
3. To evaluate and compare in vitro cytotoxic activity of c-Met re-targeted CAR T-
cells using a panel of four mesothelioma cell lines. 
4. To investigate combinatorial therapy approaches to potentiate c-Met re-targeted 
CAR T-cell immunotherapy of mesothelioma. 
5. Development of a c-Met-expressing MPM tumour xenograft model that is 
amenable to serial monitoring using bioluminescence imaging. 
6. Evaluation of in vivo anti-tumour activity of c-Met re-targeted CAR T-cells 




CHAPTER 2 Materials and Methods 
 
2.1 Molecular Biology Techniques 
 
Generic molecular biology methods are described first before the description of how 
these were used in the construction of novel plasmids used in this project.  
 
2.1.1 Restriction enzyme digestion of plasmid DNA 
The production of the novel CAR constructs required DNA digestion with restriction 
enzymes. Additionally, restriction patterns were used to accurately verify plasmid inserts. 
Digestion was performed in the presence of relevant buffers designed to optimise enzyme 
efficiency.  
 
2.1.1.1 Materials, Reagents and Equipment 
- Restriction enzymes      New England Biolabs (NEB) 
- 10x Enzyme buffer       NEB 
- 100x Bovine Surum Albumin (BSA)*    NEB 
- Nuclease Free H2O      BioLine 
- DNA template 
- Eppendorf Mastercycler Gradient PCR Machine   Eppendorf 
- 37°C Water bath    
- Ice 
 
* only when required with certain restriction enzymes 
 
2.1.1.2 Protocol  
1. A 20µl reaction mixture, as detailed below for a double digest, was produced. All 
components were kept at 4°C throughout 
a) 0.5-1.0µg DNA template 
c) 2µl NEB buffer 
d) 10-20U Enzyme 1 
e) 10-20U Enzyme 2 
f) 1µl 1:10 diluted BSA 
g) made to a final volume of 20µl with nuclease free H2O 
 
N.B. in reactions requiring a single enzyme, the 20µl reaction volume was achieved using 
additional ultrapure water. For sequential digests, a 20µl reaction containing the first 
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enzyme only was produced. The second enzyme (1.2µl) and respective buffer (3µl) were 
added after the completion of the first incubation. When performing these sequential 
digest, the enzyme requiring the buffer containing a lower salt concentration was used in 
the first reaction.  
2. Reaction mixtures were incubated for one hour in a PCR machine or water bath at the 
temperature required for optimal enzyme activity.  
3. Once completed, 20µl aliquot reactions were mixed with 4µl DNA loading buffer and 
separated by electrophoresis on an agarose gel.  
 
2.1.2 Isolation of DNA fragments using Agarose Gel Electrophoresis 
Separation of DNA fragments was achieved using agarose gel electrophoresis. The 
constant mass to charge ratio of DNA molecules means that separation is determined by 
fragment size. Migration rates are therefore influences by the pore size of the gel, which 
in turn is determined by the agarose concentration (Table 2-1). Consequently, careful 
selection of the percentage of agarose used ensured optimal resolution of the fragments 
of interest.  
 
Table 2-1. Agarose concentrations to achieve specific DNA fragments. 







(Adapted from [307]) 
 
2.1.2.1 Materials, Reagents and Equipment 
- Electrophoresis grade agarose    MP Biomedicals 
- TBE buffer*        
- Ethidium bromide     Sigma 
- DNA loading buffer     NEB 
- 1kb DNA ladder     Invitrogen 
- Gel mould      Biorad 
- Gel comb      Biorad 
- Gel tank      Life Technologies 
- Power pack      Kingshill 
- Microwave oven     Proline 
67 
 
- UV Transilluminator     UVI Tech 
- TV Zoom lens      Avenir 
- P90 Thermal Monochrome Printer   Mitsubishi 
 
Buffers and solutions: 
*10x TBE = 108g Tris-base, 55g boric acid, 9.3g EDTA in 1L deionised water; 
    
2.1.2.2 Protocol  
N.B. The protocol detailed below is for the production of a 1% 100ml agarose gel. The 
weight of agarose used and the volume of TBE into which it was dissolved differed 
depending upon the size and percentage of the gel required. 
 
1. 1g of agarose was mixed with 100ml 1xTBE and heated in a microwave oven (with 
regular agitation) until completely dissolved. 
2. After cooling under cold running water to 37°C, 0.30µg/ml ethidium bromide was 
added and the mixture swirled vigorously to ensure even distribution without the 
introduction of air bubbles.  
3. The gel was poured into a pre-cast mould, a comb inserted and left to set at room 
temperature.  
4. Prior to loading, samples were mixed 5:1 with 6x DNA loading buffer. In addition 
to the samples, a 1kb DNA ladder was loaded to allow the size of migrating DNA 
fragments to be estimated.  
5. Once loaded, the gel was run at 5-8V/cm until sufficient migration (as visualised 
by the loading dye) had occurred.  
6. The DNA was visualised with UV light at 154nm using a UV transilluminator. 
Images were taken using a TV zoom lens and thermal monochrome printer.  
 
N.B. In instances when DNA was required for further manipulation, the level of UV 
exposure was minimised to reduce the risk of mutagenesis.  
 
2.1.3 Retrieval of DNA from Agarose Gel 
DNA fragments were isolated from agarose gel to enable their insertion into a viral 
vector. Isolation of the DNA relies its ability to bind the silica membrane of a purification 
column in the presence of chaotropic salt. The DNA is subsequently eluted following the 
replenishment of the hydration gel upon the addition of water.  
 
2.1.3.1 Materials, Reagents and Equipment 
- Wizard SV Gel and PCR CleanUp System  Promega 
- Water bath 
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- Eppendorf 5415R Microcentrifuge   Eppendorf 
- 1.5mL Eppendorfs     Greiner Bio-One 
- Vortex       Rotormixer 
- Scalpel       Swann Morton Ltd 
- Balance      Mettler Toledo 
- UV Transilluminator     UVI Tech 
 
Buffers and solutions: 
Membrane Binding Solution (MBS) = 4.5M guanidine isothiocyanate, 0.5M potassium 
acetate (pH 5.0); 
Membrane Wash Solution (MWS) = 10mM potassium acetate (pH 5.0), 80% ethanol, 
16.7µM EDTA.    
 
2.1.3.2 Protocol  
1. The location of the required DNA fragment was visualised with UV light at 254nm 
using a UV transilluminator.  
2. The required DNA band was excised from the gel using a sterile scalpel and 
placed into a nuclease-free 1.5ml Eppendorf tube.  
3. The gel fragment was weighed and submerged in the requires volume of 
membrane binding solution (MBS, v/w 1µl/1mg) and incubated at 54°C with 
frequent vortexing until the gel had completely melted.  
4. The resulting mixture was added to the silica membrane within a purification 
column and centrifuged at 10,700g for one minute in a microcentrifuge.  
5. The eluate was discarded, the column washed with 700µl membrane wash 
solution and subsequently centrifuged for one minute at 10,700g. 
6. The eluate was discarded, the column washed with 500µl membrane wash 
solution and subsequently centrifuged for five minutes at 10,700g. 
7. Following an additional dry centrifugation step, the DNA bound to the membrane 
was eluted by the addition of nuclease-free water and centrifugation at 10,700g. A 
one-minute incubation step at room temperature was performed prior to 





2.1.4 Calf Intestinal Alkaline Phosphatase Treatment of DNA 
Calf Intestinal Alkaline Phosphatase (CIP) catalyses the removal of 5’ phosphate groups 
from DNA, RNA, ribo- and deoxyribonucleoside triphosphates. Since CIP-treated 
fragments lack the 5’ phosphoryl termini required by ligases, they cannot self-ligate. This 
property can be used to decrease the vector background in cloning strategies [307]. 
 
2.1.4.1 Materials, Reagents and Equipment 
- CIP (10,000U/ml)     NEB 
- DNA template      NEB 
- Nuclease free H2O     BioLine 
- Ice 
 
2.1.4.2 Protocol  
N.B. All steps of the protocol (except for incubations) were performed on ice. 
 
1. The CIP was diluted 1/30 in nuclease free H2O to a final concentration of 0.3U/µl. 
2. For each 1µg of DNA template (from a previously performed restriction digest), 
0.5U CIP was added. 
3. The mixture was incubated at 37°C for 45 minutes. 
4. Optional: CIP was incompletely inactivated by incubating the samples for 30 
minutes at 65°C. Because CIP cannot be completely heat inactivated, further 
processing of the sample was required immediately. 
5. The appropriate amount of 6x loading buffer was added and the sample was run 
on an agarose gel.  
 
2.1.5 Fragment Insertion using DNA Ligation 
New DNA fragments were inserted into a linearised vector backbone using a ligation 
reaction.  
 
2.1.5.1 Materials, Reagents and Equipment 
- T4 DNA Ligase     NEB 
- 10x T4 DNA Ligase Buffer    NEB 
- Nuclease-Free water     Promega 
- Eppendorf mastercycler Gradient PCR Machine Eppendorf 




2.1.5.2 Protocol  
1. A 20µl ligation mixture, as detailed below, was produced. The example given is 
representative of a three-piece ligation. 
a) Xµg DNA Backbone 
b) Xµg Fragment 1 
c) Xµg Fragment 2 
d) 2µl 10x DNA Ligase Buffer 
e) 2µl (4000 cohesive end units) DNA Ligase 
f) Xµl Nuclease-free water 
 
N.B. For reactions requiring ligation of fewer or more fragments, the volume of nuclease-
free water was altered to ensure a final reaction volume of 20µl.  
 
2. The reaction was incubated overnight at 15°C in the Eppendorf mastercycler 
Gradient PCR Machine.  
 
2.1.6 Analysis of DNA Concentration 
The concentration of DNA was measured using the Nanodrop ND-1000 system. The 
Nanodrop is a full-spectrum (220-750nm) spectrophotometer that can assay 1uL 
samples. The sample is pipetted onto the end of a fibre optic cable (the receiving fibre). A 
second fibre optic cable (the source fibre) is then brought into contact with the liquid 
sample causing the liquid to bridge the gap between the fibre optic eds. The gap is 
controlled to both 1mm and 0.2mm paths. A pulsed xenon flash lamp provides the light 
source and a spectrometer utilising a linear CCD array is used to analyse the light after 
passing through the sample.  
 
2.1.6.1 Materials, Reagents and Equipment 
- Nuclease Free H2O     BioLine 
- Elution Buffer      Qiagen 
- Nanodrop ND-1000     Thermo Scientific 
 
2.1.6.2 Protocol  
1. The Nanodrop is equilibrated using 1µl nuclease-free H2O. 
2. Blank measurement is made using 1µl of elution buffer. 
3. 1µl of DNA is added to the Nanodrop 
4. The DNA concentration is directly calculated by the Nanodrop software and given 
in ng/µl, using the measured absorbance and the Beer-Lambert equation. 
a) Absorbance = -log(intensitysample/intensityblank) 
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b) The Beer-Lambert equation is used to correlate the calculated absorbance 
with concentration: 
A = E * b * c 
A = the absorbance represented in absorbance units 
E = the wavelength-dependent molar absorptivity coefficient with units of litre/mol-cm 
b = path length in cm 





2.1.7 Transformation of Escherichia (E.) Coli TOP10F’ Strain 
Replenishment of plasmid stocks and selection of newly produced vectors was achieved 
by introducing the plasmid onto chemically competent E. Coli. All steps followed 
common microbiological practise, using a Bunsen burner to provide the sterile vacuum.  
 
2.1.7.1 Materials, Reagents and Equipment 
- TOP10F’ E. Coli                                                                       Invitrogen, UK 
- Plasmid DNA 
- Agar plates 
- Ampicillin 
- Super Optimal broth with Catabolite repression (SOC) media  
- Glucose       BDH 
- Water Bath 
- Ice 
- Oven set at 37°C      Genlab Ltd 
- Bunsen Burner 
- Excella E-25 shake incubator 
- Eppendorf 5415R refrigerated Microcentrifuge  Eppendorf 
- Glass spreaders  
- 100% Ethanol       Fisher Scientific 
      -  L broth 
Buffers and solutions: 
Membrane Binding Solution (MBS) = 4.5M guanidine isothiocyanate, 0.5M potassium 
acetate (pH 5.0); 
Membrane Wash Solution (MWS) = 10mM potassium acetate (pH 5.0), 80% ethanol, 
16.7µM EDTA. 
 
2.1.7.2 Protocol  
1. 25µl aliquot of competent E. Coli was thawed on ice. 
2. 1µg Plasmid DNA was added to the E. Coli and incubated for 30 minutes on ice.  
3. Bacteria were heat shocked at 42°C for 90 seconds and subsequently incubated 
on ice for 5 minutes.  
4. Following addition of 300µl SOC media, samples were shaken at 160rpm for one 
hour at 37°C.  
5. Simultaneously, agar plates (see 2.1.13) containing the required antibiotic 
(ampicillin) were warmed in an oven at 37°C. 
6. 150µl SOC media, bacteria were spread onto the pre-dried agar plate and 
incubated either at 37°C overnight, or at room temperature for 72 hours.   
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2.1.8 Production of Agar Plates 
 
2.1.8.1 Materials, Reagents and Equipment 
- LB-Agar       Novagen 
- Ampicillin       Sigma 
- Microwave Oven 
- Non-tissue culture treated 10cm petri-dishes  Falcon 
- Bunsen burner 
 
Buffers and solutions: 
Agar = 5g yeast extract, 10g peptone from casein, 10g NaCl in 1L deionised water 
 
2.1.8.2 Protocol  
1. 500ml agar was melted in a microwave oven for 20 minutes at 40% maximum 
power to obtain a molten solution. 
2. After cooling down, 50mg ampicillin was added and mixed thoroughly.  
3. The solution was distributed evenly over 20 petri dishes and left to solidify at 
room temperature.  
4. Petri dishes were stored at 4°C (upside down). 
 
 
2.1.9 Selection of Bacterial Clones 
 
2.1.9.1 Materials, Reagents and Equipment 
- L-Broth 
- Ampicillin 
- 14ml Polystyrene round-bottom tubes 
- 20µl pipette tips     Star Lab 
- Excella E-25 Shake Incubator 
 
Buffers and solutions: 
L-broth: 10g tryptone, 5g yeast extract, 0.5g NaCl 
 
2.1.9.2 Protocol  
1. 3ml of L-broth, containing 150ng of ampicillin was aliquoted into the 14ml round-
bottom tubes. 




3. The tubes were shaken at 160rpm for 16 hours at 37°C prior to being centrifuged 
at 1500g for 10 minutes to pellet the bacteria. The supernatant was discarded and 
the pellet subjected to plasmid isolation.  
 
2.1.10 Isolation of Plasmid DNA - Miniprep 
Retrieval of plasmid DNA was achieved using a QIAprep Spin Miniprep kit. Approach is 
based on the rapid alkaline procedure reported by Birnboim and Doly [308], in which 
bacterial lysis was achieved using sodium dodecyl sulphate (SDS) in the presence of 
200mM sodium hydroxide (NaOH). The resulting denaturing of proteins and 
chromosomal DNA caused by the strongly alkaline environment ensured their co-
precipitation with SDS upon neutralisation of the solution and the conversion to high salt 
conditions by the addition of potassium acetate. The supercoiled conformation of the 
plasmid DNA prevented separation of the DNA strands, thereby ensuring that it 
remained in solution. Contaminating RNA was removed by both the addition of RNAse A 
to the initial resuspension buffer and precipitation in the high salt environment of the 
neutralisation buffer. Removal of any remaining impurities was achieved by running the 
aqueous phase through a column containing a silica membrane. The presence of the 
chaotropic salt, guanidine hydrochloride, in the neutralisation buffer induced 
dehydration of the plasmid DNA, allowing it to bind strongly to the silica membrane 
[309], whilst other contaminating factors were removed in the flow-through. Following 
wash steps with chaotropic salt and ethanol-containing buffers, the purified plasmid 
DNA was eluted from the column using a low salt buffer.  
 
2.1.10.1 Materials, Reagents and Equipment 
- QIAprep spin Miniprep kit    Qiagen 
- Transformed TOP10F’ E. Coli 
- 1.5ml Eppendorfs 
- Eppendorf 5415R refrigerated Microcentrifuge Eppendorf 
 
Buffers and solutions: 
Buffer P1 = 50mM Tris-Cl, 1mM EDTA, 100µg/ml RNAse 
Buffer P2 = 200mM NaOH, 1% SDS 
Buffer EB = 10mM Tris-Cl (pH 8.5) 
 
N.B. Qiagen does not publish the full composition of the neutralising N3 buffer, buffer 
PB or buffer PE. Buffer N3 is known to contain guanidine hydrochloride (as the source of 
chaotropic salt) and acetic acid (possibly potassium acetate) to neutralise the alkaline 
environment caused by the NaOH in buffer P2. The composition of buffer PE is not 




2.1.10.2 Protocol  
1. Pelleted bacteria were resuspended in 250µl buffer P1. 
2. An equal volume of buffer P2 was added and the sample was gently inverted 
approximately 10 times to ensure complete mixing.  
3. After a five-minute incubation at room temperature, 350µl buffer N3 was added 
to each sample. Complete mixing was achieved thorough gentle inversion.  
4. Configuration at 15,700g pelleted the white precipitate in each sample.  
5. The aqueous phase was carefully transferred to a QIAprep spin column and the 
white precipitate discarded. 
6. Each column was washed with 750µl buffer PE and centrifuged at 15,700g and 
the eluate was again discarded. 
7. After an additional centrifugation at 15,700 x g to remove any residual ethanol, 
the DNA was eluted in 50µl buffer EB through centrifugation at 15,700g. 
8. The concentration of the isolated DNA was determined and stored at -20°C.  
 
2.1.11 Isolation of plasmid DNA - maxiprep 
Maxi-preps were used for the isolation of highly concentrated plasmid DNA. As with 
mini-preps, the process relies on bacterial lysis under strong alkaline conditions, with 
proteins and chromosomal DNA removed by precipitation upon neutralisation and 
conversion to a high salt environment. RNA impurities were removed through the 
addition of RNase A in the initial re-suspension buffer. Once insoluble contaminants had 
been removed by centrifugation, the supernatant (containing the plasmid DNA) was 
subjected to anion-exchange chromatography. The negatively charged plasmid DNA 
binds strongly to the positively charged diethylaminoethyl (DEAE) resin beads and is 
then eluted using a high-salt containing buffer. Intermediate washes with buffers of 
increasing salt concentrations ensured the removal of remaining contaminants. Once 
eluted, the DNA was precipitated and desalted using a series of alcohol washes before 
being dissolved in TE buffer. 
 
 
2.1.11.1  Materials, Reagents and Equipment 
• 100mL TOP10F’ E. coli containing plasmid of interest  
• QIAGEN Plasmid Maxi Kit 
• 1.5mL Eppendorf tubes 
• Oak Ridge polycarbonate centrifuge tubes 
• Oak Ridge polypropylene copolymer centrifuge tubes 
• Sorvall RC 5B Centrifuge 
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• 70% Ethanol 
• Isopropanol  
 
Buffers and Solutions: 
Buffer P1 = 50mM Tris.HCl (pH 8.0), 10mM EDTA, 100µg/mL RNase A 
Buffer P2 = 200mM NaOH, 1% (w/v) SDS 
Buffer P3 = 3M Potassium Acetate  
Buffer QBT = 750mM NaCl, 50mM 3-(N-Morpholino)-propanesulfonic acid (MOPS), 
15% (v/v) isopropanol, 0.15% (v/v) Triton X-100 
Buffer QC = 1M NaCl, 50mM MOPS, 15% (v/v) isopropanol 
Buffer QF = 1.25M NaCl, 50mM Tris.HCl (pH 8.5), 15% (v/v) isopropanol 
TE Buffer = 10mM Tris.HCl (pH 8), 1mM EDTA. 
 
2.1.11.2  Protocol 
1. Once pelleted, the bacteria were re-suspended in 10 mL buffer P1 and bacterial 
lysis was induced by addition of an equal volume of buffer P2. Mixing ensured 
complete lysis.  
2. Pre-chilled buffer P3 (10 mL) was added after a maximum of five minutes of lysis 
and the solution was well mixed to ensure complete neutralisation.  
3. The solution was incubated on ice for approximately 15 minutes before being 
centrifuged at 20,200g for 30 minutes at 4°C. 
4. The supernatant was decanted into a fresh polycarbonate centrifuge tube and 
centrifuged at 20,200g for 15 minutes at 4°C to ensure complete removal of all 
insoluble contaminants.  
5. The resulting supernatant was added to a pre-equilibrated QIAGEN-tip 500 and 
left to filter by gravity flow.  
6. The tip was washed twice using 30 mL buffer QC before the plasmid DNA was 
eluted into a polypropylene copolymer centrifuge tube using 15 mL buffer QF. 
7. The DNA was precipitated by adding 10.5 mL isopropanol and pelleted by 
centrifugation for 30 minutes at 17,700g and 4°C. 
8. The pellet was washed with 5 mL 70% ethanol to remove the salt and the DNA 
pelleted by centrifugation at 20,000g for 10 minutes.  
9. After removal of the supernatant and air-drying of the DNA pellet at 37°C for 
approximately five minutes, the DNA was re-suspended in 200 µL of TE buffer. 





2.1.12 Generation of Chimeric antigen receptor-encoding retroviral 
constructs 
 
2.1.12.1 Targeting moieties for candidate c-Met re-targeted CARs 
To engineer candidate c-Met re-targeted CARs, three peptide sequences derived from the 
N and K1 domains of HGF were engineered to create targeting moieties:  
 
(i) IK1 – in which the NK1 polypeptide was stabilised with two mutations, at 
K132E and R134E [141].  
(ii) The M2.2 D127N peptide contains several stabilising mutations within NK1. 
(iii) The cdM2.2 D127N peptide is identical to (ii) except that it contains an N-
terminal cysteine.  
 
Amino acid sequences of all three peptides are shown in Figure 2-1A. Codon optimised 
cDNAs encoding for these sequences were generated using Gene Designer software 
(version 2.0, Newark California) and were flanked by 5’ NcoI and 3’ NotI restriction sites. 
Synthetic cDNAs were provided in pUC57 for subcloning into retroviral plasmid vectors. 
 
2.1.12.2 Cloning of CAR-encoding retroviral vectors 
To engineer candidate CARs, The SFG V28z retroviral vector (a gift of Dr Lynsey 
Whilding) was used to provide the vector backbone. This vector was cleaved with NcoI 
and NotI and the large 6.3kB fragment was eluted as described in section 2.1.2. pUC57 
plasmids containing the IK1, M2.2D127N and cdM2.2D127N cDNA sequences were 
digested with NcoI and NotI and the small (640bp approximately) fragments were 
extracted (section 2.1.2) and purified (section 2.1.3). After phosphatase treatment of the 
vector (section 2.1.4), DNA fragments were ligated (section 2.1.5) and E. coli transformed 
(section 2.1.7) after which clones were amplified (section 2.1.9). Miniprep DNA samples 
were prepared (section 2.1.10) and were screened by diagnostic restriction digestion 
enzyme analysis (section 2.1.1) in order to select one clone that contained the desired 
insert. This plasmid was expanded via mini/maxiprep (section 2.1.10, 2.1.11) and used to 
transfect retroviral packaging cells, as later described in section 2.2.4. 
 
The schematic structure of the encoded CARs together with control CARs used in this 
project is shown in Figure 2-1B. The SFG T28z CAR vector was provided by Dr DM 
Davies (King’s College London). The encoded CAR targets 8 of 9 possible homo- and 
heterodimers formed by the extended ErbB network [241]. The SFG V28z CAR vector 
was provided by Dr LM Whilding. It contains a 20mer targeting moiety derived from the 
foot and mouth disease virus which binds the αvβ6 integrin, but in which a critical RGDL 
amino acid sequence was mutated to AAAA, thereby abrogating all integrin binding 
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activity.  Note that in all CARs, the CD28 hinge sequence contained a myc epitope tag 
(recognised by the 9e10 antibody) which had been inserted in SFG V28z in place of the 
MYPPPY motif (involved in the binding of CD28 to B7-1 and B7-2) [310]. Inclusion of the 
myc epitope tag allowed for detection of cell surface CAR expression by flow cytometry, 
as described in section 2.5. 
 
2.1.12.3 Cloning of 4αβ-containing retroviral vectors 
The chimeric cytokine receptor 4αβ comprises of the IL-4Rα ectodomain coupled to the 
IL-2/15Rβ endodomain. The construct was engineered by Dr SE Papa and Dr S Wilkie 
prior to the commencement of this PhD and allows the selective expansion of CAR-
engineered T-cells using IL-4 [311]. The 4αβ sequence was followed by an optimised 
furin cleavage site (RRKR), a serine glycine linker, and a T2A sequence. This cDNA was 
flanked by NcoI restriction sites, allowing for cloning upstream of individual CAR cDNAs 














Figure 2-1. Schematic overview of candidate CARs generated to target c-Met 
(A) Aligned amino acid sequences of c-Met targeting moieties (1K1, M2.2 D127N or 
cdM2.2 D127N), containing the N-terminal and first Kringle domains. The NK-1-derived 
signal peptide sequence is shown in blue. (B) Diagrams show structural features of 
candidate CARs engineered to target c-Met. The resulting CARs are referred to as N28z, 
M28z and cM28z respectively. Targeting moieties are housed within second-generation 
frameworks containing CD3ζ (signal 1) and CD28 (signal 2) modules within a fused CAR 
endodomain. The Myc epitope was added between the CD28 extracellular spacer and the 
c-Met targeting peptide to enable cell surface detection of the CAR by flow cytometry. 
The targeting moiety, T1E, within the T28z CAR+ T-cells is a promiscuous ErbB ligand 
which has been fused to a CD28 + CD3ζ endodomain, serving as a useful positive control 
when targets expressed ErbB receptors. The V28z CAR contains a 20mer peptide that 
serves as a negative-control targeting moiety. This sequence was derived from the foot 
and mouth disease virus A20mer peptide that binds with high affinity to the integrin 
αvβ6, but in which a key RGDL sequence was replaced by AAAA to abrogate all integrin 









Figure 2-2. Schematic overview of bi-cistronic retroviral constructs 
To co-express 4αβ with individual CAR constructs, SFG retroviral constructs were 
engineered to contain an intervening ribosomal skip 2A peptide from the insect virus, 
Thosea Asigna (T2A). A cassette was generated in which 4αβ was fused to a furin 
cleavage site (RRKR), SGSG linker and T2A peptide. This cassette was flanked by NcoI 
restriction sites, meaning that it could be conveniently inserted upstream of CAR cDNAs 
within SFG retroviral constructs. In these constructs, the NcoI restriction site is unique 
and coincides with the start codon (ATG) of each CAR construct. Abbreviations: LTR – 
log terminal repeat; S – signal peptide; T – chimeric receptor (in this case T28z); M – 
myc epitope tag, recognised by 9e10 antibody. It is predicted that the furin T2A peptide 
causes the ribosome to skip during translation between the terminal PG and P sequence 
within the 2A peptide, meaning that a peptide overhang is appended to the C-terminus of 
the upstream protein (here 4αβ). By inclusion of the furin cleavage site, it is hope that 








2.1.13 Generation of Retroviral constructs encoding for c-Met and HGF co-
factor molecules 
SFG retroviral vectors were engineered to express human c-Met, human CD44v6 and 
human Syndecan-1. In each case the coding sequence for each molecule were were codon 
optimised for human expression using Gene Designer software (version 2.0, Newark 
California). Sequences were flanked by 5’NcoI and 3’XhoI restriction sites and were 
synthesised by Genscript (Hong Kong, China). These sequences were cloned into the 
unique NcoI and XhoI restriction sites of the SFG retroviral vector, as described in 
section 2.1.12. 
 
2.1.14 Generation of Retroviral constructs encoding for Red fluorescent 
protein and firefly luciferase 
The SFG retroviral vector was engineered to stoichiometrically co-express firefly 
luciferase (ffLuc) and tdTomato (tdTom). This was achieved through the use of T2A 
ribosomal skip sequence. The construct was engineered using a multi-step cloning 
protocol, as described in section 2.1. Sequences were flanked by 5’NcoI and 3’XhoI 
restriction sites. Firefly luciferase was isolated from the PUC57 LUC construct via 
NcoI/BamHI restriction enzyme digestion, yielding a fragment 1.7kB. TdTom was 
isolated from SFG Myc TOM using BamHI/XhoI restriction digest yielding a fragment 
1.6kb. The SFG backbone (6.3kB size) was isolated using an NcoI/XhoI digest of the CAR 
vector SFG T4, which was kindly provided by Dr DM Davies (King’s College London). 
These sequences were cloned, via 3-step ligation protocol, into the unique NcoI and XhoI 






2.2 Cell Culture 
 
All cells were incubated at 37°C, 95% O2 / 5% CO2 
 
2.2.1 Media and Common Solutions 
 
2.2.1.1 Media 
D10  = 500ml Dulbecco’s Modified Eagle Medium 
   (DMEM) + 4.5g/L glucose  Lonza 
   50ml Foetal Bovine Serum  Sigma 
   200mM GlutaMAX   Gibco 
   50,000U Penicillin   Lonza 
   50mg Streptomycin   Lonza 
   
    
D10  = 500ml Dulbecco’s Modified Eagle Medium 
(NIH 3T3)  (DMEM) + 4.5g/L glucose  Lonza 
   50ml Calf Serum 
   200mM GlutaMAX   Gibco 
   50,000U Penicillin   Lonza 
   50mg Streptomycin   Lonza 
    
 
R10  = 500ml Roswell Park Memorial Institute 
   (RPMI) 1640 Medium without L-Glutamine 
   50ml Human Serum   Sigma  
   200mM GlutaMAX    
   50,000U Penicillin    
   50mg Streptomycin      
 
2.2.1.2 Common Solutions 
Trypsin = 0.25% Trypsin-EDTA   Gibco 
CDB  = Cell Dissociation Buffer  Invitrogen Life Tech 





2.2.2 MPM tumour cell lines 
 
H28 – Human mesothelioma cell line derived from the pleural effusion of a patient with 
malignant mesothelioma – metastatic site. Epithelioid subtype (Disease stage 4).  
 
REN – Human mesothelioma cell line. Epithelioid subtype. 
 
JU77 - Human mesothelioma cell line derived from fluid of a male patient with 
malignant mesothelioma. The patient had known exposure to crocidolite asbestos. Cell 
line is not tumourigenic in nude mice. Cells of sarcomatoid subtype (no unanimous 
consensus). Cell are spindle shaped with few vacuoles.  
 
LO68 – Human mesothelioma cell line derived from fluid of a male patient with 
malignant mesothelioma. The patient had known exposure to crocidolite asbestos. Cell 
line is non tumourigenic in nude mice. Epithelial-like subtype. Cells are spindle shaped 
with few vacuoles. 
 
 
2.2.2.1 Retroviral Packaging Cell Lines 
Gene transfer undertaken during this PhD was achieved using engineered retroviral 
vectors. The genome of each retrovirus (comprising two RNA copies) encodes at least 
four specific genes, named gag, pol, env and pro [312]. The binding of a mature 
retroviral particle to a target cell is mediated by a specific receptor or molecule on the 
surface of the host cell (Figure 2-3). These glycoproteins that bind this receptor are 
encoded by the retroviral env gene and thus responsible for the tropism of the viruses 
(i.e. the target cells with which it can interact) [312]. Following fusion of the retroviral 
envelope with the host cell membrane, the RNA genome is extruded into the host cell 
cytoplasm, upon when it is converted to a double stranded DNA copy via reverse 
transcriptase. This is subsequently integrated within the host cell genome by an integrase 
enzyme, resulting in a ‘provirus’ [312, 313]. Both of these enzymes are encoded by the pol 
gene in the retroviral genome and are contained within the packaged virus, prior to being 
released into the host cell cytoplasm after viral fusion. The transcription and translation 
of the viral genome by the host cell RNA polymerase results in the production of the 
proteins encoded by the gag gene, in addition to the production of new reverse 
transcriptase and integrase enzymes (Figure 2-3).  
 
Although expressed as a single polypeptide until the later stages of viral budding, the gag 
gene encodes for a number of distinct proteins. One example is the Moloney murine 
leukaemia virus (MoMLV), the matrix (MA, p15), p12, capsid (CA, p30) and nucleocapsid 
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(NC, p10) structural proteins are all present within the gag polypeptide [312]. The N-
terminal end of the polypeptide (the N-terminus of the MA protein) is myristoylated, 
thus anchoring it to the host cell membrane and providing a focal point for which new 
viral particles may be formed. Indeed, inhibition of myristoylation interferes with viral 
assembly [314]. At the C-terminal end of the gag-encoded polypeptide, the NC protein 
interacts with the viral genome and is responsible for ensuring its packaging into the new 
retroviral particle [315]. The reverse transcriptase and integrase enzymes are 
incorporated within the new viral particle, alongside a viral protease - the product of the 
pro gene found between the gag and the pol genes. Throughout and after budding, this 
protease is responsible for cleaving the gag-encoded polypeptide into its four constituent 
proteins. The significance of this polypeptide processing is highlighted by the fact 
mutations within the cleavage site between the p12 and CA proteins are sufficient to 
inhibit the formation of infectious MoMLV viral particles [316]. This cleavage event is 
part of the maturation process, during which retroviruses gain the ability to infect target 















Figure 2-3. Retroviral Life Cycle. Adapted from [317] 
Upon target cell infection (1), the viral particle envelope and capsid are disassembled, 
releasing the viral genome and proteins into the cytoplasm. The reverse transcriptase 
(RT) from the disassembled viral particle binds to a transfer RNA (tRNA) in the 5’ LTR 
position of the viral genome, synthesising a complementary DNA strand (2). The 
template viral RNA is then degraded by the RNAse H subunit of the RT enzyme enabling 
synthesis of a second DNA strand (3). The double stranded DNA (dsDNA) is integrated 
as a provirus within the host genome by the viral integrase enzyme (4). Host RNA 
polymerase transcribes multiple viral RNA copies (5), which are then exported from the 
nucleus and transcribed to give the gag, pol and env proteins (6). These proteins, along 
with two copies of untranslated viral RNA are integrated within a new viral particle, 
which subsequently buds from the target cell.  
 
 
The ability of retroviruses to integrate their genome into that of a host cell provides an 
appealing way of achieving stable expression of a transgene within a specific target cell 
population. However, an undesirable property is the continued virus replication 
following infection of the target cell population. One way of preventing the production of 
replication-competent retrovirus (RCR) within the target cells is to replace the gag, pro, 
pol and env genes with that of the transgene of interest. However, as detailed above, the 
proteins encoded by these four genes are essential for the production and function of 
viable virions. The use of retroviral packaging cell lines offers a way of producing viral 




The retroviral genomic sequence (containing the desired gene) is subsequently packaged 
within viruses, which are thenceforth capable of infecting the target cell of choice. 
However, as these viruses do not contain the necessary genes for the formulation of fresh 
viral particles, further replication is prevented. In order to minimise the risk of 
producing RCR, the gag-pol and env genes are expressed on separate plasmids within 
the packaging cells. Consequently, three separate recombination events are required 
before all genes are expressed in cis. The pol gene is always expressed on the same 
plasmid as gag due to the fact the gag-pro-pol genes are transcribed as a single mRNA 
transcript. The presence of a stop codon at the end of the gag coding sequence means 
that, in 95% of cases, translational read-through (caused by the misreading of the stop 
codon) results in the production of a gag-pro-pol polypeptide [318]. 
 
Retroviral packaging cells used during this PhD: 
 
2.2.2.2 H29D 
The H29D retroviral packaging cell line is based on the human embryonic kidney 
adenoviral 5-transformed cell lines (HEK293, [319]). H29D expresses the MoMLV gag-
pol genes, regulated by the cytomegalovirus (CMV) immediately early (IE) [320]. 
Expression of the vesicular stomatitis virus-G (VSV-G) env proteins results in the 
production of viral particles exhibiting a broad tropism “pantropic”. Constitutive 
expression of the VSV-G envelope protein is toxic, thus controlled expression was 
achieved via placing the VSV-G coding sequence under the control of a tetracycline-
repressed promoter [320]. Activation of transcription from the promoter is dependent 
upon the binding of a tetracycline-transactivator (tTa) molecule [321]. However, in the 
presence of tetracycline, binding of the tTa molecule to promoter is inhibited, preventing 
subsequent gene expression. Consequently, to prevent constitutive expression of the 
VSV-G protein, cells were maintained in D10 media supplemented with 2µg/mL 
tetracycline. Fresh D10 and tetracycline were added every 72 hours and cells were 
passaged upon confluency. Tetracycline was removed to allow for the production of VSV-
pseudotyped virus.  
 
2.2.2.3 PG13 
The PG13 retroviral packaging cell line is derived from the NIH 3T3 murine fibroblast 
cell line [322]. Akin to H29D cells, PG13 cells express the MoMLV gag-pol genes. 
Contrastingly, PG13 viral particles are pseudotyped with the gibbon-ape leukaemia virus 
(GaLV) envelope protein. As with the VSV-G pseudotyped virus, the PG13 GaLV 




2.2.3 Retroviral Vectors 
Retroviral vectors constitute the backbone of the virus and include necessary elements, 
such as the promoter regions required for transcription of the inserted gene(s) and the 
packaging signal (ψ) required for packaging of the mRNA transcript into new viral 
particles.  
 
2.2.3.1 SFG (based on MFG) 
The SFG retroviral vector is based on the MFG vector [323], in which gene expression is 
driven by the MoMLV long terminal repeats (LTRs). The presence of the MoMLV ψ 
packaging signal ensures efficient packaging of the RNA within the virus. The presence of 
the splice donor and splice acceptor sites enables the production of the sub-genomic 
RNA transcripts, typically required for translation of the env gene [318]. The gene of 
interest is inserted from a naturally occurring NcoI site, ensuring that its start codon is in 
the precise location previously occupied by the deleted env gene. This vector does not 
contain a eukaryotic cell-compatible selectable marker gene. It does contain an 
ampicillin resistant gene for selection following transformation of competent bacteria.  
2.2.4 Production of retroviral packaging cell lines  
For the transduction of human T-cells stable PG13-retroviral packaging cell lines were 
produced using H29D viral supernatant as an intermediate for PG13 transduction. Two 
methods of transfection were used, involving calcium phosphate or polyethyleneimine. 
Both methods are described below. 
 
2.2.4.1 Materials, Reagents and Equipment 
- CalPhos mammalian transfection kit    CloneTech 
- Vortex 
- Polyethylenimine (PEI)     Sigma 
- Plasmid DNA 
- H29D cells 
- PG13 cells 
- H29D retroviral supernatant 
 
Components of the CalPhos Calcium Phosphate transfection kit: 
- 2M Calcium Solution (CaCL2) 
- 2x HEPES-buffered saline (HBS) 
- Sterile H20 
 
2.2.4.2 Calcium-Phosphate transfection (H29D) 
Preparation of H29D cells 
1. H29D cells were transduced in 6-well culture plates. 
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2. Cells were split at least 2 days prior to transfection in 3mL D10 media 
supplemented with tetracycline.  
3. The tetracycline was removed from the H29D cells, a minimum of 2 hours prior 
to transfection by replacing the tetracycline-containing D10 with fresh D10 media 
only.  
 
Preparation of Transfection Mixture 
1. Solution A was prepared and left to incubate at room temperature for 5 minutes;  
Solution A: 
- 12.4µl 2M Calcium Solution (CaCL2) 
- 1-3µg retroviral vector 
- Sterile H2O to a final volume of 100µL 
2. Solution A was added to dropwise to 100µL 2x HBS whilst vortexing.  
3. The mixture was incubated at room temperature for 20 minutes to ensure the 
formation of precipitate, before being added dropwise to the target cells.  
4. After gentle rocking ensured complete mixing of the transfection mixture, the 
cells were incubated for 24 hours after which the media was replaced.  
5. Supernatants were harvested daily from day 3-7 post transfection and directly 
used for infection of target cells (PG13).  
 
2.2.4.3 PEI-mediated transfection (H29D) 
1. H29D packaging cell lines were prepared as described in paragraph 2.2.4.2. 
2. Transfection mixture was prepared and left to incubate at room temperature for 
20 minutes. 
- 400µl serum free DMEM 
- 5µg plasmid DNA 
- 1µl 1mM PEI 
3. Transfection mixture was added dropwise to the target cells.  
4. The cells were incubated for 3-4 hours after which the media was replaced with 
fresh D10 media.  
5. Media was again refreshed 24 hours prior to the (first) harvest of retroviral 
supernatant.  
6. Supernatants were harvested daily from day 3-7 post transfection and directly 
used for target cell infection (PG13).  
 
2.2.4.4 PG13 Transduction 
1. The media was removed from empty PG13 packaging cells and replaced with 3ml 
H29D supernatant containing the VSV-pseudotyped virions.  
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2. The PG13 were then incubated for 72 hours prior to analysis for transgene 
expression using flow cytometry.  
3. PG13 cells expressing the virus of interest were subsequently used as stable 
packaging cell lines.  
 
2.2.5 Generation of NIH 3T3 artificial antigen presenting cells  
1. PG13 cells were engineered to express human c-Met or CD44v6 (plasmids 
described in section 2.1.13) as detailed in section 2.2.4).  
2. Phoenix-eco packaging cells (purchased from the European Tissue Culture 
Collection) were seeded sparsely in 6-well plates and allowed to adhere overnight.  
3. Supernatant was removed from PG13 packaging cells and was gently filtered onto 
phoenix-eco cells. Fresh viral supernatant was added every 48 hours.  
4. After 7-9 days, phoenix-eco packaging cells were FACS analysed for confirmation 
of positive expression of the designated receptor.  
5. NIH 3T3 cells were sparsely seeded in 6-well plates and allowed to adhere 
overnight.  
6. Fresh viral supernatant from transduced phoenix eco cells was gently filtered 
onto NIH 3T3 cells and replaced with fresh virus-containing medium every 24-48 
hours.  
7. After 7-9 days culture, NIH 3T3 packaging cells were FACS analysed for 
confirmation of transduction for c-Met, CD44v6, or dual positive c-Met+CD44v6 
expression.  
 
2.2.6 PBMC isolation and activation  
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using 
Ficoll-Paque gradient. Recruitment of healthy volunteer donors for this purpose was 
approved by the Guy’s Hospital research Ethics Committee (09/H0804/92; Use of 
Donor Blood Samples for Pre-Clinical Development of Active and Passive 
Immunotherapy for Cancer and 09/H0707/086; Generation of clinical grade T-cells for 
adoptive cell therapy).  
 
2.2.6.1 Materials, Reagents and Equipment 
- Fresh Blood 
- Citrate-Dextrose Solution (ACD)    Sigma 
- 50ml Syringe       BD Biosciences 
- 21G Butterfly Needle      Greiner Bio-One 
- 50ml Falcon tubes      SLS 
- Ficoll-Paque Plus      GE Healthcare 
- Eppendorf 5804 Centrifuge     Eppendorf 
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- Pasteur Pipettes      SLS 
- Anti-CD3/Anti-CD28 Dynabeads    Invitrogen 
- R10 Medium       Section 2.2.1 
  
 
2.2.6.2 Protocol  
N.B. All steps of the procedure and all reagents used are at room temperature for optimal 
cell recovery. 
1. 15ml Ficoll-Paque was aliquoted into two separate 50ml Falcon tubes. 
2. Fresh Blood (25ml) (anticoagulated with 1x citrate-dextrose solution) was slowly 
layered onto the Ficoll-Paque and then centrifuged at 1150g for 25 minutes 
(acceleration = 0, deceleration = 0). 
3. The PBMC layer, present at the interface between the Ficoll-Paque and the 
plasma was transferred into fresh 50ml Falcon tubes using a Pasteur pipette and 
diluted to a final volume of 50ml in pre-warmed PBS and centrifuged for 10 
minutes at 550g.  
4. The cell pellet was re-suspended in 50ml PBS and centrifuged for 10 minutes at 
550g.  
5. Following aspiration of the supernatant, the cell pellet was re-suspended in 10ml 
R10 media and cells were counted.  
6. Cells were re-suspended in R10 media at a concentration of 3 x 106 cells/m and 
activated with anti-CD3/CD28 paramagnetic Dynabeads at a 3:1 cell: bead ratio.  
 
2.2.7 Production of RetroNectin coated 6-well plates 
In order to improve T-cell transduction efficiency, non-tissue culture treated plates were 
pre-treated with RetroNectin (RN). Retronectin is a fragment of the extracellular matrix 
protein fibronectin that binds the target T-cell through a CS-1 domain and a cell-binding 
domain (CBD), which interacts with the VLA-4 and VLA-5 integrin receptors 
respectively. Attachment of the virus to the heparin binding domain present in RN 
between the CS-1 and CBD causes co-localisation of the target cell and the virus, thus 
greatly improving gene transfer efficiency [324, 325].  
 
2.2.7.1 Materials, Reagents and Equipment 
- RetroNectin        TaKaRa 
- Non-tissue culture treated 6-well plates             Falcon 
- PBS 
- Pasteur pipettes 





1. 200µg of RN was re-suspended in 12mL PBS/plate.  
2. 2ml of the resulting solution was transferred using a Pasteur pipette into each 
well of a non-tissue culture treated 6-well plate, thereby giving coverage 
approximately 3.5µg/cm2.  
3. Plates were incubated for a minimum of 2 hours at room temperature or 24 hours 
at 4°C prior to use.  
4. When the plate was ready to be used, unbound RN was transferred to a new plate 
using a Pasteur pipette. RN was used for a maximum of two transduction plates.  
 
2.2.8 Retroviral-mediated Human T-cell Transduction 
To introduce the CAR constructs into T-cells, they were subjected to retroviral-mediated 
transduction. This ensured integration of the inserted coding DNA into the host T-cell 
genome, thereby permitting stable CAR expression.  
 
2.2.8.1 Materials, Reagents and Equipment 
- Activated T-cells 
- Retroviral packaging cell lines 
- Centrifuge 
- Retronectin-coated plate 
- Pasteur pipettes 
- Interleukin-2 (IL-2) (Proleukin)    Novartis 
  
2.2.8.2 Protocol  
1. After the unbound RN had been transferred to a fresh plate using a Pasteur 
pipette, each well was coated with 3ml of retrovirus-containing supernatant from 
the desired packaging cell line.  
2. Activated T-cells were counted using trypan-blue exclusion and 1 x 106 viable cells 
added to each well.  
3. Each well was supplemented with 100U/ml of IL-2.  
4. Plates were centrifuged for one hour at 50g, at room temperature. 
5. Cells were subsequently cultured for 4-6 days, after which the transduction 
efficiency was determined using flow cytometry.  
 
2.2.9 Determination of the anti-tumour potential of CAR+ T-cells 
In order to demonstrate the ability of CAR T-cells to recognise and destroy c-Met 
expressing targets, they were co-cultured with a variety of murine fibroblast cell lines and 
human tumour cell lines. Target recognition and activation of CAR T-cells monitored by 
measuring cytokine release using ELISA. Anti-tumour activity was quantified using an 
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MTT (3-[4,5-dimethylthiazol-2-yl]- 2,5I- diphenyltetrazolium bromide; thiazolyl blue) 
assay, which quantifies residual viable tumour cells. 
 
2.2.9.1 Materials, Reagents and Equipment 
- Transduced T-cells 
- NIH 3T3 aAPCs 
- Tumour cells 
- D10 media 
- R10 media 
- IL-2      
- IL-4 
- 96-well cell culture plate 
- 24-well cell culture plate 
 
2.2.9.2 Protocol – 24 well plates 
1. 2 x 105 Tumour or NIH 3T3 cells were seeded into a 24-well cell culture plate and 
allowed to adhere overnight.  
2. T-cells were counted and re-suspended in R10 media at determined 
concentrations for respective effector to target ratios, and gently pipetted onto the 
surface of the tumour monolayer. 
3. After 48 hours of incubation, 400µl supernatant was removed for analysis of 
cytokine (IL-2 and IFN-γ) secretion.  
 
2.2.9.3 Protocol – 96 well plates 
1. 2 x 104 Tumour or NIH 3T3 cells were seeded into a 96-well cell culture plate and 
allowed to adhere overnight.  
2. T-cells were counted and re-suspended in R10 media at determined 
concentrations for respective effector to target ratios, and gently pipetted onto the 
surface of the tumour monolayer. 
3. After 24/48 hours of incubation, 100µl supernatant was removed for analysis of 
cytokine (IL-2 and IFN-γ) secretion (section 2.3.1).  
 
2.2.10 Quantification of tumour-cell destruction – MTT assay  
In vitro anti-tumour activity of CAR+ T-cells was quantified using an MTT (3-[4,5-
dimethylthiazol-2-yl]- 2,5- diphenyltetrazolium bromide; thiazolyl blue) assay. MTT is a 
water soluble tetrazolium salt yielding a yellow solution when prepared in media or salt 
solution lacking phenol red. Mitochondrial dehydogenases of viable cells cleave the 
tetrazolium ring in dissolved MTT, yielding purple formazan crystals, which are insoluble 
in aqueous solutions. The crystals are dissolved in acidified isopropanol. The resulting 
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purple solution is detected optimally at a wavelength of 570nm using a 
spectrophotometer. Dead cells do not cause this change. An increase or decrease in viable 
cell number results in a concomitant change in the amount of formazan formed, enabling 
the level of target cell cytotoxicity to be extrapolated [326].  
 
2.2.10.1 Materials, Reagents and Equipment 
- MTT        Sigma 
- PBS 
- DMSO        VWR 
- FLUOstar Omega      BMT Labtech 
- Omega Software (version 1.20)    BMT Labtech 
- MARS data analysis software (version 1.20 R2)  BMT Labtech 
 
2.2.10.2 Protocol – 24-well plates 
1. MTT assays were performed in 24-well cell culture treated plates. 
2. MTT stock solution was reconstituted at a concentration of 5mg/ml in PBS. Stock 
solution is stored at -20°C.  
3. MTT stock solution was diluted 1/10 (to a concentration of 500µg/ml) in D10 
media. Medium was aspirated from the co-culture and 500µl MTT (250µg) was 
added to each well.  
4. Cell cultures were incubated for 2 hours at 37°C and 5% CO2. 
5. The supernatant was aspirated and the formed formazan crystals were 
resuspended in 300uL DMSO.  
6. Absorbance was measured spectrophotometrically at 570nm. 
7. Relative cell viability was calculated using the following equation: 
Viability = (absorbance of test well/average absorbance of untreated tumour 
monolayer)x100 
 
2.2.10.3 Protocol – 96-well plates 
8. MTT assays were performed in 96-well cell culture treated plates. 
9. MTT stock solution was reconstituted at a concentration of 5mg/ml in PBS. Stock 
solution is stored at -20°C.  
10. MTT stock solution was diluted 1/10 (to a concentration of 500µg/ml) in D10 
media. Medium was aspirated from the co-culture and 50µl MTT (25µg) was 
added to each well.  
11. Cell cultures were incubated for 1-2 hours at 37°C and 5% CO2. 
12. The supernatant was aspirated and the formed formazan crystals were 
resuspended in 50µl DMSO.  
13. Absorbance was measured spectrophotometrically at 570nm. 
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14. Relative cell viability was calculated using the following equation: 
 
Viability = (absorbance of test well/average absorbance of untreated 
tumour monolayer) x 100 
 
 
2.3 Detection of cytokine release 
 
2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
2.3.1.1 Materials, Reagents and Equipment 
- High-binding flat-bottom 96-well ELISA plates   Iwaki 
- IFN-γ Ready-Set-Go ELISA Kit     eBioscience 
- IL-2 Ready-Set-Go ELISA Kit     eBioscience 
- HGF ELISA Kit 
- FLOstar Omega plate reader     BMT Labtech 
- Omega Software (vrsion 1.20)    BMT Labtech 
- MARS data analysis software (version 1.20R2)  BMT Labtech 
 
Contents of Ready-Set-Go ELISA Kits: 
- Capture antibody 
- Detection antibody  
- Con. Standard 
- 10x Coating buffer 
- 5x Assay diluent 
- Avidin-HRP 
- Substrate solution 
-  
Buffers and solutions: 
Wash buffer = PBS + 0.05% Tween-20 
 
2.3.1.2 Protocol  
1. The capture antibody was diluted 1/250 in 1x coating buffer. Subsequently, the 
96-well ELISA plate was coated with 100µl/well of capture antibody. The plates 
were sealed and incubated overnight at 4°C.  
2. All the wells were aspirated and washed 3 times with >250µl/well wash buffer. 
The wash buffer was allowed to soak for 1 minute during each step for increased 
effectiveness of the washes.  
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3. One part 5x concentrated assay diluent was diluted in 4 parts distilled water. 
4. All wells were blocked with 200µl/well of 1x assay diluent for 1 hour at room 
temperature.  
5. Plates were washed as described in step 3.  
6. Standard curve samples were serially diluted two-fold in assay diluent to give a 
seven point standard curve ranging from an original concentration of 500pg/ml 
to 3.9pg/ml and were plated in duplicate. Background absorbance was measured 
by plating assay diluent alone. Supernatant samples from co-cultivation were 
diluted 1:20 to 1:100 to assay diluent prior to plating in triplicate. The plates were 
sealed and incubated overnight at 4°C.  
7. The plates were washed as described in step 3.  
8. Detection antibody was diluted 1/250 in assay diluent, and 100µl/well added. 
Plates were sealed and incubated for 1 hour at room temperature. 
9. Plates were washed as described in step 3.  
10. Avidin-HRP was diluted 1/250 in assay diluent, and 100µl/well added. Plates 
were sealed and incubated for 30 minutes at rom temperature. 
11. Plates were washed as described in step 3. On this occasion, plates were washed a 
total of 5 times, allowing 1-2 minutes of soaking between washes.  
12. 100µl/well of TMB substrate solution was added to each well and plates were 
incubated for 15 minutes at room temperature.  
13. The reaction was stopped by adding 50µl/well of stop solution (2M H2SO4). 
14. Absorbance was read at 450nm using the FLUOStar Omega plate reader.  
15. Standard curves and cytokine concentration were calculated using the MARS data 




2.3.2 Determination of the combined anti-tumour potential of 
chemotherapy plus CAR+ T-cells 
In order to assess whether chemotherapy agents could sensitise MPM tumour cells to c-
Met re-targeted CAR T-cells, MPM cells were co-cultured with increasing dose 
concentrations of both cisplatin ± pemetrexed to generate dose response curves. 
Designated concentration of each drug was added to MPM tumour cells for 24-hours. 
Culture medium was removed and replaced with medium containing designated number 
of CAR T-cells. Target recognition and activation of CAR T-cells monitored by measuring 
cytokine release (IL-2 and IFN-γ). Anti-tumour activity was quantified using an MTT (3-




2.3.2.1 Materials, Reagents and Equipment 
- Cisplatin     Guy’s Hospital Chemotherapy Unit 
- Pemetrexed    Guy’s Hospital Chemotherapy Unit 
- Transduced T-cells 
- MPM tumour cells 
- D10 media 
- R10 media 
- IL-2      
- 96-well cell culture plate 
 
2.3.2.2 Protocol – Dose response 
1. 2 x 104 Tumour cells were seeded into 96-well cell culture plate and allowed to 
adhere overnight.  
2. Chemotherapy agents (cisplatin ± pemetrexed) were added in decreasing 5-fold 
serial dilutions and incubated overnight at 37°C and 5% CO2. 
3. Tumour cell viability was determined by MTT – detailed in section 2.2.10. 
 
2.3.2.3 Protocol – combination protocol 
1. 2 x 104 Tumour cells were seeded into 96-well cell culture plate and allowed to 
adhere overnight.  
2. Chemotherapy agents (cisplatin ± pemetrexed) were added in decreasing 5-fold 
serial dilutions and incubated overnight at 37°C and 5% CO2. 
3. Medium containing chemotherapy agents was removed and replaced with 100ul 
fresh D10 medium.  
4. 2 x 104 T-cells (100ul) were gently seeded onto monolayers - co-cultures were 
incubated overnight at 37°C and 5% CO2. 
5. Tumour cell viability at 24/48 hours was determined by MTT – detailed in 
section 2.2.10. 
6. 100µl supernatant was removed for analysis of cytokine (IL-2 and IFN-γ) 





2.3.3 Determination of anti-tumour activity against MPM cell lines using 
combined immunotherapy with pembrolizumab and c-Met re-targeted 
CAR+ T-cells 
The PD-1 inhibitor, pembrolizumab, was tested for its ability to potentiate anti-tumour 
activity mediated by c-Met re-targeted CAR T-cells. Target recognition and activation of 
CAR T-cells monitored by measuring cytokine release (IL-2 and IFN-γ). Anti-tumour 
activity was quantified using an MTT (3-[4,5-dimethylthiazol-2-yl]- 2,5I- 
diphenyltetrazolium bromide; thiazolyl blue). 
 
2.3.3.1 Materials, Reagents and Equipment 
- Pembrolizumab (Keytruda – Merck)  Guy’s Hospital Pharmacy 
- Transduced T-cells 
- MPM tumour cells 
- D10 media 
- R10 media 
- IL-2      
- 96-well cell culture plate 
 
2.3.3.2 Protocol – combination protocol 
1. 2 x 104 MPM tumour cells were seeded into 96-well cell culture plate and allowed 
to adhere overnight.  
2. T-cells were counted and re-suspended in R10 media ± 10µg or 100µg 
pembrolizumab at respective effector to target ratios (1 T-cell: 1 tumour cell), and 
gently pipetted onto the surface of the tumour monolayer. Co-cultures were 
incubated at 37°C and 5% CO2. 
3. After 24/48 hours of incubation, 100µl supernatant was removed for analysis of 
cytokine (IL-2 and IFN-γ) secretion.  
4. Tumour cell viability at 24/48 hours was determined by MTT – detailed in 





2.4 In vivo Models  
All in vivo experiments were performed in accordance with the UK Home Office 
guidelines as stated in the project license (license number 70/6847) and personal license 
(PIL 70/23830) that governed this work. All animal models were conducted in NOD.Cg-
Prkdcscid II2rgtm1wjl/SzJ. This mice strain is immune-deficient, lacking mature T-cells, B-
cells, functional NK-cells, and is also deficient in signalling by cytokines that employ the 
common γ receptor.  
 
2.4.1 Development of an in vivo Mesothelioma Model 
In order to test the anti-tumour potential of c-Met re-targeted CAR T-cells in vivo, a 
suitable xenograft model was established. Luciferase-expressing tumour cells were 
administered by either subcutaneous (s.c.) or intraperitoneal (i.p.) routes and monitored 
for engraftment and growth. 
 
2.4.1.1 Materials, Reagents and Equipment 
- D-Luciferin 
- IVIS Lumina II Bioluminescent Imaging Platform Caliper Life Science, UK 
- Isoflourane anaesthetic     Baxter, UK 
- 1ml syringe       BD Plastipak 
- 25G Needle       BD Biosciences 
- BD Matrigel Basement Membrane Matrix 
- PBS 
 
2.4.1.2 Protocol  
The numbers of tumour cells and injection volumes used have been detailed within the 
individual experiments.  
 
Intra-peritoneal (i.p.) tumour inoculation 
1. Mice were randomised into the required number of groups. 
2. The specified number of tumour cells were re-suspended in 200µl PBS and 
injected into the intra-peritoneal cavity using a 25G needle connected to a 1mL 
syringe. 
3. Tumour growth was monitored using BLI (please refer to section 2.4.2). 
 
Subcutaneous (s.c.) tumour inoculation 
1. Mice were randomised into the required number of groups. 
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2. The specified number of tumour cells were re-suspended in 200µl PBS or 
Matrigel injected subcutaneously into the right flank using a 25G needle 
connected to a 1ml syringe. 
3. Tumour growth was monitored using BLI (please refer to section 2.4.2). 
 
2.4.2 Bioluminescence Imaging 
Bioluminescence Imaging (BLI) is a sensitive, non-invasive technique for monitoring 
tumour growth in vivo. After delivery of the D-luciferin substrate, the luciferase-
expressing tumours are visualised in situ whilst the mice are under general anaesthesia.  
 
2.4.2.1 Materials, Reagents and Equipment 
- D-Luciferin 
- IVIS Lumina II Imaging Platform  
- Isoflourane    
- 1mL syringe       
- 25G Needle       
- PBS 
 
2.4.2.2 Protocol  
1. Mice were injected i.p. with 200µl (3mg) D-luciferin and placed back in their 
cages for seven minutes. 
2. Mice were anesthetised with 3-4% gaseous isofluorane and transferred to IVIS 
Lumina platform. 
3. Nine images of increasing duration (1s, 2s, 5s, 10s, 30s, 45s, 60s, 120s, 180s) were 
taken using small binning. Throughout imaging, mice were maintained under 
anaesthesia with 1.5% isofluorane.  
4. The mice were returned to their cages once the imaging was completed and 
monitored until they had regained consciousness.  
 
2.4.3 Therapeutic Study 
To determine in vivo efficacy of T-cell immunotherapy, mice were treated with different 
doses of CAR+ or control T-cells, administered using the i.p. route of administration. 
 
2.4.3.1 Materials, Reagents and Equipment 
- D-Luciferin 
- IVIS Lumina II Imaging Platform  
- Isoflourane    
- 1ml syringe       





2.4.3.2 Protocol  
1. On Day 0, 55 male NSG mice were inoculated i.p. with 5 x 104 firefly luciferase-
expressing REN tumour cells. 
2. Five days later, the mice underwent BLI in order to confirm successful tumour 
cell engraftment. Mice were subsequently used in the proceeding study.  
3. On Day seven, mice were re-imaged to confirm tumour engraftment prior to 
treatment with T-cells the following day. 
4. Day eight, the groups were treated as follows (N.B. CAR+ T-cells were not 
corrected for transduction efficiency): 
a. 10 x 106 or 2.5 x 106 N4+ T-cells i.p. (n=5)  
b. 10 x 106 or 2.5 x 106 M4+ T-cells i.p. (n=5) 
c. 10 x 106 or 2.5 x 106 cM4+ T-cells i.p. (n=5) 
d. 10 x 106 or 2.5 x 106 V4+ T-cells i.p. (n=5) 
e. 10 x 106 untransduced UT T-cells i.p. (n=5) 
f. PBS i.p. (n=8) 




2.5 Flow Cytometry  
 
2.5.1 Cell surface staining 
 
2.5.1.1 Materials, Reagents and Equipment 
- Antibodies  (see below) 
- Fortessa Flow Cytometer (BD biosciences) 
- Cell Dissociation Buffer (Gibco) 
- Trypsin/EDTA (Gibco) 
- Ice box 
- FlowJo software 
 
2.5.1.2 Antibodies: 
Staining for N28z, M28z, cM28z + T28z, V28z 
9e10 hybridoma D10 supernatant (In house) 




Staining for 4αβ 
Mouse IgG1 anti-human CD124 PE-conjugate (BD Pharmigen) 
Goat anti-Mouse IgG1 isotype PE-conjugate (BD Pharmigen) 
 
Staining for c-MET 
Rat IgG1k anti-human c-Met (HGFR) FITC-conjugated (eBioscience) 
Anti-Rat IgG1k isotype FITC-conjugated (eBioscience) 
 
Staining for CD44v6 
Mouse IgG1 anti-human CD44v6 FITC-conjugated (eBioscience) 
IgG1 anti-mouse isotope FITC-conjugated (eBioscience) 
 
Staining for Syndecan-1 
Rat IgG1 anti-human CD138 APC-conjugated (BioLegend) 
Anti-rat IgG2b isotype APC-conjugated (BioLegend) 
 
Staining for checkpoint axis molecules 
Mouse anti-Human CD279 (PD-1) PE-conjugated (BD Pharmingen) 
Goat anti-Mouse IgG1k PE-conjugated (BD Pharmingen) 
 
Mouse anti-human CD274 (PD-L1) APC-conjugated (BioLegend) 
Mouse anti-human CD273 (PD-L2) PE-conjugated (BioLegend) 
 
Staining for ErbB receptors 
Rat anti-human ErbB1 (ICR62) (ICR) 
Rat anti-human ErbB2 (ICR12) (ICR) 
Goat anti-rat IgG PE-conjugated (Invitrogen) 
 
Staining for αvβ6 
Mouse anti-human αvβ6 (Biogen Idec) 
Goat anti-mouse IgG PE-conjugated (DAKO) 
 
2.5.1.3 Protocol – surface cell-staining 
In order to determine the cell-surface expression, cells were regularly analysed. A 
universal FACS protocol has been detailed below.  
 
1. A pre-determined number of cells were removed (adherent cells were removed 
with trypsin or cell dissociation buffer) and washed in PBS.  
102 
 
2. Cells were re-suspended in 200µl PBS in a flow cytometry tube and incubated 
with specified concentrations of primary or directly conjugated antibody/isotope 
on ice for 30 minutes. 
3. N.B. Additional step for non-conjugated antibodies -Samples were washed in 2ml 
PBS, centrifuged and re-suspended in 200µl PBS. 
4. N.B. Additional step for non-conjugated antibodies - Cells were then incubated 
with matched concentrations of secondary antibody for 30 minutes on ice in the 
dark.  
5. Samples were again washed with PBS, centrifuged and resuspended in 350µl PBS 
prior to analysis. Sample FACS tubes were kept on ice and in the dark until 
analysis. 
6. Results were compared to control using a matched staining protocol (or to cells 
stained with the secondary antibody alone where stated).  
 
2.5.2 Flow sorting 
To enable in vivo assessment of c-Met re-targeted CAR T-cells as detailed in section 2.4, 
MPM tumour cells were genetically engineered to stoichiometrically co-express firefly 
luciferase (ffLuc) and tdTomato (tdTom) (denoted LT - detailed in section ). To ensure 
high LT positive expression minimising negative outgrowth, LT+ MPM tumour cells (H28 
and REN) were prepared as detailed in section 2.5.1 (5-10 x 106 tumour cells/ml; total 
number of cells >20 x 106. Cells were transported on ice and flow sorted for LT 
expression (>95% positive) using BD FACSAriaTM II Cell Sorters (ARIA 1) within the 
Biomedical Research Centre Flow Core Unit, Guy’s and St Thomas’ NHS Foundation 
Trust and King’s College London, located at Guy’s Hospital, London. Cell acquisition and 
analysis on BD FACSAriaTM II Cell Sorters via FACSDIVA software.  
 
 
2.6 Experimental Design 
 
Experiments were conducted with biological and process repeats. Where stated, the 
number of repeats (n=x) represents biological repeats – independent experiments with 
different healthy blood donors. Within each biological repeat, process repeats were 





2.7 In vivo BLI image analysis 
 
In vivo BLI images were analysed in accordance with the following protocol. The 
luciferase enzyme present within the tumour cells allowed tumour growth to be 
monitored over the indicated timeframe by bioluminescent imaging (BLI). The images 
gained for each time point were analysed using Living Image 3.1 software. The level of 
luminescent signal released by each mouse was calculated by drawing a region of interest 
(ROI). The software automatically calculated the level of photon release within the ROI 
and this was standardised to account for the size of ROI and scan duration. The values 
plotted represent the average luminescent signal ± the standard error of the mean. 
Images detailing the luminescent signal for an individual mouse within each group are 




2.8 Statistical analysis  
 
To investigate statistical significance, values were subjected to a Student’s t-test, two-
tailed and p-values <0.05 were taken as significant. Alternatively, for the therapeutic in 
vivo study, values were subjected to a two-way ANOVA, followed by a Bonferroni post-
hoc test and p-values <0.05 were taken as significant (* p <0.05, ** p <0.005 and *** p 







CHAPTER 3 Engineering and characterisation of 
specificity of c-Met-targeted chimeric antigen 






3.1.1 Design of chimeric antigen receptors that target c-Met 
The important role of the c-Met receptor in malignant mesothelioma is detailed within 
section 1.4. Since high-level expression of this receptor is found in over 80% of 
mesothelioma tumours, I set out to engineer CARs that target this tyrosine kinase 
receptor.  
 
Engineering of a c-Met-targeted CAR requires a targeting moiety capable of specific c-
Met receptor binding. Traditionally, a single chain antibody fragment is used for this 
purpose, as was recently described by Frigault et al. [327]. Alternatively, targeting may 
be achieved using a peptide, natural ligand or derivative thereof [328]. Hepatocyte 
growth factor (HGF) is the only naturally occurring ligand that binds to c-Met. However, 
it is unsuitable as a CAR targeting moiety since it cannot bind to the c-Met receptor until 
cleaved to yield an αβ heterodimer (section 1.3). In addition, a number of splice variants 
of the HGF α chain also bind c-Met. The smallest of these comprises the N-terminal and 
1st Kringle domain and is consequently known as NK1 [329].   
 
The NK1 splice variant of HGF occurs naturally and binds to the c-Met receptor with low 
nanomolar affinity [329, 330]. The binding of NK1 to c-Met is enhanced by heparin 
sulphate proteoglycans, most likely due to their ability to promote NK1 homo-
dimerisation and the formation of a NK1/ Met/ heparin sulphate ternary complex [141]. 
Nonetheless, NK1 is a weak agonist of c-Met and is a highly unstable polypeptide. The 
NK1 polypeptide may be stabilised with potentiation of its activity by incorporating two 
mutations, at K132E and R134E [141]. This derivative peptide has been termed IK1 
(Table 3-1). 
 
To provide an additional targeting approach, CARs were also engineered using two 
alternative NK1-derived peptide moieties that bind to c-Met. Cochran and colleagues 
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undertook a directed evolution approach in which NK1 was expressed on the surface of 
yeast and mutated using error-prone PCR in order to select for variants that had higher 
stability and/ or affinity in binding assays with recombinant c-Met [331]. Using this 
approach, they isolated the M2.2 peptide in which eight mutations are present, as 
summarised in Table 3-1. Some of these mutations were located close to the known 
heparin-binding site of NK1 (e.g.K62E, Q95R, K132N, and K170E) but still permitted 
strong heparin binding by the peptide [331]. However, the M2.2 peptide had virtually no 
agonistic activity owing to the mutation at position 127 (N127D), which is located within 
the NK1 homo-dimerisation domain. Consequently, this position was mutated back to 
wild type (M2.2 D127N), resulting in restoration of functional HGF-like activity in scatter 
assays [331]. To test the importance of dimerisation in this activity, Cochran et al. 
created the cdM2.2 D127N peptide, which is identical except that it contains an N-
terminal cysteine. The latter peptide demonstrated enhanced functional activity and has 
also been used within this study to create a third candidate c-Met-targeted CAR.  
 
To create candidate CARs, the IK1, M2.2D127N and cdM2.2D127N peptides (Table 3-1) 
were fused to a second generation CAR framework in which the CD28 hinge, 
transmembrane and endodomains were placed upstream of the CD3ζ endodomain [261]. 
The CD28 hinge sequence was modified to remove the MYPPPY motif (involved in the 
binding of CD28 to B7-1 and B7-2) [310], which was substituted with a myc-derived 
epitope tag to enable detection of the CAR at the cell surface. A structural overview of the 
derived CARs was shown in Figure 2-1B (page 85) together with control CARs that have 









Table 3-1. Properties of NK1-derived peptides used to engineer 




 Sites of mutations Affinity Stability Agonistic 
activity 
Ref 
NK1 None Low 
nanomolar  
Unstable (high 
salt and low 
temperature only) 

















K62E; Q95R; N127D; 






Stable in low salt 










Revert codon 127 to 




Stable in low salt 
and at higher 
temperature 
 



















* potentiated by heparin; ** effect of exogenous heparin not reported 
 
 
3.1.2 The role of co-factors in binding of HGF to c-Met  
NK1 binds both to c-Met and heparin sulphate proteoglycans (HSPGs), which are widely 
co-expressed on the surface of mammalian cells. Furthermore, as detailed in section 
1.5.3, a number of co-factors have been described that strengthen this interaction. The 
best characterised of these is an isoform of CD44 containing the variant 6 exon 
(CD44v6). In several model systems, the ability of HGF to induce c-Met activation is 
dependent upon through ternary complex formation with CD44v6 [196]. In keeping with 
this, antagonistic peptides derived from the variant exon 6-encoded 42 amino acid 




Although CD44 is commonly upregulated on mesotheliomas [198], there has been 
relatively little study of which CD44 variants are expressed in this disease. One study has 
suggested that CD44v6 may be under-represented in mesothelioma compared to other 
lung tumours [206]. To add complexity, one recent study in CD44-deficient mice 
suggests that ICAM-1 may alternatively be recruited to provide this co-receptor function 
[207] and small studies within mesothelioma suggest that ICAM-1 is very commonly and 
highly expressed in this tumour [208]. In light of this background, it was important to 
investigate the dependence and influence of CD44v6 upon recognition of c-Met by CARs 
containing NK1-derivative targeting peptides. 
 
3.1.3 Use of NIH 3T3 fibroblast-derived artificial antigen presenting cells to 
examine target specificity of CAR T-cells 
The use of NIH 3T3 based artificial antigen-presenting cells (aAPC) to examine the 
antigenic specificity of T-cell populations was pioneered by Sadelain et al. [332].  Murine 
NIH 3T3 fibroblast cells were initially transduced to express MHC and co-stimulatory 
molecules to facilitate the study of T cell-APC interactions in mice and humans [332, 
333]. In comparative studies NIH 3T3 aAPC cells proved more efficient 
than Drosophila aAPC and were as efficient as autologous adherent PBMC and EBV-
transformed B cells for CD8+ T-cell expansion, without the additional requirement of 
feeder cells [333]. Unlike Drosophila aAPC, NIH 3T3 cells express endogenously 
processed antigens, which can stimulate CD8+ T-cell responses to both exogenously 
loaded and transfected antigen [332, 334] 
 
To broaden applicability, NIH 3T3 cells have been transduced to express a number of 
human HLA molecules to provide a panel of aAPC that can be used to derive T-cell lines 
for immunotherapeutic use, depending on the HLA type of the patient. Illustrating this, 
transfection with human HLA-A2, CD80, ICAM-1, and LFA-3 enabled the successful 
stimulation of CD8+ T-cells specific for influenza, cytomegalovirus and the hTERT and 
WT1 tumour associated antigens (TAA) respectively [333, 334] 
 
In parallel, Sadelain et al., adapted the NIH 3T3 aAPC system to evaluate the specificity 
of CAR T-cells. In this setting, antigen recognition is direct and thus NIH 3T3 cells were 
engineered to express membrane-anchored target antigen, either alone or together with 
one or more co-stimulatory receptors [335]. For example, when CAR T-cells with 
specificity for prostate-specific membrane antigen (PSMA) were stimulated on NIH 3T3 
cells transduced to co-express CD80, 4-1BBL and cell surface PSMA, CAR T-cells 
expanded efficiently in vitro. Notably, the resulting T-cells were also effective in treating 
PSMA-positive tumours in a humanised mouse model [336].  In this chapter, the NIH 
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3T3 aAPC model has been adapted to examine the specificity of three candidate CARs for 
human c-Met, either when expressed alone or in combination with CD44v6. 
 
3.1.4 Aims 
1. To engineer a panel of c-Met-specific CARs 
2. To determine the target specificity and co-factor dependency of these CARs using 















3.2.1 Cloning of the SFG retroviral vectors expressing candidate c-Met re-
targeted CARs 
Expression of all constructs in human T-cells was achieved by means of transduction 
using the SFG retroviral vector, which is derived from the MFG vector [337]. Gene 
expression is driven by the Moloney murine leukaemia virus (MoMLV) long terminal 
repeat (LTR). The presence of the MoMLV ψ packaging signal ensures efficient 
packaging of the RNA into the virus. The presence of the splice donor and splice acceptor 
sites enables the production of the sub-genomic RNA transcripts usually required for the 
translation of the env gene [338]. The gene of interest is inserted at a naturally occurring 
NcoI site, ensuring that its start codon coincides with that previously occupied by the 
deleted env gene. This vector does not contain a eukaryotic cell-compatible selectable 
marker gene but does contain an ampicillin resistance gene for selection following 
transformation of competent bacteria.  
 
Schematic structure of test and control CARs was shown in Figure 2-1B. The structures of 

















Figure 3-1. SFG Retroviral vectors encoding for candidate c-Met-specific 
chimeric antigen receptors. 
All CARs were expressed in human T-cells using the SFG retroviral vector. Constructs 
were cloned as NcoI - NotI fragments into the SFG V8 vector (Whilding and Maher, 
unpublished), replacing the targeting peptide in that construct with 1K1-derivative of 
NK-1 or the mutated M2.2 D127N or cdM2.2 D127N versions. The resultant constructs 
are referred to as SFG N28z, SFG M28z and SFG cM28z respectively. Gene expression is 
driven by the promoter activity of the Moloney murine leukaemia virus (MoMLV) long-
term repeat (LTR). The efficient packaging of SFG-based viral particles is enabled via the 
presence of the MoMLV packaging signal. SD = splice donor site; ψ = packaging signal; 
























3.2.2 Expression of candidate c-Met re-targeted CARs in primary human T-
cells 
Prior to commencing investigations to test anti-tumour activity of candidate c-Met 
specific CARs, it was important to demonstrate efficient and stable expression of these 
chimeric receptors in primary human T-cells, along with appropriate control CARs. 
Following gammaretroviral-mediated gene transfer from PG13 retroviral packaging cell 
lines (Figure 3-2A), T-cells were investigated for cell surface expression of the CARs 
using flow cytometry. All CARs contain the same myc epitope tag within the CAR spacer 
domain, enabling their detection using the 9e10 monoclonal antibody. As shown in 
Figure 3-2B, expression of all three c-Met-targeted CAR candidates could be detected at 
the cell surface following retroviral gene transfer into activated human T-cells. These 
data indicate that all chimeric constructs were expressed and trafficked correctly to the 
cell surface. Cell surface expression of ErbB-targeted CAR, T28z and the scrambled 
peptide-targeted negative control, V28z was also established using the same protocol. As 
detailed in Figure 3-2C, the mean expression of the three c-Met-targeted candidate CARs 






































Figure 3-2. Expression of CARs in PG13 retroviral packaging cells and 
transduced human T-cells. 
(A) Expression of N28z, M28z, cM28z, T28z and V28z was detected on the surface of 
PG13 retroviral packaging cells by flow cytometry, following incubation with the 9e10 
antibody which detects a shared myc epitope tag present in all CAR ectodomains (filled 
pink histogram). Filled blue histograms show parental PG13 packaging cells stained with 
the same protocol. Percentage CAR positive cells is indicated. (B) Expression of N28z, 
M28z, cM28z, T28z and V28z (filled pink histograms) detected on the surface of 
transduced primary human T-cells by flow cytometry, as described in A. Filled blue 
histograms show untransduced T-cells stained with the same protocol. Black number 
indicates percentage of CAR positive cells. Data shown in panels A and B are 
representative FACS plots. (C) Pooled data in which human T-cells were transduced 




3.2.3 Production and validation of a matched panel of c-Met and CD44v6 
expressing NIH 3T3 artificial antigen presenting cells (aAPC) 
Hepatocyte growth factor and the derived NK1 splice variant can bind to human c-Met 
[141, 215, 331, 339]. This binding interaction is augmented by a number of co-factors, the 
best characterised of which is CD44v6 [196]. Consequently, I next set out to investigate 
the target specificity of the three candidate c-Met-targeted CARs described above. The 
NIH 3T3 fibroblast cell line provides a useful model system to investigate this. Since they 
are of murine origin, they do not express either human c-Met or CD44v6. Consequently, 
the introduction of the human c-Met receptor, CD44v6 receptor or the combination of 
both c-Met and CD44v6 receptors into these cells allows the controlled evaluation of the 
targeting specificity of the CAR T-cells. Expression of both transgenes was achieved in 
NIH 3T3 cells by retroviral gene transfer (section 2.2.5). Expression of human c-Met 
and/ or human CD44v6 was demonstrated in the appropriate engineered NIH 3T3 cells 




Figure 3-3. Expression of human c-Met and/or human CD44v6 in retroviral-
engineered NIH 3T3 cells. 
NIH 3T3 fibroblasts were transduced with retroviral vectors that encode for human c-
Met and/ or human CD44v6 as labelled. Expression of the indicated transgene is shown 
by the pink histogram (c-Met) and green histogram (CD44v6). Staining of the same cells 
with a matched isotype control antibody is shown by the filled grey histograms. The 
percentages depicted within plots represent total percentage of cells that are transgene 
positive (corrected for isotype). Data are representative of similar findings in three 
independent replicate experiments.  
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3.2.4 Comparison of target-dependent cytotoxicity mediated by candidate c-
Met re-targeted CARs using NIH 3T3 aAPC cells 
Next, I established T-cell/ NIH 3T3 monolayer co-cultivation experiments in order to 
investigate the ability of the candidate c-Met-specific CARs to deliver a target-dependent 
cytotoxic signal. CAR+ T-cells (effector) were co-cultivated with the aAPC panel of NIH 
3T3 cells (target) at effector to target ratios of 1:1, 2:1 and 4:1 (1:1 = 2 x 104 NIH 3T3 and 
2 x 104 T-cells – not corrected for transduction efficiencies). Parental NIH 3T3 cells were 
used as the negative control aAPC. To provide negative CAR T-cell control populations, 
NIH 3T3 aAPC cells were also co-cultivated with T28z+, V28z+ or untransduced T-cells, 
none of which would be expected to cause target cell destruction or undergo T-cell 
activation in this co-cultivation system.  
 
Destruction of NIH 3T3 cells was quantified after 24 and 48 hours of co-cultivation using 
an MTT assay (Figure 3-4 to 3-6). These data indicate that NIH 3T3 cells engineered to 
express c-Met were highly susceptible to cytotoxic destruction by N28z, M28z and cM28z 
CAR+ T-cells. There was no significant difference in target cell killing by the three 
candidate c-Met re-targeted CARs under evaluation. By contrast, c-Met re-targeted CAR+ 
T-cells did not mediate killing of NIH 3T3 cells that expressed CD44v6 alone. In 
addition, co-expression of CD44v6 and c-Met did not enhance the sensitivity of NIH 3T3 
cells to destruction by c-Met re-targeted CAR+ T-cells. Control CAR+ T-cells did not 
induce specific cytotoxicity against c-Met-expressing or other NIH 3T3 target cells. 
Furthermore, none of the three candidate c-Met re-targeted CARs (N28z, M28z and 
cM28z) or control CARs (T28z and V28z) induced significant destruction of parental 




















Figure 3-4. Target cell destruction following T-cell co-culture with a panel of 
NIH 3T3-derived aAPC (effector to target ratio 1:1). 
Percentage viability of the indicated NIH 3T3 cell lines was determined following (A) 24 
hour or (B) 48 hour incubation at an effector to target ratio of 1:1. Artificial antigen 
presenting cells (2 x 104 cells) were seeded, followed 24 hours later by addition of 2 x 104 
N28z, M28z, cM28z, T28z, V28z or untransduced (UT) T-cells. Effector T-cells were not 
corrected for transduction efficiencies (shown in Figure 3-2). Following completion of 
the co-cultivation, T-cells were removed by decanting and residual aAPC cell viability was 
measured using an MTT assay. Data shown are mean ± SEM from five independent 
experiments. Statistical significance was determined using the unpaired Student’s t-test, 
comparing cytotoxic activity of UT T-cells with CAR+ T-cells against each aAPC line. * p 
















Figure 3-5. Target cell destruction following T-cell co-culture with a panel of 
NIH 3T3-derived aAPC (effector to target ratio 2:1). 
Percentage viability of the indicated NIH 3T3 cell lines was determined following (A) 24 
hour or (B) 48 hour incubation at an effector to target ratio of 2:1. Artificial antigen 
presenting cells (2 x 104 cells) were seeded, followed 24 hours later by addition of 4 x 104 
N28z, M28z, cM28z, T28z, V28z or untransduced (UT) T-cells. Effector T-cells were not 
corrected for transduction efficiencies (shown in Figure 3-2). Following completion of 
the co-cultivation, T-cells were removed by decanting and residual aAPC cell viability was 
measured using an MTT assay. Data shown are mean ± SEM from five independent 
experiments. Statistical significance was determined using the unpaired Student’s t-test, 
comparing cytotoxic activity of UT T-cells with CAR+ T-cells against each aAPC line: * p 
















Figure 3-6. Target cell destruction following T-cell co-culture with a panel of 
NIH 3T3-derived aAPC (effector to target ratio 4:1). 
Percentage viability of the indicated NIH 3T3 cell lines was determined following (A) 24 
hour or (B) 48 hour incubation at an effector to target ratio of 4:1. Artificial antigen 
presenting cells (2 x 104 cells) were seeded, followed 24 hours later by addition of 8 x 104 
N28z, M28z, cM28z, T28z, V28z or untransduced (UT) T-cells. Effector T-cells were not 
corrected for transduction efficiencies (shown in Figure 3-2). Following completion of 
the co-cultivation, T-cells were removed by decanting and residual aAPC cell viability was 
measured using an MTT assay. Data shown are mean ± SEM from five independent 
experiments. Statistical significance was determined using the unpaired Student’s t-test, 
comparing cytotoxic activity of UT T-cells with CAR+ T-cells against each aAPC line: * p 






3.2.5 Comparison of target-dependent cytokine release mediated by 
candidate c-Met re-targeted CARs using NIH 3T3 aAPC cells 
Supernatants harvested from three co-cultivation experiments described in the previous 
section were analysed for interferon (IFN)-γ (Figure 3-7) and interleukin (IL)-2 (Figure 
3-8) concentration by ELISA. This analysis demonstrated a modest but nonetheless 
significant increase in release of IFN-γ from candidate c-Met-targeted CAR+ T-cells upon 
co-culture with c-Met-expressing NIH 3T3 cells. Similar findings were not observed in 
matched control cultures containing T28z+, V28z+ or UT T-cells. Furthermore, release of 
IFN-γ by c-Met re-targeted CAR+ T-cells was increased during co-cultivation with c-Met-
expressing NIH 3T3 in comparison to parental NIH 3T3 cells. However, the differences 
observed did not reach statistical significance at the 4:1 effector: target ratio. These 
findings are consistent with the cytotoxicity data presented earlier (Figure 3-4 to 3-6) 
and add to the evidence that N28z, M28z and cM28z CAR+ T-cells undergo activation in 
a c-Met-dependent manner.  
 
Importantly, release of IFN-γ was not seen when c-Met re-targeted CAR+ T-cells were co-
cultivated with NIH 3T3 cells engineered to express CD44v6 alone. These results indicate 
that c-Met re-targeted CAR+ T-cells do not recognise the CD44v6 receptor alone. 
However, when both c-Met and CD44v6 receptors were co-expressed, N28z, M28z and 
cM28z CAR+ T-cells released larger quantities of IFN-γ, compared to that by c-Met-
expressing NIH 3T3 cells. These differences reached statistical significance in the case of 
N28z (at a 4:1 ratio) and cM28z (at both 1:1 and 2:1 ratios). These findings raise the 
possibility that target cells that co-express c-Met and its co-factor CD44v6 provides a 
more potent activation signal. Levels of IL-2 present in these supernatants are presented 
in Figure 3-8. Although some statistically significant differences were noted, levels were 





































Figure 3-7. Determining the concentration of IFN-γ released following CAR 
T-cell co-culture with panel of target expressing NIH 3T3 cell lines 
IFN-γ release by T-cells during co-culture with panel of NIH 3T3 cells expressing c-Met ± 
CD44v6. Untransduced T-cells or those expressing the N28z, M28z and cM28z, T28z or 
V28z CAR were co-cultured with the indicated NIH 3T3 monolayers for 48 hour at (A) 
1:1, (B) 2:1 or (C) 4:1 effector to target ratios. Supernatants were collected and the 
concentration of IFN-γ was measured by ELISA. Data were obtained in three 
independent experiments and are presented as mean ± SEM. Statistical significance was 
determined using the unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells 
cultured on the same NIH 3T3 target cell line. Other statistical comparisons are indicated 
by the presence of an overhead line that extends over the relevant comparator groups. * p 































Figure 3-8. Determining the concentration of IL-2 released following T-cell 
co-culture with panel of target expressing NIH 3T3 cell lines 
IL-2 release by T-cells during co-culture with panel of NIH 3T3 cells expressing c-Met 
and/or CD44v6. Untransduced T-cells or those engineered to express the N28z, M28z 
and cM28z, T28z or V28z CAR were co-cultured with the indicated NIH 3T3 monolayers 
for 24 hours at (A) 1:1, (B) 2:1 or (C) 4:1 effector to target ratios. Supernatants were 
removed and the concentration of IL-2 was measured by ELISA. Data were obtained in 
three independent experiments and are presented as mean ± SEM. Statistical 
significance was determined using the unpaired Student’s t-test, comparing UT T-cells 
with CAR+ T-cells cultured on the same NIH 3T3 target cell line. Other statistical 
comparisons are indicated by the presence of an overhead line that extends over the 







The growth and motility factor hepatocyte growth factor (HGF) and its receptor tyrosine 
kinase c-Met, which is the product of the MET proto-oncogene, are known to provide 
essential signals for both survival and long-distance migration of epithelial and myogenic 
precursor cells during embryogenesis. This HGF/c-Met axis for invasion and metastasis 
is utilised by a number of cancer types including mesothelioma, rendering these 
molecules attractive candidate targets for treatment of this tumour [340] [140].  
 
This chapter has detailed the engineering and initial testing of three candidate CARs to 
target c-Met. The targeting strategy employed in this PhD involved the selection of 
targeting moieties that bind specifically to c-Met and are derived from NK1, which is the 
smallest splice variant of HGF. NK1 is capable of binding c-Met with low nanomolar 
affinity, but is naturally unstable and thus from a CAR engineering perspective it was 
considered desirable to utilise stabilised versions of this peptide. Stabilisation of NK1 had 
previously been achieved with the incorporation of two mutations (K132E and R134E), 
an approach that retained full affinity and activity of this ligand. In addition, two mutant 
NK1 peptides (M2.2 D127N and cdM2.2 D127N) have also been described that 
incorporate several mutations that considerably improved binding affinity and stability 
for the HGF-Met interaction [331]. Consequently, it was hypothesised that by utilising 
the NK1 or mutant NK1 peptides as the targeting moiety of a chimeric antigen receptor 
(CAR), it would be possible to re-direct primary human T-cells against target cells 
expressing the c-Met receptor. In order to achieve full T-cell activation upon the binding 
of target antigen, the sequence for each of the NK1 peptides Ik1, M2.2 D127N and cdM2.2 
D127N were joined immediately upstream of the hinge, transmembrane and 
endodomains of CD28, followed by the signalling domain of CD3ζ chain to give three 
candidate second generation c-Met re-targeted CARs: N28z, M28z and cM28z 
respectively. The HGF (isoform 6) signal peptide was incorporated as the leader 
sequence at the 5’ site of the cDNA to ensure cell surface expression of the CAR upon 
translation.  
 
The main aim of the research described within this chapter was to determine whether the 
three c-Met re-targeted CARs were able to recognize the human c-Met receptor, leading 
to T-cell activation. Prior to investigating this, it was important to show expression and 
correct folding of the N28z, M28z and cM28z CARs at the T-cell surface. This was 
consistently confirmed by flow cytometry during independent studies. The level of T-cell 
transduction varied between the three c-Met re-targeted CAR constructs and across 
independent experiments. This variation may be attributed to a number of reasons. One 
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of the main variables across the experiments was the intrinsic difference associated with 
using T-cells from a variety of donors. Differences in surface expression levels of the 
GALV receptor, Pit1, between donors may account for some of the variation in CAR 
expression observed, since levels of expression of this receptor have previously been 
correlated with transduction efficiency [341]. Furthermore, differences in the level of 
response by donor cells to the CD3/CD28 beads may also play a decisive role in 
determining variations in T-cell transduction efficiencies, given the requirement of the 
recipient cells to enter the cell cycle in order that retroviral-mediated gene transfer can 
be achieved. Furthermore, since viral titre was not determined prior to gene transfer, the 
quantity of vector to which the T-cells were exposed would have varied between 
experiments. In addition, inherent experimental variation is also likely to cause small 
differences. Taken together, it can be concluded that the N28z, M28z and cM28z CAR 
were successfully and stably expressed in primary human T-cells. 
 
The use of engineered NIH 3T3 cells as aAPCs enabled the assessment of c-Met 
specificity of the candidate N28z, M28z and cM28z CARs. This approach also allowed me 
to test the dependence of this interaction upon expression of a key co-factor that enables 
the binding of HGF to c-Met, namely CD44v6. The significant c-Met-dependent cytotoxic 
activity and release of IFN-γ mediated by all three candidate CARs provided initial 
evidence for their functionality. No discernable difference was observed in the c-Met-
dependent re-targeting activity of N28z, M28z and cM28z in these experiments. With 
respect to cytotoxicity observed over time, greater c-Met re-targeted CAR+ T-cell killing 
was observed at longer time points (48 hours). In addition, an increase in effector T-cell 
function was seen when the ratio of effector to target cells was increased. 
 
Notably, cytokine release appeared to be enhanced when candidate c-Met re-targeted 
CAR T-cells encountered NIH 3T3 targets that co-expressed c-Met with the CD44v6 co-
factor. These findings are in keeping with the reported ability of CD44v6 to form ternary 
complexes with c-Met and HGF, thereby enhancing activation of the c-Met receptor and 
signalling [196] (section 1.5.3). Since this would be expected to increase affinity of 
binding of HGF (or the NK1 derivative) to target cells in which c-Met and CD44v6 are co-
expressed, this may account for the increased activation observed. Importantly however, 
no evidence of CAR T-cell activation was observed when NIH 3T3 aAPC expressed 
CD44v6 alone. It has also been reported that CD44v6 is required by some cell systems 
and cancers in order to facilitate the binding of HGF to c-Met [342]. However, data 
presented in this chapter demonstrate that the presence of CD44v6 is not absolutely 
essential for the ability of NK1-based candidate CARs to engage c-Met, since NIH 3T3 





In conclusion, the data presented in this chapter demonstrate that T-cells expressing the 
N28z, M28z and cM28z CARs undergo activation by NIH 3T3 aAPCs in a c-Met-
dependent manner, manifested by cytotoxicity and release of IFN-γ. Furthermore, 
activation is enhanced if NIH 3T3 cells co-express CD44v6, suggesting that co-receptor 
expression may enhance activity of these CAR T-cells. Importantly however, CD44v6 
alone does not provide a sufficient stimulus to activate any of the candidate CARs under 
evaluation. These findings set the scene for assessment of anti-tumour activity of these 





CHAPTER 4 Assessment of the in vitro cytotoxic 
activity of c-Met re-targeted chimeric antigen 




4.1 Introduction  
 
It has been reported by a number of investigators that c-Met is expressed in 74 to 100% 
of MPM tumours [146, 147, 154, 343]. This suggests that these tumours may be 
susceptible to targeting by c-Met re-targeted CAR+ T-cells [344]. In Chapter 3, I 
demonstrated that all three c-Met re-targeted CARs could recognise c-Met when 
ectopically expressed in NIH 3T3-based artificial antigen presenting cells. Next, I tested 
the anti-tumour activity of these CAR T-cells against a panel of human malignant pleural 
mesothelioma (MPM) cell lines.  
 
4.1.1 Assessment of the in vitro functionality of CAR T-cells against a panel 
of mesothelioma cell lines. 
Whilst I have shown that the candidate c-Met-targeted CARs under study can recognise 
this target when ectopically expressed in NIH 3T3 cells, this does not necessarily mean 
that they will exert cytotoxic activity against human mesothelioma tumour cells that 
over-express c-Met. To test this, I selected four pleural effusion-derived MPM cell lines 
named H28 (epithelioid), REN (epithelioid), JU77 (sarcomatoid) and LO68 (epithelioid) 
[345]. All cell lines were provided by Dr Sara Busacca, Department of Cancer Studies and 
Molecular Medicine, University of Leicester, Leicester, United Kingdom. These cells were 
characterised for expression of c-Met by flow cytometry prior to undertaking functional 
studies using CAR engineered T-cells. 
 
To evaluate cytotoxic activity in vitro, c-Met re-targeted CAR+ T-cells generated from 
healthy donors were co-cultivated with monolayer cultures of the indicated tumour cell 
lines. Tumour cell viability and cytokine release was assessed across the different cell 
lines. 
 
4.1.2 Release of HGF in mesothelioma 
Chapter 1 (section 1.4.1) summarises the evidence that HGF over-production occurs in 
mesothelioma. This could provide a source of competition for the NK1 targeted CARs 
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developed in this project, thereby inhibiting their function. Consequently, all four MPM 
cell lines were also evaluated by ELISA for their ability to secrete HGF. 
 
4.1.3 Expansion of CAR T-cells that express the 4αβ  chimeric cytokine 
receptor using IL-4 
Many patients with advanced malignancy are lymphopenic and immune compromised, 
meaning that T-cell gene transfer efficiency and expansion of cell products is frequently 
compromised. In general, patients need to undergo leukapheresis in order to harvest 
sufficient quantities of T-cells to circumvent this issue. A second challenge to successful 
adoptive cell therapy, specifically CAR T-cell immunotherapy, is the survival and 
expansion of CAR+ T-cells following infusion in vivo. Successful redirected T-cell therapy 
is dependent upon cytokine stimulation, with IL-2 and IL-15 potent stimulators. 
Traditionally, adoptive cell therapy is often combined with preceding lympodepletion 
followed by high dose IL-2 administered post T-cell infusion. However, use of IL-2 in this 
manner results in the total lymphoid population being stimulated in addition to being 
severely toxic [346]. 
 
Addressing both of these concerns, Wilkie et al., developed a chimeric cytokine receptor 
(4αβ) to enable selective stimulation of CAR+ T-cells without associated toxicity [311]. 
The 4αβ chimeric cytokine receptor couples the ectodomain of the IL-4Rα to the 
endodomain of the IL-2/IL-15-Rβ [311]. By co-expressing 4αβ with a particular CAR of 
interest, the selective expansion and enrichment of re-directed CAR+ T-cells can 
generally be ensured via exogenous IL-4 stimulation. Co-expressing both receptors was 
achieved through the use of an intervening Thosea asigna virus 2A (T2A) peptide 
downstream of a furin cleavage site (Figure 2-2, page 86) [311].  
 
Additionally, a number of tumours including mesothelioma [347] secrete IL-4 in the 
immediate microenvironment, thus potentially inducing 4αβ-CAR+ T-cell trafficking 
towards the site of the tumour followed by local expansion and survival of the gene 
modified T-cells. The 4αβ system is currently in use in a clinical trial involving CAR T-
cell immunotherapy of head and neck cancer [348]. Patients donate 130mL blood rather 
than undergoing leukapheresis and in all cases, cells products have expanded 






1. To investigate expression of c-Met and release of HGF by established MPM cell lines. 
2. To evaluate and compare in vitro cytotoxic activity of c-Met re-targeted CAR+ T-cells 
using a panel of 4 mesothelioma cell lines. 
3. To investigate the anti-tumour activity of c-Met re-targeted CAR+ T-cells that have 







4.2.1 c-Met expression in MPM cell lines 
In order to determine the suitability of the c-Met re-targeted CAR+ T-cells as a therapy 
for MPM, the c-Met expression profile of a panel of human MPM cell lines was assessed. 
All four cell lines were positive for c-Met expression in the order: H28 > JU77 > LO68 > 
REN (Figure 4-1A). Data presented in Chapter 3 suggested that co-expression of CD44v6 
may enhance the activation of c-Met re-targeted CAR T-cells, as indicated by increased 
cytokine release. Therefore, I also assessed the expression of CD44v6 in these cell lines 
by flow cytometry and found that all lacked expression of this isoform of CD44 (Figure 4-
1B). In addition, the cell lines were assessed for expression of three other co-factors that 
facilitate HGF binding to c-Met, namely ICAM-1 (Figure 4-1C), heparan sulphate 
proteoglycan (HSPG; Figure 4-2A) and Syndecan-1 (Figure 4-2B). This analysis 
demonstrated that other co-factors were expressed by all four MPM cell lines. All 
expressed high levels of HSPG, while high levels of ICAM-1 were found on Ju77, LO68 






























Figure 4-1. Expression of human c-Met, CD44v6 and ICAM-1 on malignant 
pleural mesothelioma cell lines. 
(A) Expression of c-Met was detected on the mesothelioma cell lines by flow cytometry 
(red filled histogram). Staining with a matched isotype control antibody is also shown 
(grey filled histogram). The positive control used to validate binding of the anti-c-Met-
FITC conjugated antibody was NIH 3T3 cells transfected to express human c-Met (NIH 
3T3_c-Met). (B) Expression of CD44v6 was detected on the mesothelioma cell lines by 
flow cytometry (green filled histogram). Staining with a matched isotype control 
antibody is also shown (grey filled histogram). The positive control used to validate 
binding of the anti-CD44v6-FITC conjugated antibody was NIH 3T3 cells transfected to 
express human CD44v6. Above data are representative of findings in at least five 
independent experiments. (C) Expression of ICAM-1 was detected on the mesothelioma 
cell lines by flow cytometry (open purple histogram). Control staining with a matched 
isotype control antibody is shown in grey filled histogram (staining representative of two 
























Figure 4-2. Heparan Sulphate Proteoglycan (HSPG) and Syndecan-1 expression on 
a panel of malignant pleural mesothelioma cell lines. 
(A) Expression of HSPG was detected on the mesothelioma cell lines by flow cytometry 
(red filled histogram). Staining with a matched isotype control antibody is also shown 
(blue filled histogram). Percentage HSPG positive cells is annotated on individual plots. 
Data are representative of two independent repeats. (B) Expression of Syndecan-1 was 
detected on the mesothelioma cell lines by flow cytometry (red filled histogram). Staining 
with a matched isotype control antibody is also shown (blue filled histogram). The 
positive control used to validate binding of the anti-Syndecan-1-APC conjugated antibody 
was NIH 3T3 cells transfected to express human Syndecan-1. Staining of NIH 3T3_c-Met 
cells is also shown acting as a negative control. The percentage of Syndecan-1 positive 














Figure 4-3. Expression of human ErbB1, ErbB2 and αvβ6 on malignant 
pleural mesothelioma cell lines. 
(A) Expression of ErbB1 was detected on the mesothelioma cell lines by flow cytometry 
(red filled histogram). Staining with secondary antibody (Ab) is also shown (grey filled 
histogram). (B) Expression of ErbB2 was detected on the mesothelioma cell lines by flow 
cytometry (blue filled histogram). Staining with a matched isotype control antibody is 
also shown (grey filled histogram). The negative control used to validate antibody 
binding was NIH 3T3 cells. Above data are representative of findings in at least two 
independent experiments. (C) Expression of αvβ6 was investigated on the mesothelioma 
cell lines by flow cytometry (red histogram). Control staining with a secondary antibody 








4.2.2 Cytokine release by N28z, M28z and cM28z T-cells following co-culture 
with MPM cell lines 
Next, I investigated whether expression of the N28z, M28z or cM28z CARs could re-
target human T-cell specificity against the panel of four c-Met-expressing mesothelioma 
cell lines shown in Figures 4-1 and 4-2. Activation of c-Met re-targeted CAR+ T-cells was 
compared to that of T-cells expressing control CARs or untransduced (UT) T-cells. Since 
all of these tumour cells express ErbB receptors (Figure 4-3), T-cells expressing T28z (a 
pan ErbB specific CAR [241]) were used as a positive control. T-cells expressing V28z 
(containing an inactive targeting moiety derived from a scrambled 20mer peptide 
sequence) were used as a negative control. Chimeric antigen receptors were expressed in 
activated human T-cells by retroviral transduction at an efficiency indicated in Figure 4-
4. To test CAR T-cell functionality, co-cultivation experiments were performed with all 
four MPM cell lines. T-cell activation was monitored by measurement of the release of 
IFN-γ at 48 hours (Figure 4-5) and IL-2 at 24 hours (Figure 4-6).  
 
In three independent experiments, a significant increase in IFN-γ was observed when c-
Met-targeted CAR+ T-cells were co-cultivated with all four MPM cell lines (Figure 4-5). 
Most notable difference between c-Met re-targeted CAR+ T-cells and control populations 
were observed in the co-cultures involving H28 or REN tumour cells. Despite variability 
in the concentrations of IFN-γ detected, the pattern of T-cell activation was reproducible 
across independent experiments. 
 
It should be noted nonetheless that the amount of IFN-γ released by the c-Met re-
targeted CAR+ T-cells were considerably lower than that produced by T-cells expressing 
T28z, which is a potent CAR targeted against the extended ErbB network [241]. A similar 
observation was noted upon analysis of IL-2 release by MPM-stimulated c-Met re-
targeted CAR+ T-cells. All three c-Met re-targeted CAR+ T-cell populations produced 
significantly greater levels of IL-2 when co-cultured with H28 or REN cells, when 
compared to UT or V28z+ T-cells (Figure 4-6). Once more, T28z+ T-cells produced far 

























Figure 4-4. Expression of c-Met re-targeted and control CAR by retrovirus-
transduced human T-cells. 
(A) Expression of N28z+, M28z+, cM28z+, T28z+ (positive control CAR targeted against 
the ErbB family) and V28z+ (negative control CAR with irrelevant targeting moiety) was 
detected on the surface of transduced primary human T-cells by flow cytometry. Staining 
was performed using the 9e10 antibody that binds to a c-Myc epitope tag present in the 
hinge of all five CARs, followed by PE-conjugated goat anti-mouse IgG (filled red 
histograms). Filled blue histograms show untransduced (UT) T-cells stained with the 
same protocol. Percentage of CAR positive cells is annotated on each flow cytometry data 
plot. Data are representative of four independent experiments. (B) Pooled data in which 
human T-cells were transduced using the indicated SFG CAR retroviral constructs (mean 
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 Figure 4-5. Quantification of IFN-γ release following 48hr co-culture of c-
Met re-targeted and control CAR T-cells with a panel of MPM cell lines.  
N28z+, M28z+, cM28z+, T28z+ (positive control), V28z+ (negative control) or 
untransduced (UT) T-cells were co-cultivated with the indicated MPM cell lines at an 
effector to target ratio of 1:1 (A) or 2:1 (B). After 48 hours, supernatants were collected 
and the concentration of IFN-γ was determined using ELISA. The data presented have 
been compiled from results achieved in three independent experiments and presented as 
mean ± SEM. Significance was determined using the unpaired Student’s t-test, 
comparing UT T-cells with CAR+ T-cells for each target cell line: * p <0.05, ** p <0.005 


















Figure 4-6. Quantification of IL-2 release following 24hr co-culture of c-Met 
re-targeted and control T-cells with a panel of target-expressing MPM cell 
lines. 
N28z+, M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells were co-cultivated 
with the indicated MPM cell lines at an effector to target ratio of 1:1 (A) or 2:1 (B). After 
24 hours, supernatants were collected and the concentration of IL-2 was determined 
using ELISA. The data presented have been compiled from results achieved in three 
independent experiments and presented as mean ± SEM. Significance was determined 
using the unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells for each 





4.2.3 In vitro cytolytic activity of N28z, M28z and cM28z T-cells against 
MPM cell lines. 
A key aim of this project was to determine whether c-Met re-targeted CAR+ T-cells could 
represent a potential therapy for mesothelioma. Consequently, it was important to 
determine their ability to destroy MPM cell lines. This was assessed using MTT assays to 
quantify residual tumour cell survival following co-cultivation with CAR-engineered T-
cells. N28z+, M28z+, cM28z+, T28z+, V28z+ T-cells (Figure 4-4) and UT T-cells were co-
cultured for either 24, 48 or 72 hours with a panel of MPM cell lines at an effector to 
target ratio of 1:1, 2:1 or 4:1 (Figure 4-7 to 4-9 respectively). Comparison was made with 
untreated tumour cells grown under the same conditions, but in the absence of T-cells, 
providing a measure of maximal tumour cell viability (quantified by formazan dye 
production).  
 
As shown in Figure 4-7, co-culture of H28 tumour cells with N28z+, M28z+, cM28z+ and 
T28z+ T-cells for 24 hours resulted in substantial tumour cell lysis (60%) when compared 
to all control (UT or V28z+ T-cells) cultures. This was further increased when the co-
cultures were continued for 48 hours. As expected, there was only a small (20%) 
reduction in the level of H28 cell viability following incubation with either UT or V28z+ 
control T-cells when compared to target cells grown in the absence of T-cells. In contrast, 
no difference could be discerned between the cytolytic activity of the c-Met re-targeted 
CAR+ T-cells and control T-cells on the remaining three MPM cell lines after 24 hours, 
irrespective of the effector to target ratio. At 48 hours, a small increase in tumour cell 
lysis (significant with cM28z+) could be observed on the REN cells and LO68 cells (15-
20%) when compared to control UT or V28z+ T-cells. When comparing the c-Met re-
targeted CAR+ T-cells against the T28z+ T-cells at an effector to target ratio of 1:1, the 
difference in killing of REN, JU77 and LO68 MPM cells appears to be marginal. 
However, the average transduction of T28z+ CAR T-cells was over 2-fold lower than 
N28z+, M28z+, cM28z+ T-cells. This difference is overcome by increasing the effector to 
target ratio whereby substantially increased tumour cell lysis is observed with T28z+ T-
cells when compared to either c-Met re-targeted CAR+ T-cells or UT and V28z+ T-cells 
















Figure 4-7. Cytotoxic destruction of MPM cell lines co-cultured with c-Met 
re-targeted and control CAR T-cells: effector to target ratio of 1:1. 
The indicated MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed 
to adhere overnight. Percentage viability of the indicated MPM cell lines is shown 
following 24hr (A) and 48hr (B) incubation with an equal number (2 x 104 cells) of 
N28z+, M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells. Transduced cells 
were not corrected for transduction efficiency, which is shown in Figure 4-3. Tumour cell 
viability was measured using an MTT assay at the indicated time points. Data are 
presented as mean ± SEM from four independent experiments. Significance was 
determined using the unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells 











Figure 4-8. Cytotoxic destruction of MPM cell lines co-cultured with c-Met 
re-targeted and control CAR T-cells: effector to target ratio of 2:1. 
The indicated MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed 
to adhere overnight. Percentage viability of the indicated MPM cell lines is shown 
following 24hr (A) and 48hr (B) incubation with a 2-fold excess (4 x 104 cells) of N28z+, 
M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells. Transduced cells were not 
corrected for transduction efficiency, which is shown in Figure 4-3. Tumour cell viability 
was measured using an MTT assay at the indicated time points. Data are presented as 
mean ± SEM from four independent experiments. Significance was determined using the 
unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells for each target cell 















Figure 4-9. Cytotoxic destruction of MPM cell lines co-cultured with c-Met 
re-targeted and control CAR T-cells: effector to target ratio of 4:1. 
The indicated MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed 
to adhere overnight. Percentage viability of the indicated MPM cell lines is shown 
following 24hr (A) and 48hr (B) incubation with a 4-fold excess (8 x 104 cells) of N28z+, 
M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells. Transduced cells were not 
corrected for transduction efficiency, which is shown in Figure 4-3. Tumour cell viability 
was measured using an MTT assay at the indicated time points. Data are presented as 
mean ± SEM from four independent experiments. Significance was determined using the 
unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells for each target cell 





4.2.4 Competitive ligand inhibition does not affect c-Met re-targeted CAR+ T-
cell function 
I hypothesised that the discrepancy observed between high c-Met expression and 
reduced c-Met re-targeted CAR+ T-cell mediated killing of REN, JU77 and LO68 cells 
might be due to HGF secretion by MPM cells, thus competitively inhibiting CAR T-cell 
function. To investigate this possibility, a HGF ELISA was performed on conditioned 
medium derived from all four MPM cell lines (Figure 4-10). Conditioned medium from 
NIH 3T3 fibroblast cells which are known not to release HGF were used as a negative 
control. It has previously been reported that HGF must be introduced via gene transfer to 



























Figure 4-10. Quantification of human HGF released following time course 
from a panel of MPM tumour cell lines. 
The indicated MPM tumour cell lines and NIH 3T3 cells (negative control) were seeded 
in triplicate at 2 x 104 cells per well and were allowed to adhere overnight. Thereafter, at 
24hr, 48hr and 72-hour intervals, medium was collected and the concentration of human 
HGF was determined using ELISA. Data are from two independent experiments and are 
presented as mean ± SEM. An unpaired Student t-test was undertaken which 
demonstrated no significant increase in any sample, when compared to D10 medium. 
Abbreviations: D10, DMEM culture media supplemented with FBS. D10 NIH 3T3 media; 
conditioned medium obtained from NIH 3T3 cells cultured in D10 for 24 hours. The 




The data presented suggests HGF levels in supernatant collected from all MPM cell lines 
is not significantly higher than in D10 medium (comprising DMEM + 10% FBS) or 
conditioned medium derived from NIH 3T3 cells, which are known not to release HGF 
(Figure 4-10) [349]. Taken together, the data presented suggests that ligand blocking is 
unlikely to account for poor function of the c-Met+ CAR T-cells on REN, JU77 and LO68 
MPM tumour cell lines. It should be noted however that no suitable positive sample was 
available for this analysis. 
 
4.2.5 Engineering of MPM cells to over-express CD44v6  
A variety of CD44 isoforms are commonly overexpressed in many tumours. The CD44 
variant isoform v6 is a known co-factor that facilitates the binding of HGF to the c-Met 
receptor [196]. Although N28z+, M28z+ and cM28z+ T-cells do not directly engage and 
kill NIH 3T3 cells expressing only CD44v6 (Figure 3-4 to 3-6), c-Met re-targeted CAR+ T-
cells release significantly higher levels of IFN-γ when co-cultivated with NIH 3T3 cells 
that co-express c-Met and CD44v6, compared to c-Met alone. This led me to hypothesise 
that the presence of this co-factor might enhance the cytotoxic activity of c-Met re-
targeted CAR+ T-cells against refractory MPM tumour cell lines such as REN, JU77 and 
LO68, which do not naturally express this isoform (Figure 4-1B). 
 
To test this, human CD44v6 was over-expressed in REN, JU77 and LO68 cell lines by 
retroviral-mediated gene transfer. Figure 4-11C shows that transduced cells were strongly 
positive for CD44v6 expression with the exception of LO68, in which more modest 
expression was achieved. 
 
Prior to testing these cell lines in MTT cytotoxicity assays, it was important to confirm 
that expression of CD44v6 had not altered the expression of c-Met by the MPM cell lines. 
When compared to c-Met expression on the parental MPM cell lines, the CD44v6 
transduced MPM cell lines had near identical levels of c-Met expression, as detected by 
































Figure 4-11. CD44v6 expression by retrovirus-transduced malignant pleural 
mesothelioma cell lines. 
(A) NIH 3T3 cells used as a negative control for detection of the CD44v6 receptor using 
an anti-CD44v6-FITC antibody. In all cases, CD44v6 staining is shown as a filled red 
histogram while isotype control staining is shown as the blue histogram. (B) Cell surface 
expression of CD44v6 was not detected on the indicated parental MPM cell lines using an 
anti-CD44v6-FITC antibody (red histogram). Staining of the matched isotype control 
antibody is also shown (blue histogram). (C) Following retroviral-mediated gene transfer 
of CD44v6 into MPM cells, this analysis was repeated as above (CD44v6 - red 
histogram), making comparison with a matched isotype control (blue histogram). Data 
























Figure 4-12. Retention of c-Met expression on malignant pleural 
mesothelioma cell lines engineered to overexpress human CD44v6. 
(A) NIH 3T3 cells that over-express human c-Met were used as a positive control for 
detection of this receptor using an anti-c-Met-FITC antibody. Staining was also 
confirmed on H28 MPM cells, which have previously been shown to express high levels 
of cell surface c-Met expression. Parental NIH 3T3 cells served as negative control. In all 
cases, c-Met staining is shown as a filled red histogram while isotype control staining is 
shown as the blue histogram. (B) Expression of c-Met was detected in the indicated 
parental MPM cell line using an anti-c-Met-FITC antibody (red histogram). Staining of 
the matched isotype control antibody is also shown (blue histogram). (C) Following over-
expression of CD44v6 in these cells, c-Met expression was determined by flow cytometry 
as above (red histogram), making comparison with a matched isotype control (blue 










4.2.6 Determination of N28z, M28z and cM28z T-cell activation by CD44v6 
expressing MPM cell lines 
Having validated both parental and CD44v6-over-expressing MPM cell lines, studies to 
test cytotoxic activity of c-Met re-targeted CAR+ T-cells were conducted. Representative 
examples of transduction of N28z+, M28z+, cM28z+, T28z+ and V28z+ T-cells are shown 
in Figure 4-13A while pooled transduction efficiency data from three independent donors 












Figure 4-13. Transduction efficiency of CAR T-cells used in co-cultivation 
experiments with MPM cell lines engineered to express CD44v6. 
(A) Expression of N28z, M28z, cM28z, T28z and V28z (filled red histogram) was 
detected on the surface of human T-cells using flow cytometry. Filled blue histograms 
show UT T-cells stained with the same protocol. Percentage CAR positive cells is 
annotated on each plot. (B) Pooled data in which human T-cells were transduced using 
the indicated SFG CAR retroviral constructs (mean + SEM of three independent donors).  
 
 
To investigate the effect of CD44v6 co-expression on anti-tumour activity of c-Met re-
targeted T-cells, N28z+, M28z+ and cM28z+ CAR T-cells were co-cultured with REN 
(Figure 4-14), JU77 (Figure 4-15) and LO68 MPM tumour cells (Figure 4-16). Release of 
IFN-γ in these co-cultures was compared on parental and CD44v6-engineered MPM 
tumour cell lines in each case. Activation of c-Met re-targeted CAR+ T-cells was 





















Figure 4-14. Quantification of IFN-γ release following 48hr co-culture of c-
Met re-targeted and control CAR T-cells with matched REN and 
REN_CD44v6 expressing cells.  
N28z+, M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells were co-cultivated 
with REN and CD44v6 expressing REN cells at an effector to target ratio of (A) 1:1 or (B) 
2:1. After 48 hours, supernatants were collected and the concentration of IFN-γ was 
measured using ELISA. Data were compiled from three independent experiments and 
are presented as mean ± SEM. Symbols above individual bars represent significance 
determined using the unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells 
when co-cultivated on REN cells (this test was not conducted on REN+ CD44v6 cells). 
Unpaired Student’s t-tests were also performed comparing CAR+ T-cells co-cultivated on 
REN versus REN + CD44v6 tumour cells. However no significant differences were 



























Figure 4-15. Quantification of IFN-γ release following 48hr co-culture of c-
Met re-targeted and control CAR T-cells with matched JU77 and 
Ju77_CD44v6 expressing cells.  
N28z+, M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells were co-cultivated 
with JU77 and CD44v6 expressing JU77 cells at an effector to target ratio of (A) 1:1 or 
(B) 2:1. After 48 hours, supernatants were removed and the concentration of IFN-γ was 
measured using ELISA. The data presented have been compiled from results achieved in 
three independent experiments and are presented as mean ± SEM. Symbols above 
individual bars represent significance determined using the unpaired Student’s t-test, 
comparing UT T-cells with CAR+ T-cells when co-cultivated on Ju77 cells (this test was 
not conducted on JU77 + CD44v6 cells). Where indicated by the overhead line, an 
unpaired Student’s t-test has been performed comparing N28z+ T-cells co-cultivated on 
























Figure 4-16. Quantification of IFN-γ release following 48hr co-culture of c-
Met re-targeted and control CAR T-cells with matched LO68 and 
LO68_CD44v6 expressing cells.  
N28z+, M28z+, cM28z+, T28z+, V28z+ or untransduced (UT) T-cells were co-cultivated 
with LO68 and CD44v6 expressing LO68 cells at an effector to target ratio of (A) 1:1 or 
(B) 2:1. After 48 hours, supernatants were removed and the concentration of IFN-γ was 
measured using ELISA. The data presented have been compiled from results achieved in 
three independent experiments and are presented as mean ± SEM. Symbols above 
individual bars represent significance determined using the unpaired Student’s t-test, 
comparing UT T-cells with CAR+ T-cells when co-cultivated on LO68 cells (this test was 
not conducted on LO68 + CD44v6 cells). Where indicated by the overhead line, an 
unpaired Student’s t-test has been performed comparing N28z+ T-cells co-cultivated on 
LO68 and LO68 + CD44v6 tumour cells: * p <0.05, ** p <0.005 and *** p <0.0005. 
 
 
In three independent experiments, comparing between parental and CD44v6 expressing 
tumour cells, no significant difference in IFN-γ release by N28z+, M28z+ or cM28z+ T-
cells was observed following their co-culture with REN MPM cells either effector to target 
ratio used (Figure 4-14). Following co-cultures with JU77 cells, only N28z+ T-cells 
released significantly higher amounts of IFN-γ when co-cultured with JU77_CD44v6 
cells compared to parental counterparts (Figure 4-15). A similar result was observed 
following co-culture with LO68 cells, with N28z+ CAR T-cells releasing significantly 
147 
 
greater amounts of IFN-γ on LO68_CD44v6 compared to LO68 cells (Figure 4-16). 
Despite variability in the concentrations of IFN-γ detected, the pattern of T-cell 
activation was reproducible across independent experiments. Although statistical 
significance was reached with N28+ T-cells on two of the three MPM cell lines, it is worth 
noting the level of IFN-γ released was still either below or comparable to levels produced 
by cM28z+ T-cells. Reliably across independent donors, the concentrations of IFN-γ 
released by the c-Met re-targeted CAR+ T-cells were considerably lower than that 
achieved by T-cells that express T28z when co-cultured with both JU77 and LO68 cells. 
However, this disparity was not observed during co-culture with REN MPM cells (Figure 
4-14).  
 
4.2.7 Comparison of susceptibility of parental and CD44v6 transduced MPM 
cells to cytotoxic destruction by N28z+, M28z+ and cM28z+ CAR T-cells 
Measurement of T-cell-mediated MPM cell destruction was achieved in three 
independent experiments performed using the same protocol described above (section 
4.2.3). Following confirmation of CAR expression (Figure 4-13), N28z+, M28z+, cM28z+, 
T28z+, V28z+ and UT T-cells were co-cultured with MPM cells for 24 - 72 hours at an 
effector to target ratio of 1:1, 2:1 or 4:1 (Figure 4-17 to 4-19 respectively). At 24 hours, c-
Met re-targeted CAR+ T-cells induced a similar level of lysis of parental MPM cells and 
those transduced to express CD44v6; with no significant difference between the c-Met 
re-targeted CAR+ T-cells and control T-cells. At 48 hours, a statistically significant 
increase in tumour cell lysis could be observed on the REN cells of 40% (N28z & M28z) 
and LO68 cells with 20% increase in tumour cell lysis when comparing the c-Met re-
targeted CAR+ T-cells to UT or V28z+ T-cells (Figure 4-18B). No difference was observed 
between the killing of parental and CD44v6-transduced MPM cells at 48 hours. At 72 
hours (Figure 4-18C), the only cell line that suggested CD44v6 might enhance tumour 
cell lysis mediated by c-Met re-targeted CAR+ T-cells was the JU77 cell line. However, 
this was not observed with increasing effector to target ratios, arguing that this difference 
does not have biological relevance. Overall, the data presented across the three effector to 
target ratios at the different time points suggest that the presence of CD44v6 did not 
enhance the efficacy of c-Met re-targeted CAR+ T-cell mediated tumour cell lysis. Of note 
however is the increased anti-tumour activity observed with the c-Met re-targeted CAR+ 
T-cells (especially at 48 and 72 hours) when co-cultured with parental MPM cells, when 
compared to the data shown in Figure 4-7 to Figure 4-9. This may in part be due to the 
increased transduction efficiency of the c-Met re-targeted CAR T-cells, which was almost 


























Figure 4-17. Cytotoxic destruction of matched parental and CD44v6 
expressing MPM cell lines co-cultured with c-Met re-targeted and control 
CAR T-cells: effector to target ratio of 1:1. 
A panel of MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed to 
adhere overnight. Percentage viability of MPM cell lines is shown following (A) 24hr, (B) 
48hr or (C) 72hr incubation with an equal number (2 x 104 cells) of N28z+, M28z+, 
cM28z+, T28z+, V28z+ or untransduced (UT) T-cells. Transduced cells were not corrected 
for transduction efficiency (shown in Figure 4-12B). Tumour cell viability was measured 
using an MTT assay at the indicated time points after removal of T-cells by gentle 
washing. Data presented as mean ± SEM from three independent experiments. 
Significance was determined using the unpaired Student’s t-test, comparing T-cell 
populations between matched cell lines (comparing N28z on REN v REN_CD44v6) * 































Figure 4-18. Cytotoxic destruction of matched parental and CD44v6 
expressing MPM cell lines co-cultured with c-Met re-targeted and control 
CAR T-cells: effector to target ratio of 2:1. 
A panel of MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed to 
adhere overnight. Percentage viability of MPM cell lines is shown following (A) 24hr, (B) 
48hr or (C) 72hr incubation with 4 x 104 cells of N28z+, M28z+, cM28z+, T28z+, V28z+ or 
untransduced (UT) T-cells. Transduced cells were not corrected for transduction 
efficiency (shown in Figure 4-12B). Tumour cell viability was measured using an MTT 
assay at the indicated time points after removal of T-cells by gentle washing. Data are 
presented as mean ± SEM from three independent experiments. Significance was 
determined using the unpaired Student’s t-test, comparing T-cell populations between 






























Figure 4-19. Cytotoxic destruction of matched parental and CD44v6 
expressing MPM cell lines co-cultured with c-Met re-targeted and control 
CAR T-cells: effector to target ratio of 4:1. 
A panel of MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed to 
adhere overnight. Percentage viability of MPM cell lines is shown following (A) 24hr, (B) 
48hr or (C) 72hr incubation with 8 x 104 cells of N28z+, M28z+, cM28z+, T28z+, V28z+ or 
untransduced (UT) T-cells. Transduced cells were not corrected for transduction 
efficiency (shown in Figure 4-12B). Tumour cell viability was measured using an MTT 
assay at the indicated time points after removal of T-cells by gentle washing. Data 
presented as mean ± SEM from three independent experiments. Significance was 
determined using the unpaired Student’s t-test, comparing T-cell populations between 




4.2.8 Expansion of T-cells using the IL-4/ 4αβ  chimeric cytokine receptor 
system  
The 4αβ chimeric cytokine receptor couples the ectodomain of the IL-4Rα to the 
endodomain of the IL-2/IL-15-Rβ (Figure 4-20A) [311]. By co-expressing 4αβ with a 
particular CAR of interest, the selective expansion and enrichment of re-directed CAR+ 
T-cells can be enhanced via exogenous IL-4 stimulation. Co-expression of both receptors 
was achieved through the use of an intervening Thosea asigna virus 2A (T2A) peptide 
downstream of a furin cleavage site (Figure 4-20B) [311].  
 
The observation of increased c-Met re-targeted CAR+ transduction efficiencies positively 
correlating with tumour cell cytolysis led me to co-express the 4αβ chimeric cytokine 
receptor with N28z, M28z and cM28z resulting in SFG N4, M4 and cM4 respectively 
(Figure 4-20C-D). By this means, I hoped to develop a reliable system to generate highly 
transduced cell products for further experiments.	  
 
4.2.9 Interferon-γ  release by N4, M4 and cM4 T-cells following co-culture 
with MPM cell lines 
To investigate whether expression of the N4+, M4+ and cM4+ CARs enabled re-targeting 
of T-cell specificity against mesothelioma, engineered T-cells were co-cultured with four 
MPM tumour cell lines. Following expansion using IL-4 for 9 days, activation of 4αβ+ c-
Met re-targeted CAR+ T-cells was compared to that of T-cells expressing control CAR or 
untransduced (UT) T-cells. T-cells expressing V28z (containing an inactive targeting 
moiety derived from a scrambled peptide sequence) were used as a negative control. 
During the co-culture period, T-cell activation was monitored by measurement of the 
release of IFN-γ. Two effector-to-target ratios were assessed, namely 1:1 and 2:1 (T-cells: 
tumour cells).  
 
In three independent experiments, N4+, M4+ and cM4+ T-cells released a significantly 
greater concentration of IFN-γ during co-culture with all four of the MPM tumour cells 
when compared to UT T-cells (Figure 4-21). Reliably across independent donors, the 
concentrations of IFN-γ released by the c-Met re-targeted CAR+ T-cells were 
considerably lower than that achieved by c-Met re-targeted CAR+ T-cells previously 
cultured with REN (Figure 4-14) and JU77 cells (Figure 4-15). However, this disparity 
was not observed during co-culture with LO68 MPM cells (Figure 4-16). This result does 
however highlight the effect of the relatively poor transduction efficiencies observed in 

























Figure 4-20. Co-expression of 4αβ chimeric cytokine receptor with Met-
targeted CARs 
(A) The combined expression of the c-Met+ (e.g. cM28z) CAR and the 4αβ chimeric 
cytokine receptor is referred to cM4 (representative example shown), N4 (N28z), M4 
(M28z) or V4 (V28z) respectively. In 4αβ, the IL-4Rα ectodomain has been coupled to 
the IL-2/15Rβ endodomain. Upon binding with IL-4, the receptor dimerises with the 
common γ-chain (γc) (shown in dark blue). (B) Within the N4, M4, CM4 (shown) and V4 
combinations, the coding sequences are separated by the T2A peptide derived from the 
Thosea asigna plant virus, which induces a ribosomal ‘skip’ and therefore misses a 
peptide bond between the glycine and proline (as indicated by the right pair of scissors). 
Expression of the T2A peptide sequence at the C-terminus of the mature 4αβ protein is 
prevented by the presence of a furin cleavage site (as indicated by the left pair of 
scissors). The furin cleavage site is linked to the T2A peptide by a serine-glycine linker. 
LTR: long terminal repeats; Ψ: packaging signal; ★: HGF leader sequence. Note: size of 
the blocks is not representative of the sizes of individual elements. (C) Representative 
FACS plots detecting CAR expression on the cell surface of T-cells after 9 days of IL-4  
culture. UT (blue) and respective CAR+ T-cells (pink). (D) The average transduction 
efficiency of 4αβ+ c-Met+ T-cells (N4, M4 and CM4) alongside control T-cell population 




4.2.10 In vitro cytolytic activity of N4, M4 and cM4 T-cells against MPM cell 
lines 
To test anti-tumour activity of 4αβ c-Met re-targeted CAR+ re-targeted T-cells, their 
ability to destroy MPM tumour cell lines was determined. As detailed in Chapter 4, T-
cell/ tumour cell co-cultivation experiments were performed and viable tumour cells 
were quantified thereafter using an MTT assay. Following confirmation of 4αβ and CAR 
expression (Figure 4-20), N4+, M4+, cM4+, V4+ and UT T-cells were co-cultured for 48 
hours with an established panel of c-Met expressing MPM tumour cell lines at an effector 
to target ratio of 1:1 or 2:1. Supernatants were harvested and were analysed for IFN-γ 
content (Figure 4-21). Cytotoxicity was quantified by MTT assay (Figure 4-22). 
 
In three independent experiments, co-culture of H28, REN and LO68 tumour cells with 
N4+, M4+ and cM4+ T-cells all resulted in significantly increased release of IFN-γ (Figure 
4-21) and tumour cell killing (Figure 4-22), when compared to all control (UT or V4+ T-
cells) cultures. As expected, this was further increased when the number of effector T-
cells was increased (2:1). Once again, H28 tumour cells proved most susceptible to c-Met 
re-targeted CAR T-cell mediated killing. However, significant anti-tumour activity was 
also observed on both REN and LO68 cells. Co-cultures with the latter MPM cell line 
resulted in similar levels of cytolytic activity, with M4+ and cM4+ cells (E-T 2:1 in 
particular). By contrast, there was little tumour cell killing observed when c-Met re-















































Figure 4-21. IFN-γ release during N4+, M4+ and CM4+ T-cell co-cultures with 
a panel of MPM cell lines 
N4+, M4+, CM4+, V28z+ or untransduced (UT) T-cells were co-cultivated with panel of 
four MPM tumour cell lines. After 48 hours, supernatants from either effector to target 
ratio of (A) 1:1 or (B) 2:1 were removed and the concentration of IFN-γ measured using 
ELISA. The data presented was compiled from results achieved in three independent 
experiments and presented as mean ± SEM. Significance was determined using the 
unpaired Student’s t-test, comparing UT T-cells with CAR+ T-cells: * p <0.05, ** p 




































Figure 4-22. in vitro cytolytic activity of N4+, M4+ and CM4+ T-cells against a 
panel of MPM tumour cell lines 
MPM tumour cell lines (2 x 104 cells) were seeded in triplicate and allowed to adhere 
overnight. Percentage viability of (A) H28, (B) REN, (C) LO68 and (D) JU77 tumour 
cells  is shown following 48hr incubation with either 2 x 104 or 4 x 104 cells of N4+, M4+, 
cM4+, V4+ or untransduced (UT) T-cells. Transduced cells were not corrected for 
transduction efficiency (shown in Figure 4-19D). Tumour cell viability was measured 
using an MTT assay (48hr). Data presented as mean ± SEM from three independent 
experiments. Significance was determined using the unpaired Student’s t-test, comparing 





The overall aim of the work undertaken in this chapter was to investigate the in vitro 
anti-tumour activity of a panel of three c-Met re-targeted CARs (named N28z, M28z and 
cM28z) engineered to target the c-Met receptor tyrosine kinase.  
 
In Chapter 3, I showed that all three candidate CARs could re-target human T-cells 
against c-Met expressing NIH 3T3-based aAPCs. Consequently, I next investigated their 
anti-tumour activity using a panel of MPM tumour cell lines. I selected four commonly 
studied cell lines representative of epithelioid and sarcomatoid subtypes of MPM (LO68, 
H28, JU77 and REN) and found that all expressed c-Met at varying levels. Accordingly, I 
hypothesised that these MPM tumour cells would promote the activation of N28z+, 
M28z+ and cM28z+ T-cells, facilitating a direct comparison of their in vitro anti-tumour 
activity.  
 
Functionality of the CARs was investigated by measurement of IFN-γ and IL-2 
production and tumour cell cytotoxicity. These experiments demonstrated that 
significantly greater quantities of IFN-γ were released by c-Met re-targeted CAR+ T-cells 
in comparison to control T-cells, when stimulated by MPM tumour monolayers. A 
substantial increase in IL-2 production by c-Met re-targeted CAR+ T-cells was also 
observed (significant for H28 and REN). However, in the initial experiments I 
undertook, significant tumour cell killing was only apparent when c-Met-targeted CAR T-
cells were cultured with H28 tumour cells. This observation was made in multiple 
independent experiments analysing tumour cell viability by MTT. By contrast, no 
significant killing of REN, JU77 or LO68 MPM cells was observed. This was an 
unexpected result given the significant levels of c-Met expression seen on these tumour 
cells. Since T28z+ T-cells caused destruction of these tumour cells despite poorer 
transduction efficiency, this shows that tumour cells are not inherently resistant to the 
cytotoxic machinery deployed by CAR T-cells. It should be noted however that both CARs 
are directed against two different targets - therefore any direct comparison of their 
functionality is subject to this limitation.  
 
Initially, I hypothesised that the activation of N28z+, M28z+ and cM28z+ T-cells requires 
c-Met expression to be above a certain threshold. In keeping with this, H28 cells 
expressed the highest level of cell surface c-Met among the panel of 4 MPM cell lines 
used and were efficiently killed using these CAR T-cells. Such a threshold effect might 
have been advantageous for clinical translation of c-Met+ CAR T-cells since it could be 
speculated that low levels of c-Met expressed by healthy tissue (e.g. liver) would be 
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insufficient to promote activation, thus reducing potential for “on-target, off-tumour” 
toxicity. However, subsequent studies conducted using highly transduced T-cells 
revealed the ability of all three candidate c-Met-targeted CARs to mediate destruction of 
all four Met-expressing MPM tumour cell lines.  
 
An alternative explanation for the lack of straightforward relationship between c-Met 
expression and activation of c-Met retargeted T-cells is the possibility that some 
mesothelioma cell lines produce HGF [150]. However, none of the MPM cell lines used in 
this study produced significant quantities of this cytokine, as detected by ELISA analysis. 
This argues that receptor blockade by natural ligand is not a significant hindering factor 
to the activity of the candidate c-Met re-targeted CARs under study here. 
 
Data presented in Chapter 3 raised the possibility that co-expression of CD44v6 
enhanced the activation of c-Met-targeted CAR T-cells, indicated by greater release of 
IFN-γ without enhancement of cytotoxicity against c-Met-engineered NIH 3T3 
fibroblasts. CD44v6 is the best characterised co-factor that facilitates the binding of HGF 
to c-Met. Since all of my CARs retain key elements from HGF (derived from the N and K1 
domains), I hypothesised the engagement between c-Met, CD44v6 and the CAR targeting 
moiety might promote enhanced target-dependent T-cell activation. However, a similar 
effect of CD44v6 was not observed in functional studies performed using MPM tumour 
cells that were engineered to over-express this co-factor. While tumour cells were not 
uniformly positive for CD44v6 following gene transfer, it would nonetheless have been 
expected that IFN-γ release would have been enhanced if CD44v6 promoted enhanced 
binding of these NK1-derived CARs to c-Met, leading to increased CAR T-cell activation. 
A possible explanation for the discrepant results obtained using both models relates to 
the fact that NIH 3T3 cells are derived from immortalised mouse fibroblasts, whereas all 
MPM tumour cells are of human origin. Consequently, NIH 3T3 cells may not express 
one or more molecules that are found on human tumour cells and which can substitute 
for the co-factor function of CD44v6. Examples include Syndecan-1 and ICAM-1, both of 
which were expressed by MPM tumour cells and which in some models can replace 
CD44v6 as a co-factor to promote the binding of HGF to c-Met [207]. Further 
investigation of this finding is clearly warranted. 
 
In light of the variable efficiency of gene transfer encountered in this study, I also 
explored the use of the 4αβ/ IL-4 system to expand CAR T-cells. However, I did not 
achieve reproducible enrichment of CAR T-cells using this system for reasons that 
remain unclear. CAR T-cells expanded using this system demonstrated similar 
functionality to those expanded using IL-2, although the level of IFN-γ recorded was 
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notably lower than previously achieved with well-transduced c-Met re-targeted CAR T-
cells.  
 
The experiments described in this chapter permitted an initial comparison of the 
functionality of the three candidate c-Met-targeted CAR molecules developed in this 
project. However, no convincing or reproducible difference in cytotoxicity or cytokine 
release mediated by these CAR molecules was observed. These findings are in agreement 
with the data presented in Chapter 3 although it is acknowledged that in vivo comparison 
of functionality is still necessary before one can conclude that these molecules are 
equipotent. 
 
In summary, the data presented in this chapter show that N28z+, M28z+ and cM28z+ T-
cells are effectively re-targeted against a panel of c-Met-expressing MPM tumour cell 
lines, providing that high transduction efficiency is achieved. Confirmation of successful 
targeting was achieved using a variety of experimental readouts, including target cell 
destruction and T-cell cytokine secretion. In light of the requirement for highly efficient 
gene transfer in order to elicit reproducible anti-tumour activity, I next elected to explore 
approaches in which c-Met re-targeted CAR T-cells are combined with alternative 
therapeutic approaches in use in MPM, such as chemotherapy and immune checkpoint 






CHAPTER 5 Investigation of the use of chemotherapy or 
immune checkpoint blockade to potentiate 
immunotherapy of mesothelioma using c-Met-




5.1 Introduction  
 
Data presented in Chapter 4 demonstrate that all three candidate c-Met-targeted CARs 
exert anti-tumour activity against the H28 MPM cells. Anti-tumour activity was also 
demonstrated against the REN, LO68 and JU77 cell lines, albeit dependent upon high 
efficiency CAR T-cell gene transfer. In light of these findings, I next explored whether the 
therapeutic potency of this approach could be potentiated using two other therapeutic 
modalities that are commonly used to treat mesothelioma, namely combination 
chemotherapy and immune checkpoint blockade.  
 
5.1.1 Use of chemotherapy in combination with CAR+ T-cell immunotherapy 
Combination chemotherapy regimens used to treat mesothelioma are described in detail 
in section 1.1.7. A commonly used regimen in current use employs a combination of 
cisplatin and pemetrexed [81]. It has previously been shown that chemotherapy can 
sensitise tumour cells to destruction by CAR T-cells, even when tumour cells are 
intrinsically chemotherapy resistant [350]. Here, I set out to see if cisplatin and/or 
pemetrexed could similarly be used to sensitise tumour cells to destruction by c-Met re-
targeted CAR+ T-cells. 
 
5.1.2 Combined use of immune checkpoint blockade with CAR T-cell 
immunotherapy 
 
A summary of the use of checkpoint blockade within MPM are described in detail within 
section 1.1.7. Both CAR T-cell therapy and checkpoint blockade have had striking success 
to date, however both treatment modalities are in their infancy, and requiring further 
investigation into untapped potential. Moreover, approaches to further optimise outcome 
are ongoing. One method stems from the strong rationale for the combination of 
checkpoint inhibition with CAR T-cell therapy – systemic immunotherapy in 
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combination with local, targeted immunotherapy. For maximal anti-tumour effect, 
adoptive T-cells require a permissive environment – checkpoint blocking antibodies 
remove T-cell inhibition; however, studies to date suggest their effectiveness is 
dependent upon functional tumour-specific T-cells. Thus, providing re-directed tumour-
specific CAR T-cells in conjunction with checkpoint inhibitors has the potential for 
enhanced anti-tumour efficacy.  
 
This combinatorial approach, using CAR T-cells and checkpoint inhibition (PD-1 
blocking antibody), was first investigated by John et al. [351]. A transgenic Her-2 mouse 
model was used, treated with Her-2 CAR T-cells, PD-1 mAb or a combination of both 
agents.  The authors demonstrated Her-2 CAR+ (CD28) T-cell engagement with PD-L1+ 
Her-2+ tumour cells triggered PD-1 upregulation on CAR T-cells. Additionally, PD-1 
blockade enhanced proliferation and anti-tumour function of Her-2 CAR T-cells – an 
enhanced regression of established Her-2 breast carcinoma-transplanted tumours was 
observed compared to control arms receiving Her-2 CAR+ T-cells alone [351]. PD-1 
blockade significantly enhanced intracellular expression of Ki-67, in addition to IFN-γ 
and granzyme B in CAR+ T-cells. Notably, utilising the aforementioned Her-2 transgenic 
mouse model, the authors demonstrated the safety of this combinatorial approach, citing 
no pathology to Her-2+ brain or mammary tissues [351]. 
 
An alternative novel approach to merging CAR T-cell therapy with checkpoint blockade is 
being explored preclinically, in which CAIX-targeted CAR T-cells have been engineered 
to secrete PD-L1 antibodies within the tumour milieu. Utilising a humanised murine 
model of clear cell renal cell carcinoma (ccRCC), the authors demonstrated significant 
delay in tumour growth and tumour weight decrease of 50-80% when compared with 
anti-CAIX CAR T-cells alone [352]. Similarly, expression of PD-L1 and Ki-67 within the 
tumours decreased and elevated granzyme B was observed CAR+ T-cells.  
 
Consequently, I set out to investigate whether the therapeutic potency of this approach 
could be potentiated for MPM using c-Met re-targeted CAR+ T-cells in combination with 
a PD-1 blocking antibody.   
 
5.1.3 Aims 
1) To investigate whether standard of care chemotherapy can sensitise MPM tumour 
cells to c-Met re-targeted CAR+ T-cell immunotherapy in vitro. 
2) To evaluate and compare in vitro anti-tumour activity of c-Met re-targeted CAR T-
cells in the presence or absence of the PD-1 inhibitor, pembrolizumab, using a panel 






5.2.1 Establishing the maximal dose of cisplatin / pemetrexed that elicits 
limited direct cytotoxic effect against MPM cell lines 
The ultimate goal of these experiments was to investigate if chemotherapy could be used 
to sensitise MPM tumour cells to destruction by c-Met re-targeted CAR T-cells. 
Consequently, it was important to select doses of these drugs that had a modest cytotoxic 
effect against the tumour (set at <20%), thereby allowing me to evaluate whether tumour 
cell destruction could be potentiated by subsequent exposure to CAR T-cells. Cisplatin 
and/ or pemetrexed were added to MPM cells for 24 hours before being washed off. 
Viability of tumour cells was monitored over the ensuing 48 hours (experimental plan 
summarised in Figure 5-1). Dose-response curves for cisplatin alone (Figure 5-2), 
pemetrexed (Figure 5-3) or cisplatin plus pemetrexed (Figure 5-4) were performed, using 
the MTT assay to determine the cytotoxic effects of each dose level on MPM cells. Dose 
ranges assessed were in accordance with previous experience with previously published 
data and were as follows: cisplatin 0-200µM ± pemetrexed 0-500µM.  
 
 
Figure 5-1. MPM tumour seeding and treatment protocol timeline for 
chemotherapy dose response studies – cisplatin and pemetrexed. 
2 x 104 Tumour cells were seeded in three 96-well plates per cell line (Day 0) and were 
incubated overnight. Chemotherapy agents - cisplatin 0-200µM ± pemetrexed 0-500µM 
were added (Day 1) in decreasing 5-fold serial dilutions to enable dose response to be 
determined. After 24 hours, tumour cell viability was assessed using an MTT assay (Day 
2). Medium from second and third plates for each respective cell line were replaced with 
fresh D10 (not containing chemotherapy agents). After 24 hours (Day 3) and 48 hours 





















Figure 5-2. Dose response studies of cisplatin-mediated cytotoxicity of MPM 
tumour cell lines.  
2 x 104 MPM tumour cells were seeded in 96-well plates incubated as detailed in Figure 
5-1. Cells were cultured in the presence of cisplatin 0-200µM for 24 hours (A) “Day 2”, 
followed by 24 hours (B) “Day 3” or 48 hours (C) “Day 4” after cisplatin removal. Cell 
viability was determined by MTT assay. (D) The EC50, calculated in µM is stated where 
applicable data presented are the mean ± SEM from two independent experiments. 
Calculations were evaluated using Graphpad Prism software. EC50, half maximal 
response – the concentration of drug required eliciting 50% cell death. The arrow depicts 
the 3.2µM concentration resulting in ≤20% cell death – note starting % viability of 

























Figure 5-3. Dose response studies of pemetrexed-mediated cytotoxicity of 
MPM tumour cell lines.  
2 x 104 MPM tumour cells were seeded in 96-well plates incubated as detailed in Figure 
5-1. Cells were cultured in the presence of pemetrexed 0-500µM for 24 hours (A) “Day 
2”, followed by 24 hours (B) “Day 3” or 48 hours (C) “Day 4” after cisplatin removal. Cell 
viability was determined by MTT assay. (D) The EC50, calculated in µM is stated where 
applicable data presented are the mean ± SEM from two independent experiments. 
Calculations were evaluated using Graphpad Prism software. EC50, half maximal 
response – the concentration of drug required eliciting 50% cell death. NA, not 




























Figure 5-4. Dose response studies of combined cisplatin + pemetrexed-
mediated cytotoxicity of MPM tumour cell lines.  
2 x 104 MPM tumour cells were seeded in 96-well plates incubated as detailed in Figure 
5-1. Cells were cultured in the presence of both cisplatin 0-200µM + pemetrexed 0-
500µM  for 24 hours (A) “Day 2”, followed by 24 hours (B) “Day 3” or 48 hours (C) “Day 
4” after cisplatin removal. Cell viability was determined by MTT assay. (D) The EC50, 
calculated in µM is stated where applicable data presented are the mean ± SEM from two 
independent experiments. The arrow depicts the 3.2µM cisplatin concentration resulting 
in ≤20% cell death (as identified in Figure 5-2 – please note starting % viability of certain 
MPM cell lines are not 100%. Calculations were evaluated using Graphpad Prism 
software.  EC50, half maximal response – the concentration of drug required eliciting 







Treatment of all four MPM cell lines with cisplatin alone or cisplatin ± pemetrexed 
resulted in complete dose-dependent killing from 24 hours onwards, with the exception 
of H28 and REN tumour cells in which complete dose-dependent killing was observed 
from 48 hours onwards. By contrast, pemetrexed alone did not elicit tumour cell death at 
doses of up to 500µM. The dose of cisplatin that resulted in ≤20% tumour cell death 
across all three time points evaluated was 3.2µM for all cell lines (as indicated by a blue 
arrow on Figure 5-2). It is important to note the starting tumour cell viability is not 100% 
for each cell line thus this threshold was calculated within each respective MPM cell line. 
Additionally, increased variability was observed thus to further validate this selection, I 
set up an independent experiment in which H28 (Figure 5-5), REN (Figure 5-6) and 
JU77 (Figure 5-7) cells were treated for 24 hours with cisplatin (3.2µM) in combination 
with either 300, 400 or 500µM pemetrexed. Although further variability was observed 
within this experiment, a combination of 3.2µM cisplatin with 500µM pemetrexed 
resulted in ≤20% cell death at 24 hours (with the exception of H28 cells). The 
concentration of either cisplatin ± pemetrexed required eliciting 50% cell death (EC50) 
has been noted in tables within Figure 5-2 to Figure 5-4.  
 
The experimental scope of this particular study was to assess the sensitisation effect of 
chemotherapy on the more unresponsive MPM tumour cell lines for CAR T-cell mediated 



















Figure 5-5. Validation of in-vitro sensitivity of H28 cell line to cisplatin + 
pemetrexed. 
2 x 104 H28 tumour cells were seeded in 3x 96-well plates incubated as detailed in Figure 
5-1. Cisplatin 3.2µM ± pemetrexed 300-500µM were added to the culture medium the 
following day. Three 96-well plates were set up as detailed in Figure 5-1. After 24 hours, 
cell viability was assessed via MTT assay (A-Day 2), followed by 24 hours (B-Day 3) with 
no cisplatin ± pemetrexed in the medium. Cell viability was determined by MTT assay. 


















Figure 5-6. Validation of in-vitro sensitivity of REN cell line to cisplatin + 
pemetrexed. 
2 x 104 REN tumour cells were seeded in 3x 96-well plates as detailed in Figure 5-1. 
Cisplatin 3.2µM ± pemetrexed 300-500µM were added to the culture medium the 
following day. After 24 hours, cell viability was assessed via MTT assay (A-Day 2), 
followed by 24 hours (B-Day 3) with no cisplatin + pemetrexed in the medium. Cell 





















Figure 5-7. Validation of in-vitro sensitivity of JU77 cell line to cisplatin + 
pemetrexed. 
2 x 104 JU77 tumour cells were seeded in 3x 96-well plates as detailed in Figure 5-1. 
Cisplatin 3.2µM ± pemetrexed 300-500µM were added to the culture medium the 
following day. After 24 hours, cell viability was assessed via MTT assay (A-Day 2), 
followed by 24 hours (B-Day 3) with no cisplatin + pemetrexed in the medium. Cell 








5.2.2 Interferon-γ  release by N28z-, M28z- and cM28z-engineered T-cells 
when co-cultured with chemotherapy treated or untreated MPM cell 
lines  
Next, I investigated whether 24 hours sensitisation of MPM tumour cells with cisplatin 
and pemetrexed enhances the release of IFN-γ by c-Met+ CAR T-cells when co-cultivated 
with mesothelioma tumour cell lines. Experimental design in shown in Figure 5-8A and 
transduction efficiency of c-Met re-targeted and control CAR T-cells are shown in Figure 
5-8B. In these experiments, T-cells expressing control V28z CAR or untransduced (UT) 
T-cells were used as negative controls. One effector-to-target ratio was assessed - 1:1 (T-
cells: tumour cells).  
 
In three independent experiments, c-Met+ CAR T-cells did not release a significantly 
greater concentration of IFN-γ during co-culture with all four of the MPM tumour cells 
that had been pre-treated with cisplatin and pemetrexed (Figure 5-9). When comparing 
between T-cells with chemotherapy against chemotherapy alone (benchmark), a 
significantly greater concentration of IFN-γ during co-culture with all tumour cells was 
only observed with c-Met+ CAR T-cells. As expected, chemotherapy did not elicit 
increased IFN-γ production by V28z+ or UT T-cells (Figure 5-9). Despite variability in the 
concentrations of IFN-γ detected, the pattern of T-cell activation was reproducible across 


















Figure 5-8. Investigation of the sensitising effect of chemotherapy exposure 
of MPM cells to subsequent addition of Met re-targeted CAR T-cells.   
(A) Experimental design: 2 x 104 tumour cells were seeded in three 96-well plates per cell 
line (Day 0) and incubated overnight. Cisplatin (3.2µM) + pemetrexed (500µM) were 
added after 24 hours (Day 1). After a further 24 hours, medium containing chemotherapy 
agents was replaced with fresh D10 medium and 2 x 104 c-Met re-targeted or control 
(V28z+ / UT) T-cells were added to co-cultures. After a further 24 or 48 hours, tumour 
cell viability was assessed using an MTT assay. Medium from 48-hour co-cultures was 
stored for subsequent cytokine analysis. (B) Transduction efficiency of c-Met re-targeted 








































Figure 5-9. IFN-γ release by CAR T-cells when co-cultured with 
chemotherapy treated or untreated MPM cells. 
N28z+, M28z+, cM28z+, V28z+ or untransduced (UT) T-cells were co-cultivated at a 1:1 
ratio with panel of four MPM tumour cell lines that were untreated or had been pre-
treated with cisplatin and pemetrexed as described in Figure 5-8A. After 48 hours, 
supernatants were removed from co-cultures with (A) H28, (B) REN, (C) JU77 or (D) 
LO68 tumour cells and the concentration of IFN-γ measured using ELISA (mean ± SEM; 
n=3 independent replicates). Symbols above individual bars represent significance 
determined using the unpaired Student’s t-test, comparing chemotherapy alone with 
combined T-cell + chemotherapy. An unpaired Student’s t-test has been performed 
comparing T-cells co-cultivated on MPM cells and MPM cells + chemotherapy, however 
no significant findings were observed: * p <0.05, ** p <0.005 and *** p <0.0005. 
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5.2.3 Cytotoxicity of N28z-, M28z- and cM28z-engineered T-cells when co-
cultured with chemotherapy treated or untreated MPM cell lines  
Next, I set out to test if cisplatin and/ or pemetrexed at the doses indicated above could 
sensitise MPM cell lines to enhanced destruction by c-Met re-targeted CAR+ T-cells 
(experimental plan shown in Figure 5-8A). Following confirmation of CAR expression 
(Figure 5-8B), N28z+, M28z+, cM28z+, V28z+ and UT T-cells were co-cultured with H28, 
REN, LO68 or JU77 MPM tumour cells that had been pre-treated with chemotherapy, 
making comparison with untreated control tumour cells.  
 
When c-Met re-targeted CAR+ T-cells were cultured with H28 cells, tumour cell lysis was 
significantly increased when compared to UT or V28z+ T-cells. After 24 hours, a slight 
increase in H28 cell death was observed in cM28z+ T-cell cultures, comparing 
chemotherapy pre-treated and untreated cultures (Figure 5-10A). After 48 hours, no 
convincing difference was observed with tumour cells that had been pre-sensitised with 
chemotherapy drugs (Figure 5-10B). A statistical significance was observed with cM28z 
T-cells at 24-hours and N28z T-cells at 48-hours, although none of these differences 
were substantial in magnitude and thus are likely to be of questionable biological 
significance.  
 
In the case of REN MPM cultures, c-Met re-targeted CAR+ T-cells combined with 
chemotherapy resulted in a small but significant increase in tumour cell lysis after 24 
hours when compared to c-Met re-targeted CAR+ T-cells alone (Figure 5-11A). After 48 
hours, this difference increased substantially in N28z+, M28z+ and cM28z+ T-cells with a 
50% average increase in tumour cell lysis with the combined therapy when compared to 
T-cells alone (Figure 5-11B). A similar pattern emerged in co-cultures of the JU77 cell 
line (Figure 5-12) and LO68 cell lines (Figure 5-13), which was maximal 48 hours after 




























Figure 5-10. Cytotoxic effect of combining chemotherapy with CAR+ T-cells 
against MPM: H28 cell line. 
H28 MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, M28z+, 
cM28z+, V28z+ or untransduced (UT) T-cells. Tumour cells had been pre-treated for the 
preceding 24 hours with cisplatin (3.2µM) and pemetrexed (500µM) or nil. Transduced 
cells were not corrected for transduction efficiency (shown in Figure 5-8B). Cell viability 
was measured using an MTT assay after 24 hours (A) or 48 hours (B). Data has been 
presented as mean ± SEM from three independent experiments. Significance was 
determined using the unpaired Student’s t-test, either comparing UT T-cells with CAR+ 
T-cells for each target cell line or CAR+ T-cell plus chemotherapy against chemotherapy 









































Figure 5-11. Cytotoxic effect of combining chemotherapy with CAR T-cells 
against MPM: REN cell line. 
REN MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, M28z+, 
cM28z+, V28z+ or untransduced (UT) T-cells. Tumour cells had been pre-treated for the 
preceding 24 hours with cisplatin (3.2µM) and pemetrexed (500µM) or nil. Transduced 
cells were not corrected for transduction efficiency (shown in Figure 5-8B). Cell viability 
was measured using an MTT assay after 24 hours (A) or 48 hours (B). Data has been 
presented as mean ± SEM from three independent experiments. Significance was 
determined using the unpaired Student’s t-test, either comparing UT T-cells with CAR+ 
T-cells for each target cell line or CAR+ T-cell plus chemotherapy against chemotherapy 































Figure 5-12. Cytotoxic effect of combining chemotherapy with CAR T-cells 
against MPM: JU77 cell line. 
JU77 MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, M28z+, 
cM28z+, V28z+ or untransduced (UT) T-cells. Tumour cells had been pre-treated for the 
preceding 24 hours with cisplatin (3.2µM) and pemetrexed (500µM) or nil. Transduced 
cells were not corrected for transduction efficiency (shown in Figure 5-8B). Cell viability 
was measured using an MTT assay after 24 hours (A) or 48 hours (B). Data has been 
presented as mean ± SEM from three independent experiments. Significance was 
determined using the unpaired Student’s t-test, either comparing UT T-cells with CAR+ 
T-cells for each target cell line or CAR+ T-cell plus chemotherapy against chemotherapy 





























Figure 5-13. Cytotoxic effect of combining chemotherapy with CAR T-cells 
against MPM: LO68 cell line. 
LO68 MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, 
M28z+, cM28z+, V28z+ or untransduced (UT) T-cells. Tumour cells had been pre-treated 
for the preceding 24 hours with cisplatin (3.2µM) and pemetrexed (500µM) or nil. 
Transduced cells were not corrected for transduction efficiency (shown in Figure 5-8B). 
Cell viability was measured using an MTT assay after 24 hours (A) or 48 hours (B). Data 
has been presented as mean ± SEM from three independent experiments. Significance 
was determined using the unpaired Student’s t-test, either comparing UT T-cells with 
CAR+ T-cells for each target cell line or CAR+ T-cell plus chemotherapy against 







5.2.4 In vitro evaluation of combination treatment of MPM cell lines with 
PD-1 blockade and c-Met re-targeted CAR+ T-cells  
There is increasing interest in the use of PD-1 blockade as a therapeutic approach in 
MPM. Consequently, it was of interest to determine if this approach could be used to 
potentiate the anti-tumour activity of c-Met re-targeted CAR+ T-cells against MPM. 
Firstly, the PD-L1 and PD-L2 expression profile of the MPM cell lines was assessed by 
flow cytometry. Figure 5-14 shows that all four MPM cells expressed PD-L1, ranging from 



























Figure 5-14. PD-L1 and PD-L2 expression profile of a panel of human MPM 
cell lines.  
The PD-L1 and PD-L2 expression profile of the MPM cell lines was assessed by flow 
cytometry (filled red histograms). Filled blue histograms show staining with a matched 
isotype control antibody. (A) Jurkat cells that had been engineered to over-express PD-
L1 served as positive control while parental Jurkat cells were a negative control in this 
analysis. (B) Expression of PD-L1 on the indicated MPM cells. (C) Parental Jurkat cells 
were used as control for PD-L2 expression profiling – however low expression of PD-L2 
appear to be present and qRT-PCR would be required for further analysis. (D) 
Expression of PD-L2 on the indicated MPM cell lines. Data are representative of 2 
independent experiments that yielded similar results. 
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Jurkat cells that had been engineered to over-express PD-L1 (gift of Dr Marc Davies, 
King’s College London) served as positive control while parental Jurkat cells were a 
negative control in this analysis. Only JU77 cells expressed very high levels of PD-L2, 
although no suitable controls were available for this analysis.  
 
Based on these expression profiles, I hypothesised that PD-1 blockade with the 
pembrolizumab monoclonal antibody would potentiate the anti-tumour activity of c-Met 
re-targeted CAR+ T-cells, especially against the REN and JU77 cell lines. To test this, c-
Met re-targeted CAR+ T-cells (transduction efficiency shown in Figure 5-15) were 
combined with ± 10µg pembrolizumab during a 48-hour co-cultures with MPM cell lines 
(REN, JU77, LO68) at a 1:1 effector to target ratio. T-cells expressing V28z CAR or UT T-
cells were used as negative controls. During the co-culture period, T-cell activation was 
monitored by measurement of the release of IFN-γ (Figure 5-16).  
 
It is extremely difficult to calculate an in vitro dose based upon doses used in vivo, 
because in vivo doses take into account the pharmacokinetics that are absent in an in 
vitro setting. In clinical studies, the highest dose given to patients was 10mg/kg, which 
crudely translates to an in vitro calculation of 10µg/ml. This concentration was taken as 
the baseline. Additionally, to ensure complete saturation, an elevated dose of 100µg/ml 
was also evaluated. This study design was undertaken as a model to establish whether 
blocking PD-1 correlated with improved anti-tumour activity of c-Met re-targeted CAR T-
cells. Moreover, the 100µg/ml dose is far greater than one would ever achieve in vivo, 
however was conducted to ensure complete saturation in the event a synergistic effect 
may be seen.  
 
In three independent experiments, there was no significant increase in IFN-γ release by 
MPM-stimulated c-Met re-targeted CAR T-cells when cultured in the presence or 
absence of pembrolizumab. Although variability in the concentrations of IFN-γ was 
detected, the trend of T-cell activation was reproducible across independent experiments, 
highlighting the consistency of this result.  
 
Next, I investigated if PD-1 blockade could potentiate tumour cell killing mediated by c-
Met re-targeted CAR T-cells. Quantification of T-cell mediated tumour cell destruction 
was achieved using MTT assays. Following confirmation of CAR expression (Figure 5-15), 
N28z+, M28z+, cM28z+, V28z+ or UT T-cells were co-cultured for 48 hours with REN 
(Figure 5-17), JU77 (Figure 5-18) or LO68 (Figure 5-19). In these experiments, I also 




Forty eight hours after T-cell addition, similar levels of killing of REN or JU77 cells was 
observed when comparing CAR+ T-cells alone or in combination with pembrolizumab. 
This was noteworthy since both cell lines expressed the highest levels of PD-L1. By 
contrast, a modest but significant enhancement of killing of LO68 cells by c-Met re-







Figure 5-15. CAR T-cell transduction efficiencies.  
Example of CAR T-cell transduction percentages obtained for use in experiments 
evaluating the combination of pembrolizumab with c-Met re-targeted CAR T-cells using 









































Figure 5-16. IFN-γ release during c-Met re-targeted CAR+ T-cell co-cultures 
with or without pembrolizumab on panel of MPM cell lines. 
N28z+, M28z+, cM28z+, V28z+ or untransduced (UT) T-cells were co-cultivated at an 
effector to target ratio of 1:1 with a panel of four MPM tumour cell lines ± 10µg/ml PD-1 
checkpoint inhibitor pembrolizumab. The bar shown on the extreme right shows tumour 
cell cultures in which pembrolizumab alone was added (e.g. no T-cells). After 48 hours, 
supernatants were removed from co-cultures with (A) REN, (B) JU77, (C) LO68 tumour 
cells and the concentration of IFN-γ measured using ELISA (mean ± SEM; n=3 
independent experiments). Significance was determined using the unpaired Student’s t-
test, comparing UT T-cells with CAR+ T-cells: comparisons between pembrolizumab-

































 Figure 5-17. Cytotoxic effect of combining PD-1 blockade with CAR T-cells 
against MPM: REN cell line. 
REN MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, M28z+, 
cM28z+, V28z+ or untransduced (UT) T-cells + pembrolizumab at two indicated doses 
(10µg / 100µg). Pembrolizumab was added without T-cells to those cultures indicated by 
the black and white hatched bars. T-cells were not corrected for transduction efficiency 
(shown in Figure 5-15). Residual tumour cell viability was measured using an MTT assay 
after 48 hours. Data are presented as mean ± SEM from three independent experiments. 
Significance was investigated using the unpaired Student’s t-test comparing only T-cells 
with pembrolizumab plus T-cells – as depicted by horizontal line. A test (above 
individual bars) was also conducted comparing T-cells supplemented with 
pembrolizumab against each respective dose of pembrolizumab (* denotes 10µg 
pembrolizumab comparisons) (+ denotes 100µg pembrolizumab comparisons); A further 
statistical test test was conducted between 10ug and 100ug of pembolizumab, denoted by 




























Figure 5-18. Cytotoxic effect of combining PD-1 blockade with CAR T-cells 
against MPM: JU77 cell line. 
JU77 MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, M28z+, 
cM28z+, V28z+ or untransduced (UT) T-cells + pembrolizumab at two indicated doses 
(10µg / 100µg). Pembrolizumab was added without T-cells to those cultures indicated by 
the black and white hatched bars. T-cells were not corrected for transduction efficiency 
(shown in Figure 5-15). Cell viability was measured using the MTT protocol after 48 
hours. Data presented as mean ± SEM from three independent experiments. Significance 
was investigated using the unpaired Student’s t-test comparing either T-cells against 
respective dose of pembrolizumab plus T-cells (* with line) or T-cells plus 
pembrolizumab against the respective dose of pembrolizumab alone (* denotes 10µg 
pembrolizumab comparisons) (+ denotes 100µg pembrolizumab comparisons); (×) 
denotes unpaired Student’s t-test comparing pembrolizumab doses alone without T-cells: 


































Figure 5-19. Cytotoxic effect of combining PD-1 blockade with CAR T-cells 
against MPM: LO68 cell line. 
LO68 MPM cells were co-cultivated with an equal number (2 x 104 cells) of N28z+, 
M28z+, cM28z+, V28z+ or untransduced (UT) T-cells + pembrolizumab at two indicated 
doses (10µg / 100µg). Pembrolizumab was added without T-cells to those cultures 
indicated by the black and white hatched bars. T-cells were not corrected for 
transduction efficiency (shown in Figure 5-15). Cell viability was measured using the 
MTT protocol after 48 hours. Data presented as mean ± SEM from three independent 
experiments. Significance was investigated using the unpaired Student’s t-test comparing 
either T-cells against respective dose of pembrolizumab plus T-cells (* with line) or T-
cells plus pembrolizumab against the respective dose of pembrolizumab alone (* denotes 
10ug pembrolizumab comparisons) (+ denotes 100ug pembrolizumab comparisons); (×) 
denotes unpaired Student’s t-test comparing pembrolizumab doses alone without T-cells: 










The overall aim of the work undertaken in this chapter was to investigate whether the 
anti-tumour activity of a panel of c-Met re-targeted CARs (N28z, M28z and cM28z) 
could be further potentiated through combining chemotherapy or immune-checkpoint 
inhibitors with CAR T-cell therapy.  
 
Initial experiments were conducted with a combination of cisplatin and pemetrexed, a 
doublet chemotherapy regimen that is commonly used in the treatment of patients with 
MPM. Doses were selected to have relatively low intrinsic cytotoxic activity, in order to 
investigate for a sensitising effect of these drugs to subsequent addition of c-Met re-
targeted CAR+ T-cells. These experiments revealed that a concentration of 3.2µM 
cisplatin alone or in combination with pemetrexed (500µM) caused low level killing of all 
four MPM tumour cell lines within 48 hours. Next, MPM tumour cells were pre-treated 
with this cocktail of drugs for 24 hours prior to their removal and addition of c-Met re-
targeted CAR+ T-cells. These experiments demonstrated no convincingly reproducible 
increase in CAR T-cell activation (indicated by release of IFN-γ). However, a statistically 
significant - albeit biologically modest - increase in killing of REN, JU77 and LO68 MPM 
cells was observed after addition of CAR T-cells.  
 
Both of these findings are consistent with a previous report of the sensitising effect of 
chemotherapy in models of ovarian cancer. In that setting, pre-treatment of platinum-
resistant SKOV-3 tumour cells or derived xenografts with carboplatin achieved 
significant sensitisation to cytotoxic destruction by ErbB re-targeted CAR T-cells, in the 
absence of enhanced T-cell activation [350]. 
 
The immune-potentiating effects of chemotherapy drugs is increasingly being 
appreciated [353]. A number of studies have evaluated the immunomodulatory effects of 
low-dose chemotherapy, such as the increased APC function of DC and depletion of Tregs 
[354, 355]. In MPM, immunomodulatory roles have previously been identified for agents 
cisplatin and pemetrexed. Studies have shown that patients treated with platinum-based 
chemotherapy have greater CD8+ tumour infiltrating T-cells, correlating with improved 
survival [97]. A study by Su et al., reported that pemetrexed is able to sensitise tumour 
cells to immune cell killing via the upregulation of the death receptor, DR5 [356]. 
Likewise, cisplatin has also been reported to increase the sensitivity of tumour cells to 
cell lysis induced by CD8+ T-cells [357]. Although the mechanism underlying this effect 
was unclear, more recent reports have shown cisplatin can activate the Fas-ligand 
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(CD95) related apoptotic pathway in tumour cells [358]. Nonetheless, mechanisms 
underlying the sensitising effect remain to comprehensibly be determined.  
 
Substantial further investigation would also be required to further optimise the 
therapeutic potential of this combinatorial approach. Such an analysis would require 
testing of a broader range of doses of cisplatin and pemetrexed (including dose levels that 
are more potently cytotoxic), employing a spectrum of CAR T-cell effector to target ratios 
and an extended panel of MPM cell lines that include tumour cells that are naturally 
sensitive or resistant to the cytotoxic effects of these agents. Once in vitro sensitisation 
was better characterised, it would then be appropriate to explore such regimens in vivo 
in mice bearing established MPM tumour xenografts.  
 
In an alternative approach, I explored the combination of CAR T-cell immunotherapy in 
combination with a PD-1 inhibitor, pembrolizumab. Pembrolizumab is currently 
undergoing clinical development for the treatment of patients with this cancer. As 
detailed in chapter 1, numerous inhibitory immune-checkpoint pathways, such as PD-1, 
CTLA-4, FasL the anti-tumour ability of TILs in MPM and other tumour types. 
Furthermore, the PD-1/PD-L1 axis has been shown to suppress the activation of CAR T-
cells within the tumour microenvironment [359, 360]. Moon et al. showed that CAR T-
cells undergo rapid loss of function within tumours – a change that was correlated to the 
up-regulation of intrinsic T-cell inhibitory enzymes and cell surface expression of 
inhibitory receptors [361]. The use of checkpoint inhibitors targeting the PD-1/PD-L1/2 
axis or CTLA4 pathway has previously been demonstrated to enhance clinical response in 
a number of cancers, such as melanoma and renal cancer [99, 113] and similar findings 
are now emerging in trials of these agents in MPM [112].  
 
Elevated expression of PD-L1 in mesothelioma provides a strong rationale for 
investigation of the clinical use of PD-1 or PD-L1 inhibition in patients with MPM. It has 
been reported greatest expression of inhibitory markers were found in sarcomatoid 
subtypes, directly correlating to poorer prognosis. The panel of four mesothelioma cell 
lines were tested for the cell surface expression of both PD-L1 and PD-L2. Greatest 
expression of both ligands was identified in the JU77 (sarcomatoid) cell line, with REN 
cells also expressing high levels of PD-L1. Lower levels of PD-L1 expression were 
identified on LO68 cells, with H28 cells expressing the lowest levels. The REN, JU77 and 
LO68 cell lines were subsequently taken forward to evaluate whether the combination of 
c-Met re-targeted CAR+ T-cells with an anti-PD-1 blocker, pembrolizumab, could further 
enhance the anti-tumour activity observed against the respective mesothelioma cell lines. 
Two concentrations, 10µg/mL and 100µg/mL were chosen to initially identify whether 
the combination yielded significant differences. The activation of c-Met re-targeted CAR+ 
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T-cells was assessed by measurement of release of IFN-γ following stimulation by MPM 
cell lines. This analysis revealed that pembrolizumab did not enhance the activation of c-
Met re-targeted CAR+ T-cells when stimulated on MPM cells that express cognate target.  
 
Further assessment of whether functionality of c-Met re-targeted T-cells was potentiated 
by anti-PD-1 therapy involved an assessment of tumour cell viability in co-cultivation 
assays (Figure 5-17). Once again, these studies failed to unmask any convincing 
potentiating effect of pembrolizumab on CAR T-cell mediated anti-tumour activity, with 
the possible exception of LO68 tumour cells which express minimal levels of PD-1 
ligands. Following the relatively insignificant differences observed with this 
combinational approach, further experimental designs should be considered. One 
alternative in vitro approach method that could unmask effects of PD-1 blockade entails 
re-stimulation of c-Met re-targeted CAR+ T-cells on fresh tumour cell monolayers, every 
72-96 hours. Significant differences may emerge with repeated stimulation of c-Met re-
targeted CAR+ T-cells upon the same tumour monolayer, particularly as exhaustion 
markers such as PD-1 are upregulated on T-cells.  
 
Additionally, further assessment using in vivo studies would be required to truly 
understand whether the combination of anti-PD-1 therapy combined with c-Met re-
targeted CAR+ T-cell therapy may enhance c-Met directed anti–tumour activity. Such a 
finding would be consistent with a recently reported study involving Her2 transgenic 
mice [351]. As detailed in section 5.1.2, adoptively infused Her2-specific CAR+ T-cells 
were combined with a mAb to PD-1, resulting in enhanced proliferation and functional 
capability of Her2-specifc T-cells. Potent regression of established Her2 positive 
sarcomas and breast cancers were induced [351]. Although checkpoint inhibitors such as 
anti-PD-1 antibodies are clinically available and generally well tolerated (over 7000 
patients have received anti-PD-1 therapy [362]), a more refined method to merge CAR T-
cell engineering with checkpoint blockade is also being explored in preclinical studies. 
“Chimeric switch-receptors” are chimeric proteins that fuse the extracellular/ 
transmembrane domains of CTLA-4 or PD-1 to traditional intracellular signalling 
domain such as CD28 or 4-1BB. Using this approach, a potentially inhibitory signal 
delivered by a PD-1 ligand is transformed into positive stimulatory signal, leading to 
potentiation of anti-tumour activity [363]. PD-1/CD28 chimeric molecules have been 
shown to enhance cytokine secretion with superior in vivo anti-tumour activity in two 
xenograft melanoma models [364]. A subsequent study using PD-1/CD28 CAR T-cells 
against aggressive models of human solid tumours resulted in significant regression of 
tumour volume due to enhanced CAR TIL infiltration and decreased susceptibility of 
tumour-induced hypofunction [365]. Building upon this novel emerging data, further 
188 
 
investigations would be required to fully understand the potential therapeutic value of 
this combinational approach in relation to mesothelioma specifically.  
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CHAPTER 6 Determining the anti-tumour efficacy of 






Data presented in Chapters 3-5 of this thesis demonstrate that all three candidate CARs 
developed in this project can confer specificity for c-Met upon engineered T-cells, 
enabling them to destroy target cells in a c-Met-dependent manner. Clinical development 
of a strategy such as this requires the generation of a pre-clinical data package that 
demonstrates the efficacy and safety of this approach using the therapeutic agent itself 
(e.g. human CAR engineered T-cells). Consequently, I next set out to develop xenograft 
models in order to evaluate the anti-tumour activity of c-Met re-targeted CAR T-cells 
against an established MPM tumour xenograft burden.  
 
6.1.1 Assessing the therapeutic efficacy of CAR+ T-cells in vivo  
A significant hurdle in the translation of novel cancer therapies into the clinic is 
reproducing results observed in vitro using more physiologically appropriate systems. In 
particular, the testing of anti-tumour activity of CAR re-directed T-cells in vivo is a vital 
step in this pre-clinical development process. To date, a variety of different CAR+ T-cells 
targeting a diverse spectrum of tumour associated antigens have been evaluated in this 
manner [231, 366].  
 
The need for assessing CAR T-cell functionality using animal models stems from the 
multitude of complex interactions that occur in vivo and which are not recapitulated by 
in vitro assay systems. Examples include the need to optimise T-cell homing and trans-
endothelial migration within tumour deposits, attributes that cannot easily be monitored 
within current in vitro systems. Additionally, investigation of the inhibitory and 
regulatory influences of the tumour microenvironment on CAR engineered T-cells can be 
studied using some in vivo models, in particular those that involve the use of immune 
competent mice. While these do not allow the study of human CAR T-cells, an increasing 
number of humanised mouse models are under development, which may help to address 




6.1.2 Establishment of animal models of malignant mesothelioma 
Mesothelioma can be recapitulated in murine models using the same defined carcinogen 
(e.g. asbestos exposure) as has been implicated in most human disease. Although these 
models have clear relevance to the human MPM, the long lag time (1.5 years) and poor 
(25%) success rate renders this option unsuitable for most investigations [367].  
 
Subcutaneous models using murine mesothelioma cell lines were widely used to evaluate 
many of the chemotherapy agents used clinically today [368]. An advantage of these 
models is the fact that tumours grow reproducibly within a short time frame in immune 
competent hosts and are readily amenable to serial measurement without the need to kill 
the animal to quantify tumour burden. However, development of tumours at an 
anatomically irrelevant site may result in significant differences in response to therapy 
when compared to orthotopic models [369]. The microenvironment of subcutaneous 
tissue bears little resemblance to the tissue milieu within which human mesothelioma 
tumours are found.  
 
To model MPM most precisely, it is logical to inject tumour cells into the pleural cavity. 
Previous literature has described a number of such intrapleural models [370, 371]. 
Additionally, consistent with human disease, tumour cells grow along the serosal surface, 
forming nodules [370, 371]. However, this imposes substantial technical challenges, 
considering in particular the difficulty in obtaining successful access to the pleural space 
in mice. In order to test CAR T-cell immunotherapy, such access would be required on 
two separate occasions, in order to engraft the tumour and subsequently to deliver T-
cells to this site. The latter approach is justified (rather than intravenous administration 
of T-cells) in light of the propensity of MPM to spread locally. Furthermore, recent data 
published using a mesothelin-targeted CAR demonstrate that efficacy of this therapeutic 
approach is substantially enhanced if T-cells are delivered into the pleural cavity rather 
than into the bloodstream [235].   
 
To establish an in vivo model that balances all of these requirements, I elected to 
establish an intraperitoneal xenograft model. Peritoneal mesothelioma accounts for 
almost 10% of all cases, demonstrating the clinical relevance of this approach. Like MPM, 
tumours tend to progress by loco-regional spread, providing a rationale for direct 
delivery of CAR T-cells to this body cavity. Intraperitoneal injection of tumour cells and 
T-cells is considerably less invasive that intrapleural injection in mice. Finally, the same 
biological features, in terms of pathology, histology and progression are reportedly 
conserved in intraperitoneal mesotheliomas [372, 373]. While xenograft models do not 
allow the study of interaction between the immunotherapy and the host immune system, 
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they do allow the investigation of the therapeutic agent (e.g. human CAR T-cells) for its 
efficacy and safety, as is required by regulatory bodies in clinical trial applications. 
 
One of the hurdles with successfully implemented orthotopic models is the challenge of 
measuring tumour burden. However, this may been countered with the use of 
bioluminescence imaging techniques [374]. Such an approach enables the serial real time 
and non-invasive imaging of tumour status in immune compromised animals. Tumours 
are engineered to express luciferase enzymes, most commonly from the firefly (Photinus 
pyralis). Following the administration of a substrate (d-luciferin), tumours emit light in 
proportion to their size. This allows the assessment of tumour burden and therapeutic 




1. Development of a c-Met-expressing MPM tumour xenograft model that is amenable to 
serial monitoring using bioluminescence imaging. 
2. Evaluation of in vivo anti-tumour activity of c-Met re-targeted CAR T-cells against an 




6.2 Results  
 
6.2.1 Generation of firefly luciferase-expressing MPM tumour cell lines 
 
To enable the non-invasive in vivo monitoring of MPM xenograft growth using 
bioluminescence imaging (BLI), the REN and H28 tumour cell lines were engineered by 
retroviral transduction to stably co-express both firefly luciferase (ffLuc) and the red 













Figure 6-1. Stable expression of the SFG LT construct in mesothelioma cell 
lines 
(A) Structure of the SFG LT retroviral vector. Stoichiometric co-expression of firefly 
luciferase (ffLuc) and tdTomato was achieved through the use of a T2A ribosomal skip 
sequence. LTR: long terminal repeats; SD: splice donor; Ψ: packaging signal; SA: splice 
acceptor; Note: size of the blocks is not representative of the sizes of individual elements. 
(B) Transduced REN LT cells were visualised by fluorescence microscopy (representative 
images showing parental REN and REN LT cells). (C) Function of ffLuc in tumour cells 
was confirmed by luciferase assay, making comparison between medium alone, parental 
REN cells and REN LT cells seeded at 1x104 or 2x104 and read after 24 hours. 
Representative of two independent repeats. Following transduction, mesothelioma cell 
lines were flow sorted for tdTomato expression, yielding Ren LT (D) and H28 LT cell 
lines (E), which were used to establish xenografts in NSG mice.  
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6.2.2 Developing a clinically relevant c-Met expressing xenograft model of 
MPM 
Since the most potent in vitro anti-tumour activity of c-Met re-targeted CAR T-cells was 
observed using H28 MPM cells, I first set out to develop a xenograft model using ffLuc-
expressing H28 cells. NSG mice were inoculated with tumour cell doses of between 0.5 to 
10 x 106 tumour cells using the intraperitoneal (i.p.) route. Despite the detection of signal 
after tumour cell inoculation, tumour progression was not achieved with this model 
however (Figure 6-2A). Similarly, subcutaneous (s.c.) inoculation of H28 tumour cells 
alone or supplemented with matrigel [375, 376] did not achieve robust tumour 
engraftment (Figure 6-2B).  
 
Next, I decided to switch models to investigate xenograft formation by ffLuc-expressing 
REN LT MPM cells (REN LT). NSG mice (three mice per group) were inoculated with 0.5 
and 2 x 106 tumour cells. An initial pilot study identified REN LT xenograft was 
developed aggressively with animals developing very high tumour burden within two 
weeks (Figure 6-3).  
 
 
Figure 6-2. Developing an in vivo MPM xenograft model: H28 cells 
NSG mice (n=3 per dose) were inoculated with the indicated dose of ffLuc-expressing 
H28 cells, either into the peritoneal cavity (A) or subcutaneously (B). Tumour growth 
was monitored at the indicated intervals using bioluminescence imaging. Quantification 
of luminescence signal released by individual mice was determined by drawing a region 
of interest (ROI) around each specific mouse. Using Living Image 4.1 software, photon 
release within the ROI was calculated and standardised to account for the scan duration. 




































Figure 6-3. Developing an in vivo MPM xenograft model: REN LT cells pilot 
study 1 
NSG mice (n=3 per dose) were inoculated with the indicated dose of ffLuc-expressing 
REN LT cells into the peritoneal cavity. Quantification of luminescence signal released by 
individual mice was determined by drawing a region of interest (ROI) around each 
specific mouse. Using Living Image 4.1 software, photon release within the ROI was 
calculated and standardised to account for the scan duration. The data is expressed as 





In light of the rapid pace of tumour progression seen, I decided to further optimise this 
model. The number of administered tumour cells was titrated to determine the lowest 
number that reproducibly engrafted within NSG mice, thereby potentially extending the 
therapeutic window for adoptive CAR+ T-cell transfer. Tumour cell doses of 0.5 x 106, 1.5 
x 105 and 5 x 104 tumour cells were injected i.p. into NSG mice. All three doses resulted in 
reproducible tumour engraftment within a reasonable time frame (35 days; Figure 6-4). 
An exponential growth phase was observed in all three dose-groups between day 22 and 
day 35, at which point all animals were sacrificed. A dose of 5 x 104 REN LT cells was 
























Figure 6-4. Developing an in vivo MPM xenograft model: REN LT cells pilot 
study 2 
NSG mice (n=3 per dose) were inoculated with the indicated dose of ffLuc-expressing 
REN LT cells into the peritoneal cavity. Quantification of luminescent signal released by 
individual mice was determined by drawing a region of interest (ROI) around each 
specific mouse. Using Living Image 4.1 software, photon release within the ROI was 
calculated and standardised to account for the scan duration. The data is expressed as 




6.2.3 Assessing the anti-tumour efficacy of c-Met re-targeted CAR+ T-
cells 
 
Next, I investigated anti-tumour activity of c-Met re-targeted CAR+ T-cells in vivo, 
following adoptive transfer into NSG mice with established REN LT xenografts. Mice 
were imaged using BLI and were weighed regularly throughout the study, in order to 











Figure 6-5. MPM tumour inoculation and treatment protocol timeline for in 
vivo studies 
This figure shows a schematic overview of how experiments shown in Figure 6-6 and 6-7 




In a randomised study, 55 mice were inoculated i.p. with 5 x 104 REN LT tumour cells. 
Treatment groups were assigned numbers and all treatment and imaging was carried out 
in a blinded fashion. Five days post tumour cell administration; the mice were imaged 
using BLI to confirm tumour engraftment. Mice were re-imaged on day 7 to quantify 
baseline tumour burden prior to being treated the following day with N4+, M4+, cM4+ or 
V4+ T-cells that had been cultured in IL-4 for 12 days. Prior to infusion, the T-cells were 
analysed for surface expression of the CAR constructs (Figure 6-6). CAR T-cells were 
administered i.p. at a dose of either 2.5 or 10 x 106 cells (total T-cell dose, not corrected 
for transduction efficiency). Untransduced (UT) T-cells that had been cultured in IL-2 
were injected at the highest dose (10 x 106). To quantify tumour progression in the 




At the lower T-cell dose, only N4+ and CM4+ T-cells elicited a modest and transient 
therapeutic response, when compared to those receiving UT T-cells, V4+ T-cells or PBS. 
Anti-tumour activity was evident for 7 days following treatment, after which tumour 
burden increased, mirroring control groups (Figure 6-7).  Plots of BLI data for individual 
















Figure 6-6. c-Met re-targeted CAR+ T-cell transduction efficiencies used for 
in vivo treatment study 
Flow cytometric analysis to show (A) transduction efficiency of c-Met re-targeted and V4 
CAR+ T-cells 12 days post retroviral transduction (CAR+ T-cells cultured in IL-4 
supplemented medium, whilst UT cultured in IL-2 supplemented medium). T-cells were 
stained for CAR expression using the 9e10 antibody which recognises a myc epitope tag 
in the CAR ectodomain (red histograms). Untransduced (UT) T-cells were similarly 
stained to generate the negative control (blue histograms). Panel (B) shows the same 
CAR+ T-cells 12 days post retroviral transduction probed for CD124 cell surface 









































Figure 6-7. Anti-tumour activity of c-Met re-targeted CAR T-cells in mice 
with established expressing REN LT MPM tumour xenografts (low treatment 
dose). 
Mice were inoculated with 5 x 104 ffLuc expressing REN LT tumour cells (i.p.). 
Engraftment of tumour cells was confirmed using BLI imaging. N4+, M4+, cM4+ and V4+ 
T-cells (cultured in IL-4) (not corrected for transduction efficiency) were injected i.p. at a 
dose of 2.5 x 106 T-cells. (A) Serial BLI imaging was conducted throughout the study to 
assess baseline tumour growth and anti-tumour activity. (B) Body weight (g) was 
measured throughout the study to monitor for potential toxicity. Data show mean + SEM 
















Figure 6-8. Bioluminescence imaging data for individual mice shown in 
Figure 6-7.  







By contrast, treatment with the higher dose of 10 x 106 N4+, M4+ and cM4+ CAR T-cells 
resulted in rapid and more pronounced anti-tumour activity (Figure 6-9; plots of 
individual mice shown in Figure 6-10). In vivo efficacy was only maintained by cM4+ 
CAR T-cells, which exhibited a significant decrease in tumour burden compared to PBS 
only animals. Notably, a second phase of anti-tumour activity was observed with a 
number of the infused T-cell populations with onset between day 21 to day 28. This effect 
was most marked with cM4+ CAR T-cells, leading to a steady and progressive decrease in 
tumour burden through to day 48 of the study. Similar albeit less pronounced and ill-
sustained tumour regression activity was seen with UT and V4 T-cells, which is contrary 
to results observed in vitro.  
 
Irrespective of the treatment T-cell population and dose administered, the average 
weight of each group was maintained or steadily increased over the course of the study, 
indicative of no serious toxicity (Figure 6-7 and Figure 6-9). However, animals from 
control groups and c-Met re-targeted CAR T-cell groups were euthanised upon 
symptoms potentially associated with GvHD, such as piloerection and physical hunching 
(Figure 6-11). However, similar clinical symptoms were also observed in control animals’ 
euthanised due to tumour burden (Figure 6-11) therefore further assessment is required. 
Techniques such as H&E and IHC staining for immune cell infiltration, in addition to 
FACS analysis for CAR T-cells within the circulation would be essential before a weighted 




Figure 6-9. Anti-tumour activity of c-Met re-targeted CAR T-cells in mice 
with established REN LT MPM tumour xenografts (high treatment dose). 
Mice were inoculated with 5 x 104 ffLuc expressing REN LT tumour cells i.p. Engraftment 
of tumour cells was confirmed via BLI imaging one day prior to T-cell transfer. N4+, M4+, 
cM4+ and V4+ T-cells (cultured in IL-4) (not corrected for transduction efficiency) were 
injected i.p. at a dose of 10 x 106 T-cells. (A) Serial BLI imaging was conducted 
throughout the study to assess baseline tumour growth and anti-tumour activity. 
Important – one animal from N4 group was excluded from data shown in this panel due 
to a presumed failed T-cell injection. Panel (B) shows all of the data with inclusion of the 
mouse in the N4 treatment group in which T-cell injection failure occurred. (C) Body 
weight (g) of all animals was measured throughout the study to monitor for potential 







Figure 6-10. Bioluminescence imaging data for individual mice shown in 
Figure 6-9.  






Figure 6-11. Kaplan – Meier survival curve for mice with established REN LT 
MPM tumour xenografts administered high treatment dose of c-Met re-
targeted CAR+ and control T-cells shown in Figure 6-9 and 6-10.  
Mice were inoculated with 5 x 104 ffLuc expressing REN LT tumour cells i.p. N4+, M4+, 
cM4+ and V4+ T-cells (cultured in IL-4) (not corrected for transduction efficiency) were 
injected i.p. at a dose of 10 x 106 T-cells. Kaplan – Meier analysis determined using 
Graphpad Prism software. The x-axis shows days post tumour inoculation. Treatment 











The overall aim of the work presented in this chapter was to evaluate the therapeutic 
activity of c-Met re-targeted CAR+ T-cells following adoptive transfer to mice harbouring 
established c-Met expressing MPM xenografts. Consequently, the development of a 
suitable xenograft MPM mouse model was the first step required to undertake this work. 
To balance the need for experimental feasibility and clinical relevance, I explored the 
development of intraperitoneal (i.p.) xenograft models. Of the two (H28 LT and REN LT) 
MPM cell lines tested, only REN LT tumour cells engrafted stably. Similar i.p. models 
have previously been established in NSG mice in the pre-clinical development of a CAR 
targeted against Fibroblast Activation Protein (FAP) for treatment of MPM [377].  
 
To investigate in vivo efficacy, N4, M4 and cM4+ T-cells were adoptively transferred into 
NSG mice bearing established i.p. tumours and their subsequent effect upon tumour 
growth was investigated. T-cells were delivered directly to the peritoneal cavity since 
regional delivery means that T-cells are provided direct to the site of disease, maximising 
potential for efficacy and minimising risk of toxicity. The delayed administration of CAR 
T-cells, one week post tumour inoculation, meant that animals within each of the 
treatment groups had a similar established tumour burden. Using bioluminescence 
imaging, I monitored the evolution of tumour burden mice treated with c-Met re-
targeted or control CAR T-cells, making comparison with UT T-cells, or PBS alone. At the 
lower treatment does of 2.5 x 106 T-cells (Figure 6-7 and 6-8), an initial modest decrease 
in signal was observed in both N4 and cM4 treatment groups. However, this reduction 
did not reach statistical significance. By contrast, at the higher treatment dose (Figure 6-
9 and 6-10), c-Met re-targeted T-cells demonstrated rapid and significant anti-tumour 
activity compared to PBS, control CAR-engineered and UT T-cells treatment groups. The 
lowest level of tumour burden was observed in mice receiving cM4+ T-cells in which 
progressive reduction in disease burden was seen over the duration of the study. This 
result contrasts with in vitro comparison of these CARs, which did not unmask any 
significant or reproducible difference between their anti-tumour activities.  
 
Data presented in Chapter 4 of this thesis repeatedly demonstrate that neither UT nor 
V28z+ T-cells mediate anti-tumour activity against MPM cells in vitro, indicated by 
failure to induce tumour cell killing or cytokine release. However, the in vivo study 
presented here clearly shows a significant delay in tumour progression in mice treated 
with V4+ T-cells (day 14/21 onwards) and UT T-cells (day 28 onwards) when compared 
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to those receiving PBS (Figure 6-9 and Figure 6-10). The exact reason for this unexpected 
activity is unclear at this stage. When investigating the anti-tumour potential of MUC-1 
retargeted [378] or ErbB retargeted CAR T-cells [241], truncated signalling constructs 
did cause delay in tumour growth. Such an effect could have been mediated by the ability 
of the control CAR to promote co-localisation of the T-cells and tumour cells. However, 
this would not be expected with untransduced T-cells or with V4 CAR engineered T-cells, 
in which the targeting moiety lacks any known binding activity. Alternatively, one could 
speculate that alloreactivity of these control T-cell groups might have contributed 
importantly to anti-tumour activity. It is well known that human T-cells can engraft in 
NSG mice and that xenogeneic graft versus host disease may occur after several weeks. 
Consequently, it can be speculated that recognition of human alloantigens in the MPM 
tumour xenograft could have selected for alloreactive T-cells within the untransduced 
and V4-engineered control groups. Such an effect could also have contributed to efficacy 
of cM4+ and N4+ T-cell groups, perhaps explaining the second wave of therapeutic 
activity seen after day 21. It is unclear why this effect was not seen with M4+ T-cells. 
Irrespective of mechanism, this result highlights the differences that may be observed 
between in vitro and in vivo studies, thereby clearly demonstrating the importance for 
relevant animal xenograft models.  
 
There are a number of possible explanation for the superior activity of cM4+ T-cells 
compared to the other c-Met re-targeted CAR T-cell groups. First, it would be interesting 
to investigate the in vivo survival and expansion of these T-cells, making comparison 
with appropriate control groups. A second possibility relates to the stability of the cM4 
targeting peptide, which has been reported to be increased compared to the IK1 parental 
peptide.  Enhanced stability of CAR expression within transduced T-cells in vivo may 
have contributed to increased anti-tumour activity in a manner that was not seen in 
short-term in vitro studies. Third, it is possible that cM28z T-cells are more resistant to 
activation-induced cell death or to induction of anergy, upon repeated in vivo 
stimulation with tumour. These possibilities could be studied by repeated in vitro 
stimulation of c-Met re-targeted CAR T-cells on MPM tumour cell monolayers and by in 
vivo imaging of these CAR T-cells in tumour-bearing mice. The latter could be 
accomplished by dual bioluminescence imaging, whereby a luciferase that employs a 
distinct substrate (e.g. renilla luciferase) is co-expressed with the CAR in adoptively 
infused T-cells. Such an approach would allow separate BLI analysis of tumour and CAR 
T-cell status following administration of the relevant substrates (coelenterazine and d-






CHAPTER 7 General Discussion 
 
 
7.1 Overview and synthesis 
 
The overall aim of this PhD was to investigate whether primary human T-cells could be 
genetically re-targeted against c-Met and whether this approach could be developed as a 
novel therapy for MPM. 
 
A panel of three c-Met re-targeted CARs were engineered. Targeting was achieved using 
stabilised derivatives of NK1, the smallest splice variant of HGF that is known to bind to 
c-Met. A second generation CAR signalling framework was used, comprising a fusion of 
the CD28 co-stimulatory endodomain placed upstream of that derived from human 
CD3ζ [261]. 
 
A fundamental starting point in the in vitro characterisation of these CARs was the 
demonstration that they could be stably expressed at the cell surface of primary human 
T-cells. Next, targeting specificity for c-Met was validated using a panel of aAPC murine 
fibroblast NIH 3T3 cells that had been genetically engineered to express c-Met and/or its 
best characterised co-factor, CD44v6. Specificity of targeting was confirmed by the 
demonstration that all three candidate CARs could enable human T-cells to elicit specific 
destruction of Met-expressing target cells in co-cultures. Cell lysis was accompanied by 
CAR T-cell activation as indicated by cytokine production (IL-2 and IFN-γ).  
 
Next, I evaluated the cytotoxic potential of these candidate CARs against immortalised 
MPM tumour cell lines. Variance in activation and cytotoxicity of CAR T-cells against a 
panel of four c-Met-expressing MPM cell lines was evident. This may reflect intrinsic 
differences in the susceptibility of these tumour cells to cytotoxic destruction since all 
four cell lines expressed readily detectable levels of c-Met. Although enhanced activation 
was seen when c-Met and CD44v6 were co-expressed by NIH3T3 cells, this was not 
observed when stimulation was provided by c-Met expressing tumour cells. While all 
four cell lines were negative for CD44v6, they did express alternative co-factors such as 
Syndecan-1 and ICAM-1, which may have compensated for this. Enhanced anti-tumour 
activity of c-Met re-targeted CAR T-cells was clearly observed when higher efficiency 
gene transfer was attained, manifesting as destruction of MPM cells derived from both 




In light of the variability in tumour cell destruction observed, I next investigated if 
cisplatin and/or pemetrexed chemotherapy could enhance sensitivity of MPM tumour 
cells to killing by c-Met re-targeted CAR T-cells. These cytotoxic agents were selected 
since they are commonly used in combination to treat patients with MPM. Furthermore, 
platinum-based chemotherapy has recently been shown to sensitise ovarian tumour cells 
to destruction by ErbB re-targeted CAR T-cells [350]. In keeping with that earlier study, 
an increase in the activation of c-Met re-targeted T-cells was not observed following 
chemotherapy pre-treatment. Nonetheless, a modest increase in the lysis of some MPM 
cell lines was detected after their exposure to poorly cytotoxic doses of cisplatin and 
pemetrexed. This finding encouraged me to investigate alternative combinatorial 
approaches that might prove more effective upon in vitro testing. The use of checkpoint 
inhibitors targeting CTLA-4 and PD-1/PD-L1 has yielded impressive results in certain 
solid tumours, providing an opportunity for combinatorial therapy with CAR T-cells 
[109, 351, 379]. Pembrolizumab is a PD-1 inhibitor that achieved promising preliminary 
results in a small phase I study of MPM patients (76% overall disease control and 28% 
partial response), supporting the potential combined use of this agent with c-Met re-
targeted CAR T-cells [112]. During this PhD, no significant increase in activation of c-Met 
re-targeted CAR+ T-cells was observed in the presence of pembrolizumab. By contrast, a 
modest but significant enhancement of killing of one intrinsically unresponsive MPM cell 
line (epithelial) by c-Met re-targeted CAR T-cells was observed in the presence of 
pembrolizumab. Further studies analysing c-Met re-targeted CAR T-cell activation upon 
repeated exposure to target antigen, including an analysis of differentiation and 
exhaustion marker expression by c-Met re-targeted CAR T-cells in addition to suitable in 
vivo modelling would broaden the analytical scope of this approach. Additional studies 
targeting PD-L2 and other checkpoint molecules such as LAG-3 and TIM-3 would also 
lay the foundation for selecting the optimal combination therapies for MPM.  
 
The final aim of this thesis was to characterise the therapeutic potential of c-Met re-
targeted CAR T-cells in an in vivo setting. In light of the modest effect of chemotherapy 
pre-sensitisation and immune checkpoint blockade when combined with c-Met re-
targeted CAR T-cells in vitro, I elected to move to in vivo studies using CAR T-cells 
alone. A crucial observation in the evaluation of these engineered T-cells was that N4+ 
and cM4+ T-cells retain their anti-tumour activity in vivo. Using a xenograft model based 
upon the REN MPM cell line, tumour regression was observed in both N4+ and cM4+ T-
cell treated mice. cM4+ T-cell treated animals showed the most significant reduction of 
tumour burden. This contrasts with the result of in vitro studies that did not discriminate 
between the anti-tumour activity of all three candidate c-Met-specific CARs. The superior 
anti-tumour activity by cM4+ T-cells compared to N4+ and M4+ T-cells warrants further 
investigation. Although beyond the scope of this thesis, it would be of interest to 
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undertake in vivo T-cell imaging studies to investigate whether differences in longevity 
between the panel of c-Met re-targeted CARs was of relevance to this observation. Blood 
analysis for circulating CAR+ T-cells in addition to enhanced sensitivity qPCR analysis 
would also provide further insight into this possibility.  
 
 
7.1 Previous attempts to engineer c-Met re-targeted CAR+ T-
cells 
 
The targeting strategy employed in this PhD to engineer c-Met re-targeted CAR+ T-cells 
involved the use of a derivative of HGF, the sole natural ligand for c-Met. Recently, an 
alternative approach using an scFv derived c-Met re-targeted CAR was described by 
Frigault et al [327]. CAR expression was achieved in human T-cells either using transient 
mRNA transfection or lentiviral transduction, enabling the authors to test a variety of co-
stimulatory domains (CD28, 4-1BB and ICOS). Using cytotoxicity assays, they 
demonstrated that scFv re-targeted c-Met re-targeted CAR T-cells could mediate target-
dependent tumour cell lysis in vitro. Unexpectedly however, when the CAR contained a 
CD28/CD3ζ second-generation endodomain, it exhibited constitutive activity that 
resulted in accelerated T-cell differentiation, expression of exhaustion markers and 
impaired anti-tumour activity. This constitutive activity could be circumvented by 
expression of the CAR at lower levels in T-cells, using a weaker promoter system. 
Nonetheless, even with the implementation of this solution, the CAR performed poorly 
when evaluated in vivo in mice bearing a c-Met-expressing ovarian Skov-3 xenograft. 
The non-constitutively active CAR T-cells achieved comparable anti-tumour activity to 
control CD19-targeted CAR T-cells, while the constitutively active CAR performed 
considerably less well than the control [327]. Infiltration of tumours by c-Met re-targeted 
(non-constitutive CAR) and CD19 re-targeted control T-cells were similar, while poorer 
infiltration was seen with the constitutively active c-Met re-targeted CAR+ T-cells. These 
data indicate that a strong alloreactive effect was operative in this model, without any 
significant further enhancement of anti-tumour activity by the c-Met re-targeted CAR. 
Such a finding resonates with the evidence presented in chapter 6 of this thesis that 
alloreactivity may contribute to anti-tumour activity of CAR engineered T-cells against 
tumour xenografts that have been established in NSG mice. Nonetheless, I observed a 
significant further decrease in tumour burden when N4+ or cM4+ CAR+ T-cells were 
administered to NSG mice engrafted with a REN LT MPM tumour xenograft, making 
comparison with control CAR or untransduced T-cells. Consequently, these data 
represent the first evidence that c-Met re-targeted CAR+ T-cells can mediate specific anti-





7.2 Alternative CAR T-cell targets in mesothelioma 
 
7.2.1 Mesothelin 
There have been a number of other studies that have investigated the development of 
CAR T-cell immunotherapy for MPM. Adusumilli et al. reported potent anti-tumour 
activity with an scFv-derived mesothelin (MSLN) targeted second generation CAR 
(CD28/CD3ζ) [235]. Impressively, the authors established an intra-pleural mouse model 
of MPM, enabling accurate assessment of systemic and regional delivery of CAR T-cells. 
The latter overcame barriers to tumour homing that otherwise limit CAR T-cell 
immunotherapy of solid tumours. Systemic delivery resulted in CAR T-cells being 
sequestered in the lungs, delaying entry to the pleural tumour. By contrast, MSLN CAR 
T-cells administered intrapleurally eradicated established MPM tumours at 30-fold 
lower doses compared to systemic CAR T-cell delivery [235]. This approach is currently 
under evaluation in a phase I clinical trial (NCT02414269). The use of a similar 
orthotopic model was not selected in this PhD for the reasons outlined in section 6.1.2. 
Similarly, a clinical trial using SS1-antibody-derived MSLN CAR T-cells is currently being 
evaluated in a Phase I study at the University of Pennsylvania (NCT02159716), in 
patients with solid malignancies, some of which are MPM+. 
 
7.2.2 Fibroblast activation protein-α  
The tumour-associated stroma has been reported to occupy up to 90% of the tumour 
volume and its role in initiating and sustaining tumour growth is the subject of great 
interest from the perspective of possible therapeutic intervention [380]. Cancer-
associated fibroblasts (CAFs) are a key component of the tumour-associated stroma, 
significantly influencing the formation of a highly pro-tumourigenic and 
immunosuppressive microenvironment [381]. Fibroblast-activation protein-α (FAP) is 
predominantly expressed on the surface of reactive tumour-associated fibroblasts and is 
also expressed by MPM tumour cells [382]. Additionally, expression has recently also 
been reported by tumour-associated macrophages (TAMs) [383]. CAR T-cells targeting 
tumour-associated antigens (TAA) often fail to eradicate CAFs, which may potentiate 
tumour progression directly via paracrine secretion of cytokines and growth factors. 
Following acceptable pre-clinical functionality with a second-generation (CD28/CD3ζ) 
CAR, the clinical evaluation of FAP CAR T-cells in MPM patients is currently ongoing 
(NCT01722149). This Phase I study is assessing the safety and feasibility of delivering 
FAP CAR T-cells directly into the pleural cavity via a pleural catheter [384]. Results from 
the first patient treated with this approach were reported. In combination with three 
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cycles of chemotherapy, 1 x 106 CD8+ FAP CAR T-cells were injected and no adverse 
events due to CAR T-cells were observed [384].  
 
 
7.3 Limitations of c-Met re-targeted CAR+ T-cell 
immunotherapy of mesothelioma and possible next 
steps 
 
7.3.1 Loss of efficacy through antigen loss 
Recent clinical data has highlighted the risk of antigen escape leading to disease relapse 
following CD19 CAR T-cell immunotherapy of acute lymphoblastic leukaemia [298]. 
Theoretically, this risk also applies to use of CAR T-cells that are directed against other 
single targets, such as c-Met, FAP or mesothelin. Countering this is the fact that c-Met 
contributes to disease pathogenesis in MPM (section 1.4) and consequently it would 
expected to be subject to selective pressure within the tumour for maintained expression. 
A number of alternative approaches have also been proposed which may help to 
minimise this risk further. For example, a recent study has described the design of a 
dual-specific “TanCAR”, which recognises two distinct target antigens independently. 
Engagement of either antigen results in CAR T-cell activation, although greater 
activation is reported when both antigens are bound simultaneously [385].  
 
7.3.2 Risk of toxicity 
An alternative risk associated with the use of c-Met re-targeted CAR+ T-cell 
immunotherapy is the risk of on-target off tumour toxicity. This reflects the fact that c-
Met is expressed at lower levels in healthy tissues, such as the liver. Previous experience 
with systemic delivery of CAR T-cells for solid tumours (CAIX- and HER2- targeted) has 
resulted in serious [304] and lethal [300] toxicity respectively. As alluded to above, since 
MPM spreads mainly by loco-regional progression in the pleural or peritoneal cavity, 
regional delivery systems provide a theoretically attractive approach to maximise 
delivery to the site of disease while minimising risk of toxicity. Human HGF exerts 
biological activity on mouse cells that express the c-Met receptor [386, 387]. 
Consequently, it is possible that the CARs described in this project are also able to engage 
the mouse orthologue of c-Met. Further studies are warranted to investigate this 
possibility, since confirmation of strong biological activity against mouse c-Met would 
support the undertaking of safety testing of human c-Met re-targeted CAR+ T-cells in 
immune compromised mice. Such an approach has been used to obtain regulatory 




In additional to regional delivery, an alternative approach that may reduce risk of toxicity 
involves the separation of signalling domains between dual-expressed CARs targeting 
different antigens. Such systems can be designed to ensure that maximal activation of 
CAR T-cells occurs when both targets are engaged simultaneously, thereby increasing 
precision of tumour targeting. This strategy was initially exemplified by Wilkie et al., 
with an ErbB2- and MUC1- specific CAR that signalled through CD3ζ and CD28, 
respectively [280]. Functional co-expression was demonstrated against target cells 
expressing multiple combinations and densities of the respective antigens. In vitro 
tumour cell lysis and efficient T-cell proliferation was only achieved upon interaction 
with target cells expressing both target antigens. However, significant cytotoxicity was 
observed when target cells expressed ErbB2 alone. This limitation was subsequently 
overcome by Kloss et al., who developed a dual targeting CAR with similar signalling 
domains and targeted against two prostate cancer antigens, namely prostate-specific 
membrane antigen and prostate-specific stem cell antigen. [281]. They exploited a low 
affinity targeting moiety that was coupled to CD3ζ alone, meaning that cytotoxicity was 
not seen unless the second fusion receptor (coupled to CD28) was bound simultaneously.  
In MPM, dual targeting strategies can be envisioned in which targeting of c-Met and 
mesothelin or FAP is titrated to maximise immune attack within the tumour while 





Taken together, the data presented in this thesis show that CAR-modified T-cells can be 
successfully re-directed against c-Met, achieving sustained anti-tumour activity both in 
vitro and in vivo. This is accompanied by greater cytokine secretion (IL-2 and IFN-γ). 
Furthermore, in vivo assessment of c-Met CARs has suggested that cM4 CAR+ T-cells are 
superior in comparison to N4 and M4 CAR+ T-cells resulting in a decrease in tumour 
burden. These encouraging findings warrant further investigation into the translational 
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CHAPTER 9 APPENDIX 































































































































































































































































































































































































Figure 9-1. Circular plasmid maps of SFG c-Met chimeric antigen receptors. 
Schematic depicting (A) SFG N28z, (B) SFG M28z and (C) SFG cM28z. Key individual 







































Figure 9-2. Circular plasmid maps of SFG T28z and V28z chimeric antigen 
receptors. 
(A) Schematic depicting SFG T28z. (B) Schematic of SFG V28z. Key individual modules 
























Figure 9-3. Circular plasmid maps of SFG 4αβ c-Met chimeric antigen 
receptors. 
Schematic depicting (A) SFG N4, (B) SFG M4 and (C) SFG cM4. Key individual 




























Figure 9-4. Circular plasmid map of SFG V4 chimeric antigen receptor. 








Figure 9-5. Bioluminescence imaging data for individual mice shown in 
Figure 6-9 – in vivo therapeutic study.  
NSG mice were inoculated with 5 x 104 REN tumour cells intraperitonealy (IP) in 200µL 
PBS and tumours were allowed to grow over a time period of 7 days prior to T-cell 
administration (IP) of Day 8. Mice (each group n=5 except for PBS (n=8)) were treated 
with 10 x 106 UT, V4, N4, M4 or CM4 transduced T-cells. Control animals (PBS) were 
administered 200µL PBS to identify baseline tumour growth. Sequential BLI of tumour 
size (as total flux (p/s)) prior to (Day 5 and Day 7) and after (Day 11 onwards) T-cell 
administration. The data from each group over every given time point is presented on the 
same scale. x indicates mouse devoid of tumour. The luciferase enzyme present within 
the tumour cells allowed tumour growth to be monitored over the indicated timeframe by 
bioluminescence imaging (BLI). The images gained for each time point were analysed 
using Living Image 3.1 software. The level of luminescent signal released by each mouse 
was calculated by drawing a region of interest (ROI). The software automatically 
calculated the level of photon release within the ROI and this was standardised to 
account for the size of ROI and scan duration.  
 
 
 
